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The adoptive transfer of T cells expressing transgenic tumor antigen-specific T cell 
receptors (TCRs) is a continuously developing immunotherapeutic strategy for patients with 
advanced tumors, showing promising results in early clinical trials. Nevertheless, there is a 
strong need to improve efficiency and safety to enhance the clinical benefit for more patients 
and the identification of suitable therapeutic TCRs remains quite challenging.  
T cells expressing a high-affinity TCR recognizing self-antigens on self-major 
histocompatibility complex (MHC) molecules are mostly eliminated by negative selection in 
the thymus to avoid autoimmunity. Since tumor antigens are often over-expressed self-
antigens, TCRs that develop in a thymic-selected TCR repertoire are largely of low to 
intermediate affinity. Alternatively, high-avidity T cells recognizing self-antigens can be 
found in the non-tolerant allogeneic MHC-reactive T cell repertoire that have not 
encountered the target peptide-MHC complex during thymic selection. Hence, these T cells 
can serve as sources of high-affinity TCRs that can be utilized to equip patient-derived 
lymphocytes with receptors mediating the desired anti-tumor specificity. 
As previous studies have confirmed that high-avidity T cells specific for different tumor 
antigens can be isolated from the allogeneic MHC-reactive T cell repertoire using in vitro 
priming procedures, in this project the allogeneic priming approach was performed utilizing 
NY-ESO-1 as target antigen and the human leukocyte antigen (HLA)-A2 as allogeneic 
restriction element. Both molecules were introduced as in vitro transcribed (ivt)RNA into 
monocyte-derived dendritic cells (DCs) which were then utilized as antigen presenting cells 
(APCs) for stimulation and expansion of autologous CD8-enriched T cells with the final aim 
to isolate NY-ESO-1-specific T cells. The innovations of the approach were: i) the utilization 
of the complete coding region of the antigen to allow presentation of epitopes that were not 
biased by MHC binding prediction programs; ii) a unique selection process of primed T cells 
enabling the identification of T cells specific for unknown immunogenic epitopes of NY-
ESO-1. This was possible by utilizing modified K562 cells for stimulation while the 
activation-induced T cell marker CD137 was verified on T cells. Among the isolated T cell 
clones, the clone 5-271 showed the desired specificity and was further analyzed. The TCR 
5-271 sequence was cloned in vectors to enable transgenic expression in recipient T cells. 
The epitope recognized by the isolated TCR was identified and fine typed. Interestingly, the 
TCR was specific for a new unconventional peptide derived from the protein encoded by 
an alternative open reading frame (ORF) of NY-ESO-1 and presented on HLA-A2 
molecules. To evaluate the potential for therapeutic use of the isolated TCR, T cells 
expressing the transgenic TCR were tested for tumor cell recognition, killing capacity, 
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peptide sensitivity and CD8-dependency. TCR 5-271-transgenic T cells recognized the 
tested tumor cell lines only after target antigen-loading. Additionally, low peptide sensitivity 





Der adoptive Transfer von T-Zellen, die einen Tumorantigen spezifischen T-Zellrezeptor 
(TZR) exprimieren, ist eine sich kontinuierlich weiterentwickelnde Strategie der 
Immuntherapie für Patienten im fortgeschrittenen Krebsstadium mit vielversprechenden 
Ergebnissen in frühen klinischen Untersuchungen. Nichtsdestotrotz ist eine Verbesserung 
der Effizienz und der Sicherheit dringend nötig, um den klinischen Nutzen für mehr 
Patienten zu erhöhen, und auch die Identifikation von geeigneten therapeutisch nutzbaren 
TZRs gestaltet sich immer noch schwierig. 
T-Zellen, die einen hoch-affinen TZR exprimieren, der Selbst-Antigene auf selbst- 
Haupthistokompatibilitätskomplexen (MHC) erkennt, werden, um Autoimmunität zu 
verhindern, meistens durch die negative Selektion im Thymus eliminiert. Da Tumorantigene 
häufig überexprimierte Selbst-Antigene sind, sind TZRs die im Thymus selektioniert worden 
sind weitgehend von niedriger Affinität. Alternativ können hoch-avide T-Zellen für Selbst-
Antigene in einem nicht-toleranten allogenen MHC-reaktiven T-Zellrepertoire gefunden 
werden, da diese im Thymus nicht für das Zielpeptid auf dem allogenen MHC selektioniert 
wurden. Daher können diese T-Zellen als Quelle für hoch-affine TZR dienen, um von 
Patienten stammende Lymphozyten mit Rezeptoren auszustatten, die die gewünschte 
Antitumorspezifität vermitteln. 
Da frühere Studien bestätigt haben, dass T-Zellen mit hoher Affinität für verschiedene 
Tumorantigene aus dem allogenen MHC-reaktiven T-Zellrepertoire unter Verwendung von 
in vitro De-novo-Induktionsverfahren isoliert werden können, wurde in diesem Projekt der 
allogene De-novo-Induktionsansatz, unter Verwendung von NY-ESO-1 als Zielantigen und 
des humanen Leukozytenantigen (HLA)-A2 als allogenem Restriktionselement, 
durchgeführt. Beide Moleküle wurden als in vitro transkribierte (ivt)RNA in von Monozyten-
stammende dendritische Zellen (DZ) eingebracht, welche dann als Antigen-präsentierende 
Zellen (APZ) zur Stimulation und Expansion von autologen CD8-angereicherten T-Zellen 
verwendet wurden um NY-ESO-1-spezifische T-Zellen zu isolieren. Die Innovationen des 
Ansatzes waren: i) die Verwendung der vollständigen kodierenden Region des Antigens, 
um die Präsentation von Epitopen zu ermöglichen die nicht durch Programme zur 
Vorhersage der MHC-Bindung beeinflusst sind; ii) ein einzigartiger Selektionsprozess der 
die Identifizierung von T-Zellen ermöglicht, die für unbekannte immunogene Epitope von 
NY-ESO-1 spezifisch sind. Dies wurde ermöglicht indem modifizierte K562-Zellen zur 
Stimulation verwendet wurden, während der Aktivierungs-induzierte T-Zell-Marker CD137 
auf T-Zellen nachgewiesen wurde. Unter den isolierten T-Zellklonen zeigte der Klon 5-271 
die gewünschte Spezifität und wurde weiter analysiert. Die TZR 5-271-Sequenz wurde in 
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Vektoren kloniert, um eine transgene Expression in Rezipienten-T-Zellen zu ermöglichen. 
Das erkannte Epitop der isolierten TZRs wurde identifiziert und fein typisiert. 
Interessanterweise war der TZR spezifisch für ein Peptid, das von einem alternativen 
offenen Leserahmen (ORF) von NY-ESO-1 kodiert und auf HLA-A2-Molekülen präsentiert 
wurde. Um das Potential für eine therapeutische Verwendung des isolierten TZR zu 
bewerten, wurden T-Zellen, die den transgenen TZR exprimieren, auf Tumorzellerkennung 
und -eliminierung, Peptidsensitivität und CD8-Abhängigkeit getestet. TCR 5-271-transgene 
T-Zellen erkannten die getesteten Tumorzelllinien nur nach Zielantigen-Beladung. 
Außerdem wurde eine geringe Peptidempfindlichkeit und Reaktivität beobachtet, obwohl 
der TCR in der Lage war CD8-unabhängig zu agieren.
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1  Introduction 
1.1 Tumor immunosurveillance and immunoediting 
Tumor development is a multistep process including the accumulation of genetic changes 
that endow normal somatic cells with unlimited growth capacities and render such newly 
transformed cells resistant to natural cell death mechanisms [1]. In the last decades, several 
observations have demonstrated the critical role of the immune system in suppressing 
tumor growth. Firstly, it has been observed that immunosuppressed patients show an 
increased risk for developing tumors [2], [3]. Moreover, evidence of spontaneous tumor 
regression as well as correlations between the presence of lymphocytes in the tumor 
environment and improved prognosis have been observed for different types of tumors [4]–
[6]. Tumor cells can be identified and destroyed by the immune system before they can 
cause detectable tumor masses. The immune system can therefore prevent tumor 
progression (immunosurveillance). However, tumors also develop in the presence of a 
functional immune system. Experiments in mice have shown that tumors derived from 
immunodeficient mice are more immunogenic than tumors derived from immunocompetent 
mice [7]. These findings have led to the hypothesis that the immune system not only 
controls tumor formation by destroying tumor cells, but also influences tumor 
immunogenicity. This dual role of the immune system is named tumor immunoediting and 
comprises three phases: elimination, equilibrium and escape [8]. These three phases occur 
in a sequential order, however in some cases tumor cells can either naturally or influenced 
by external factors, enter in one of the last two phases without passing through earlier 
phases. The elimination phase encompasses the original concept of immunosurveillance. 
Here, innate and adaptive immune systems work together to identify and destroy 
transformed cells escaping intrinsic controls before the growing tumor becomes clinically 
observable. Progression to subsequent phases is prevented if the developing tumor is 
successfully deleted at this stage. In the case of partial tumor elimination, the residual tumor 
cells can enter in the equilibrium phase during which the immune system prevents tumor 
outgrowth and shapes the tumor immunogenicity. Tumor cells can remain in this dormancy 
phase for the entire life, without leading to clinical manifestations. On the other hand, as a 
consequence of the intrinsic genetic instability of tumor cells and of the sustained immune 
selection pressure during the equilibrium phase, tumor cells can bypass immune 
recognition by being poorly immunogenic and can emerge as growing tumors, entering into 
the escape phase [9]. Different mechanisms can lead to tumor cell escape and 
consequently to visible tumor growth. Tumor cells can acquire certain characteristics to 
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either reduce their immune recognition or to increase their resistance to immune effector 
functions. Loss of immunogenic epitope expression, defects in antigen processing 
mechanisms, down-regulation of major histocompatibility complex (MHC) molecules, lack 
of co-stimulation and induction of anti-apoptotic mechanisms are common strategies 
developed by tumor cells to evade immune responses. Alternatively, the immune system 
can be impaired by increased tumor-induced immunosuppression within the tumor 
microenvironment, i.e. production of immunosuppressive cytokines or recruitment of 
regulatory immune cells that function as immune suppressor cells [10], [11]. The broadened 
knowledge of the immune system’s role in tumor development and the tumor immune 
escape mechanisms has supported the idea of exploiting the immune system to treat 
established tumors as an attractive alternative strategy to improve the conventional cancer 
therapies. Several immunotherapeutic approaches that aim to enhance the effector 
functions of the immune system and to counteract tumor-induced immunosuppressive 
mechanisms have been developed in the last years. 
1.2 Cancer immunotherapy 
Designated “Top Scientific Breakthrough” by Science magazine in 2013, cancer 
immunotherapy is recently gaining considerable momentum [12]. Immunotherapy has 
revolutionized the field of conventional chemotherapy and radiation therapy by using the 
immune system to destroy tumors instead of directly attacking the tumor itself. 
First evidence that the immune system can eradicate tumors has been observed in studies 
of bone marrow transplantation, along with donor-derived lymphocyte infusion (DLI) from 
healthy donors to patients with hematological malignancies [13]. However, the transfer of 
allogeneic heterogeneous T cells has been associated frequently with severe adverse 
effects, designated as graft-versus-host disease (GVHD) [14]. To bypass this safety issue, 
approaches exploiting autologous T cells have been investigated. The first evidence that 
autologous T cells can mediate tumor eradication was reported in 1988 by the adoptive 
transfer of ex vivo expanded autologous tumor-infiltrating lymphocytes (TILs) in patients 
with metastatic melanoma [15]. Nevertheless, only limited responses and short-term 
persistence of the transferred T cells were observed in treated patients. A critical 
improvement in TIL therapy was achieved in 2002 showing that a lymphodepleting 
preparative regimen prior to TIL infusion was able to increase tumor regression as well as 
the persistence of the transferred T cells [16]. Starting from this finding, autologous TIL 
therapy has been used successfully to treat patients with metastatic melanoma [17], [18]. 
Nowadays, the clinical effects observed in advanced melanoma with TIL therapy are mainly 
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attributed to the presence of T cells recognizing mutated antigens in the transferred T cell 
populations [19], [20]. Despite encouraging results in melanoma patients, the principal 
limitation of this approach for broad application is the poor immunogenicity of tumors that 
impedes the isolation of TILs for many patients and for several tumor types.  
To overcome the need for tumor-reactive T cells in tumor samples, multiple therapeutic 
tumor vaccines have been developed to induce T cells specific for different tumor antigens 
starting from the autologous T cell repertoire [21], [22]. However, the majority of these 
vaccinations failed to induce complete remission in patients with advanced tumors. These 
results might be due to large tumor burdens of vaccinated patients, tumor-mediated 
immunosuppressive environments, development of tumor escape variants and 
compromised immune systems of the patients after systemic chemotherapy administration. 
Moreover, as the majority of vaccines were directed against self-antigens aberrantly 
expressed in tumors, immunotolerance might have interfered with the induction of effective 
T cell responses. 
An alternative approach that has been developed in the last years encompasses 
monoclonal antibodies designed for blocking checkpoint molecules involved in inhibitory 
pathways induced by tumor cells to evade immune controls [23]. The final aim of these 
checkpoint inhibitors is to favor and restore pre-existing anti-tumor immune responses. 
Advances in the identification of the molecules involved in immune-suppressive pathways 
have opened the way to the development of multiple checkpoint inhibitors. The inhibitory 
receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) expressed on T cells and involved in 
the down-regulation of the initial stages of T cell activation has been investigated as the 
first target of checkpoint inhibitors [24]. According to the encouraging prolongation of overall 
survival observed in the first clinical trials, the anti-CTLA-4 antibody was approved by the 
US Food and Drug Administration (FDA) in 2011 as therapy for melanoma patients with 
metastatic disease. Subsequently, antibodies targeting the inhibitory interaction of 
programmed cell death protein-1 (PD-1) and programmed cell death protein-1 ligand (PD-
L1) have been developed and tested in clinical studies with promising and durable clinical 
responses in several types of solid tumors [25]–[28]. Recently, these antibodies have also 
received the approval by the FDA as therapy for melanoma, non-small cell lung cancer and 
renal cell carcinoma. As hypothesized for TIL therapy, the clinical effects observed after 
treatment with checkpoint inhibitors are supposed to be mainly due to the presence of pre-
existing T cells targeting mutated antigens in treated patients [29]–[31]. A combination of 
either different checkpoint inhibitors or of checkpoint inhibitor with other immunotherapeutic 
strategies might improve the curative potential of these checkpoint inhibitors and enlarge 
their range of applications [32]. 
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Since tumor antigens are often over-expressed self-antigens, the clinical efficacy of 
immunotherapeutic strategies described so far is strongly limited by the tolerance of the 
autologous immune system to the most relevant tumor antigens. The adoptive transfer of 
genetically engineered tumor-specific T cells has been developed as an alternative strategy 
to bypass immunotolerance [33], [34]. This approach provides the possibility to equip 
autologous T cells with receptors mediating the desired anti-tumor specificity and showing 
enhanced functionality before transferring them into patients. The final aim is to enable the 
redirected T cells to effectively recognize and destroy tumors. To note, T cell gene 
engineering offers the possibility to create T cells with the desired anti-tumor specificity and 
enhanced functionality by selecting not only the optimal receptor according to specific 
properties, but also the composition of the genetically modified T cell population that is 
transferred into patients. T cells undergo progressive differentiation after encountering the 
antigen and their differentiation state inversely correlates with the capacity of proliferation 
and persistence [35]. Several clinical studies have shown that the therapeutic efficacy of 
adoptively transferred T cells is strictly dependent on their ability to expand and persist in 
vivo [18], [36], [37]. In pre-clinical models, it has been observed that the infusion of T cell 
populations comprising less differentiated cells is characterized by enhanced proliferative 
capacity, long-term persistence and superior anti-tumor responses [38], [39]. These 
observations suggest that the composition of the T cell population might drastically 
influence the success of adoptive T cell therapy. Therefore, the possibility to orchestrate 
and optimize the composition of the genetically engineered T cell population for the infusion 
represents an additional advantage of this therapeutic strategy for ensuring maximal clinical 
efficacy. Once the optimal T cell population for adoptive therapies is selected, its specificity 
can be re-directed by transferring either a chimeric antigen receptor (CAR) or a 
conventional αβ T cell receptor (TCR) into the cells.  
CARs are recombinant proteins comprising an extracellular target binding module that is 
usually a single-chain antibody fragment, a transmembrane domain to anchor the receptor 
into the cell membrane and one or more intracellular TCR-derived signaling domains that 
transmit activation signals into T cells [40]. As these synthetic receptors show antibody-like 
specificities, they can recognize surface molecules expressed on target cells in a MHC-
independent manner. Consequently, CARs are not affected by immune-escape strategies 
developed by tumor cells such as down-regulation of MHC molecules or alterations in 
processing mechanisms.  On the other hand, loss of target antigen expression remains a 
possible mechanism arising in the tumors to evade CAR-mediated T cell responses. 
Recently, the adoptive transfer of T cells genetically modified with a CAR targeting the B 
cell lineage restricted CD19 molecule has successfully induced long-lasting remission in 
patients with hematological malignancies [41]–[43]. Due to these promising results, this 
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protocol has recently received the approval by the FDA as therapy for the treatment of 
pediatric patients with acute lymphoblastic leukemia (ALL) and of adult patients with diffuse 
large B cell lymphoma (DLBCL). Targeting only cell surface molecules, CAR T cell therapy 
is limited by the number of suitable targets expressed on tumor cells and as a consequence 
the range of applications is quite restricted. Furthermore, T cells expressing CARs have not 
shown so far the same encouraging results in solid tumors as in hematological malignancies 
[44]–[46]. This might be mainly due to the highly immunosuppressive environment 
surrounding solid tumors. 
In contrast, TCRs are heterodimeric protein complexes composed of one α chain and one 
β chain. The TCR heterodimers are expressed on the cell surface of T cells in 
association with the CD3 complex, which is comprised of a series of non-polymorphic 
proteins that serve as the signaling apparatus of the TCR. On the molecular level, TCRα 
and TCRβ chains are assembled randomly from a multitude of germline encoded gene 
segments during early T cell development in the thymus. In the process of gene segment 
rearrangement, the TCRα chain is assembled from one polymorphic variable (TRAV) and 
joining (TRAJ) gene segment in combination with the monomorphic constant region 
(TRAC). The recombined part of the TCRβ chain consists of one polymorphic variable 
(TRBV) and joining (TRBJ) gene segment with an additionally interspersed diversifying 
(TRBD) gene segment and one of the two constant region (TRBC). During the process of 
gene segment rearrangement, germline encoded sequences adjacent to the joining regions 
get modified incidentally. The resulting hypervariable sequences that span the individual 
V(D)J segment junctions are known as complementarity determining region (CDR) 3. CDR3 
regions determine the center of the antigen-binding site of the TCR. The peripheral antigen-
binding sites of the TCR, which are mainly in contact with the MHC molecules, consist of 
CDR1 and CDR2 loops that are encoded within TRAV and TRBV gene segments. More 
precisely, TCRs recognize peptides derived from intracellular processed proteins that are 
presented on the surface of antigen presenting cells (APCs) in complex with MHC 
molecules. In particular, TCRs of CD8+ T cells recognize peptides derived from endogenous 
(cytosolic) proteins that are presented on MHC class I molecules, whereas TCRs of CD4+ 
T cells recognize peptides derived from exogenous antigens that have been taken-up by 
APCs and that are presented on MHC class II molecules. Although with less efficiency, 
exogenous antigens can be alternatively presented to CD8+ T cells on MHC class I 
molecules by physiological cross-presentation mechanisms [47]. Importantly, to avoid 
autoimmunity, T cells expressing TCRs that recognize self-peptides presented on self-MHC 
molecules with high-affinities leading to the generation of potential auto-reactive T cells are 
deleted during T cell development in the thymus by negative selection. The resulting self-
tolerant MHC-restricted T cell repertoire comprises a wide range of T cells able to react to 
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foreign antigens, while it usually lacks high-avidity T cells specific for self-antigens [48], [49]. 
Unlike CAR-based approaches, the transfer of therapeutic TCRs into T cells allows the 
targeting of any antigen that undergoes intracellular processing and that is presented on 
MHC molecules of the desired target cells. In the tumor microenvironment, stroma cells can 
take-up protein fragments released from dying tumor cells and present tumor epitopes on 
their MHC molecules. Consequently, stroma cells may become susceptible to TCR‐
mediated recognition. The targeting of tumor embedded cells may represent an important 
advantage of TCR-based strategies for successful therapy of solid tumors compared to 
CAR-based therapy [50]. 
In the last years, several clinical studies have been conducted using TCR-modified T cells 
for the treatment of several tumor types. In the first published clinical trial, T cells expressing 
a transgenic TCR targeting the melanoma antigen recognized by T cells (MART-1) were 
applied to melanoma patients. The therapeutic TCR was isolated from a TIL clone derived 
from a melanoma patient who showed a nearly complete regression after TIL therapy. 
However, only modest clinical responses were observed in the treated patients [37]. In a 
subsequent trial, a TCR specific for MART-1 derived from TILs of the same melanoma 
patient but showing higher affinity compared to the first TCR tested, was transferred in 
recipient cells and used to treat advanced melanoma. Although tumor regression was 
obtained in 30% of the patients treated, on-target/off-tumor toxicity was observed against 
healthy tissues comprising melanocytes as skin, eyes and ears [51]. Unexpected severe 
side effects have been reported also in two other studies targeting the MAGE family 
member A3 (MAGE-A3) by using T cells transduced with patient-derived and affinity-
enhanced TCRs. In these cases, the observed toxicity against healthy tissues was due to 
previously unknown cross-reactivity of the introduced TCRs which cross-recognized self-
peptides highly homologous to the actual target epitope (off-target/off-tumor toxicity) [52]–
[54]. On the other hand, an affinity-enhanced TCR targeting the cancer/testis antigen NY-
ESO-1 have shown promising results in terms of safety and efficacy for the treatment of 
melanoma, synovial cell sarcoma and myeloma. Clinical responses without any toxicity 
were observed in 55%, 61% and 80% of the treated patients, respectively [55]–[58]. These 
studies suggest the powerful curative potential of the adoptive transfer of TCR-engineered 
T cells. However, the observation of severe side effects has shown the need of further 
improvements to reduce potential toxicity and to enhance the therapeutic efficacy of TCR-
based approaches. The rigorous selection of suitable target antigen as well as of 
corresponding therapeutic TCRs are essential prerequisites for developing successful TCR 
gene therapies with minimal toxicity and maximal efficacy. 
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1.3 Choice of target antigens for TCR-based cancer therapies 
Thorough evaluation of the expression profile of the potential target antigen is the first 
element to be considered for developing TCR-based cancer therapies. An optimal target 
antigen should be expressed only in tumor cells or its expression in normal tissues should 
ideally be limited to immune-privileged organs to avoid undesired on-target/off-tumor 
toxicity reactions. To obtain complete tumor eradication, the target antigen should be 
present in all tumor cells or at least in the cells that drive tumor outgrowth. To avoid the risk 
of antigen-loss escape variants and consequent ineffective tumor destruction, a target 
antigen functionally relevant for tumor survival should be preferably selected. Furthermore, 
the target antigen should be expressed in a large group of patients and be presented on 
frequent human leukocyte antigen (HLA) molecules to allow the development of therapies 
suitable for a broad range of patients. As only very few antigens fulfill all these criteria, the 
identification of appropriate targets for TCR-based therapies is quite challenging. 
Nevertheless, potential target antigens for different tumor indications have been identified 
by evaluating the multitude of different intracellular proteins expressed in tumor cells. 
Generally, tumor antigens can be classified into three categories: viral oncogenes, tumor-
specific antigens and tumor-associated antigens [59], [60]. Tumor antigens produced by 
oncogenic viruses are ideal antigens for targeting virus-transformed tumor cells, since the 
expression of viral proteins is restricted to infected cells. However, only 15% of tumors are 
estimated to be associated with viral infections [61]. The second class of tumor antigens, 
the so-called tumor-specific antigens (TSAs), comprises tumor aberrations leading to the 
formation of mutated gene products (neo-antigens) [62]–[65] . Since neo-antigens are often 
essential for tumor cell survival and accumulate in tumor cells, they are quite interesting 
targets for TCR gene therapy. However, mutations and corresponding neo-antigens are 
mainly patient-specific, thereby their use as targets require highly personalized therapeutic 
approaches. To date, most of the TCR gene therapy approaches focus on tumor-associated 
antigens (TAAs) [62], [66]. The heterogeneous group of TAAs encompasses cancer/testis 
antigens (CTAs) (e.g. MAGE-A3 and NY-ESO-1), differentiation antigens (e.g. MART- 1; 
tyrosinase, melanocyte antigen; CD20, B lymphocyte antigen) and self-proteins over-
expressed in tumor cells (e.g. p53, transcription factor; EGFR, epidermal growth factor 
receptor). One advantage of TAAs is their expression in different types of tumors and 
consequently their broad range of applications. However, the potential expression of these 
target antigens in healthy tissue includes the risk of on-target/off-tumor toxicity through 
unwanted TCR-mediated recognition. 
Independently of the category of the tumor antigen, once a tumor antigen-specific TCR is 
isolated, the specific peptide recognized by the therapeutic TCR needs to be identified and 
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fine-typed. Although the target antigen shows the desired expression profile restricted to 
the tumor, alternative peptides highly homologous to the target epitope might be present in 
the proteome and expressed in healthy tissues. Thus, potential TCR-mediated cross-
recognition of these alternative peptides need to be carefully investigated to predict 
undesired off-target/off-tumor toxicity [67], [68]. 
1.4 Isolation of tumor antigen-specific T cells and corresponding 
TCRs 
Required characteristics of a therapeutic TCR are efficient tumor cell recognition and 
optimal affinity for the target tumor antigen in order to be able to discriminate between tumor 
cells and normal tissues. To date, multiple strategies have been established for the isolation 
of tumor antigen-specific T cells and corresponding therapeutic TCRs for subsequent 
genetic transfer into adequate recipient cells. 
Therapeutic TCRs can be isolated from ex vivo expanded tumor-reactive T cell clones 
derived from TILs of tumor patients [37], [69], [70]. However, tumors are poorly 
immunogenic and consequently the frequency of tumor-reactive T cells is very low. The 
isolation methods using patient material are often hampered by poor cell viability as a result 
of immune depleting treatments or systemic impacts of advanced disease. Additionally, due 
to the negative selection in the thymus, TCRs recognizing self-antigens with high-affinity 
are rarely included in the autologous TCR repertoire. Since the most relevant tumor antigen 
are over-expressed self-antigen, the isolation of suitable therapeutic TCRs recognizing 
TAAs from autologous T cell repertoires is extremely laborious and often leads to the 
identification of TCRs with only sub-optimal efficacy. To improve the clinical efficacy of 
these autologous TCRs, strategies to increase TCR affinity have been developed and 
applied to several TCRs [71]–[74]. These systems are powerful and attractive methods to 
convert low-affinity TCRs derived from an immunotolerant repertoire into high-affinity TCRs 
able to efficiently recognize tumor cells. However, reduced specificity and increased cross-
recognition leading to dramatic side effects have been observed in two clinical trials using 
affinity-enhanced TCRs targeting MAGE-A3 [52]–[54]. These findings show the need for 
additional pre-clinical approaches to extensively characterize therapeutic TCRs in terms of 
potential toxicity prior to clinical applications. 
An alternative TCR isolation strategy is based on in vivo priming in mice. Since the murine 
T cell repertoire is not affected by natural negative selection against human antigens, 
human MHC-transgenic mice can be exploited to isolate murine-derived therapeutic TCRs. 
These transgenic mice vaccinated with peptides derived from human tumor antigens 
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represent a source of murine T cells bearing high-affinity TCRs for human peptides 
presented on human MHC molecules [75]. However, the use of tumor antigen-specific 
murine TCRs in the clinic is problematic, due to their high degree of immunogenicity in the 
xenogeneic human host [76]. To overcome this limitation, human transgenic mice carrying 
the complete human T cell repertoire as well as one human MHC class I allele (HLA-
A*02:01) have been generated [77]. In contrast, these mice are deficient in murine TCRαβ 
as well as in murine MHC class I expression. This in vivo system enables the isolation of 
fully human TCRs from a T cell repertoire unselected for human antigens but restricted to 
HLA-A*02:01. To date, TCRs specific for different tumor antigens have been successfully 
isolated using these transgenic mice [77], [78]. However, these mice only expressing HLA-
A*02:01, thereby they are suitable only for the isolation of TCRs restricted to this MHC class 
I allele. The applicability of this in vivo system is also limited by the potential presence of 
peptides highly homologous to the actual human target epitope in the murine peptidome.  
Alternatively, as negative selection in the thymus is limited to self-peptides presented on 
self-MHC molecules, high-avidity T cells recognizing TAAs can be found in the non-tolerant 
allogeneic MHC (allo)-reactive T cell repertoire that have not encountered the target peptide 
and the MHC molecules during thymic selection. Therefore, high-avidity T cells recognizing 
peptides derived from any TAA can be potentially isolated if these peptides are presented 
on allogeneic MHC molecules [79].  Multiple protocols for in vitro induction of allogeneic 
MHC (allo)-restricted tumor antigen-specific T cells have been developed in the last years 
using cells derived from healthy donors as starting material (approaches designated as 
allogeneic priming approaches) [80]–[83]  
1.5 Aim of the project 
Adoptive transfer of T cells expressing transgenic tumor antigen-specific TCRs is a 
promising therapy for patients with advanced tumors. Nevertheless, there is an important 
need to improve efficiency and safety aiming to enhance the clinical benefit for more 
patients. Additional therapeutic TCRs, able to efficiently recognize tumor target cells without 
showing undesired cross-recognition and consequently potential toxicity, need to be 
identified and extensively characterized. Therefore, the aim of this project was to isolate T 
cells and corresponding TCRs specific for new epitopes derived from the tumor antigen NY-
ESO-1 and presented in the context of HLA-A2 molecules by using an in vitro allogeneic 
priming approach.  
Previous studies have shown that in vitro allogeneic priming approaches enabling the 
access to the non-tolerant high-affinity allo-restricted T cell repertoire can be used as 
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efficient procedures to induce functional enhanced TCRs specific for different TAAs [80]–
[83]. Our research group established a protocol to isolate allo-restricted tumor antigen-
specific T cells using mDCs derived from healthy donors negative for the MHC molecule of 
interest as APCs [84]. Briefly, mDCs are transfected with in vitro transcribed RNA (ivtRNA) 
encoding the foreign MHC molecule together with ivtRNA encoding the full-length target 
antigen and used for stimulation and expansion of autologous T cells. This method is highly 
flexible since mDCs and T cells can be derived from any healthy donor who does not carry 
the MHC molecule selected as the allogeneic molecule, any known tumor antigen can be 
used as target and any allogeneic MHC molecule can be introduced into mDCs. Moreover, 
the use of ivtRNA encoding the full-length tumor antigen allows the potential isolation of T 
cells specific for any immunogenic peptides derived from the antigen of interest. Due to 
these advantages, this allogeneic priming protocol was selected for the isolation of NY-
ESO-1-specific HLA-A2-restricted T cells in this study. 
The HLA-A*02:01 allele was chosen as the restriction element since it is the most frequent 
MHC class I allele in Caucasian populations and it has already been used for in vitro 
primings to efficiently isolate T cells specific for different TAAs [85]. NY-ESO-1 was selected 
as the target antigen because it is one of the most promising and immunogenic CTA [86]–
[88]. Indeed, NY-ESO-1 is expressed in multiple tumor types like melanoma, synovial 
sarcoma, lung, esophageal, liver, gastric, prostate and ovarian tumors as well as adult T 
cell leukemia/lymphoma (ATLL), but it is not detectable in any healthy tissues except for 
testis. Moreover, natural humoral and cellular immune responses against NY-ESO-1 have 
been demonstrated in tumor patients [89], [90]. Due to these characteristics, NY-ESO-1 
has already been used as the target antigen in different immunotherapeutic strategies. 
Therapeutic vaccines have proved that NY-ESO-1 is safe for patients and also 
immunogenic, leading to both CD4+ and CD8+ T cell responses [91]. The adoptive transfer 
of T cells genetically engineered with an affinity-enhanced HLA-A2-restricted NY-ESO-1-
specific TCR in melanoma, synovial cell sarcoma and myeloma patients has shown 
promising results in terms of safety and efficacy [55]–[58]. To date, several epitopes 
presented on different MHC class I and II molecules and recognized by CD8+ and CD4+ T 
cells have been described for NY-ESO-1 [87]. Nevertheless, the peptide NY-ESO-1157-165 is 
the only immunogenic epitope in the context of HLA-A2 molecules identified so far. 
Importantly, to enable functional characterization as well as the isolation of individual TCR 
sequences after a priming procedure, the desired T cells need to be selectively separated 
as single-cell and expanded. To date, the most common strategy used for this purpose is 
based on pre-assembled peptide-loaded MHC molecules (multimers) [92]–[94]. With the 
knowledge of immunogenic epitopes and corresponding MHC alleles, T cells with the 
defined peptide specificity can be efficiently detected using multimers. However, certain 
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criteria limit the unrestricted use of multimer-based techniques. First, if presented epitopes 
of relevant candidate antigens are unknown, peptides for multimer production need to be 
selected by using epitope prediction tools. The complexity of the multi-step process leading 
to the formation of the peptide:MHC complex and the limited data regarding MHC-bound 
peptides, as well as the limited number of experimentally confirmed immunogenic epitopes, 
make the epitope prediction by algorithms challenging and often unreliable [95], [96]. 
Currently available software algorithms can fail to accurately predict epitopes that are 
naturally processed and presented on tumor cells and that can elicit T cell responses. 
Hence, multimers binding peptides that are not physiologically relevant in tumor cells could 
be generated leading to unsuccessful isolation of the desired T cells. Second, the 
availability of multimers is limited by insufficient peptide:MHC complex stability and by 
sequence-dependent difficulties in MHC protein folding for some HLA molecules. To 
overcome these limitations, alternative sorting methods have been established that are 
based on the analysis of e.g. cytokine secretion or surface molecule expression by T cells 
upon stimulation with APCs carrying the appropriate MHC restriction and target antigen 
[97]–[101]. Unlike the multimer-based approach, these methods allow the isolation of 
antigen-specific T cells irrespective of pre-defined specificity. Thus, they represent a 
powerful system to enable identification of T cells specific for previously unknown 
immunogenic peptides for a selected target antigen. However, the applicability of these 
alternative strategies in the context of an allogeneic priming approach is hampered by the 
high number of allo-restricted T cells that are reactive independently of the presence of the 
desired tumor target antigen within the priming culture. These unwanted allo-reactive T cells 
are indistinguishable from the desired tumor-reactive T cells using sorting methods based 
on either the expression of T cell activation markers or on cytokine release by T cells, 
limiting the efficiency of these sorting procedures. Improvements are needed to increase 
the success and the efficiency of these alternative sorting strategies. Thus, an additional 
aim of this project was to develop an innovative sorting strategy based on the T cell 
activation-induced marker CD137 in order to allow the isolation of the desired T cells 






Table 1. Equipment 
Product Source 
Balance Sartorius 
C-Chip Neubauer Improved Carl Roth 
Cell Analyzer LSRFortessaTM BD Bioscience 
Cell Sorter FACSAria FusionTM BD Bioscience 
Centrifuge 1-16K Sigma-Aldrich 
Centrifuge Heraeus X3R Thermo Fisher Scientific 
Chemical hood MC6® Waldner 
ChemiDoc™ XRS+ System Bio-Rad 
CoolCell® Cell Freezing Containers Biocision 
Cooling incubator with shaker (bacteria) Tritec 
Electrophoresis chamber and power supply Bio-Rad 
Electroporator Gene Pulser Xcell™ Bio-Rad 
Elix® water purification system Merck 
Freezer (-150°C, -80°C) Panasonic 
Freezer (-20°C) Liebherr 
Fridge (4°C) Liebherr 
Ice machine Scotsman AF103 Ice Flaker Hubbard Systems 
Incubator (human cells) Thermo Fisher Scientific 
IncuCyte ZOOM® device Essen BioScience 
Integral water purification system Milli-Q® Merck 
Irradiation device (Xstrahl RS225) Xstrahl 
MACS separator Miltenyi Biotec 
Magnet for cell separation applications  Thermo Fisher Scientific 
Micropipettes  Eppendorf 
Microscope Primovert Zeiss 
Microwave Bosch 
Multichannel pipettes Thermo Fisher Scientific 




Table 2. Consumables 
Product Source 
NanoDrop 2000 Thermo Fisher Scientific 
Pipettors Integra 
Sterile laminar flow hood  Thermo Fisher Scientific  
Thermocycler  Eppendorf 
Thermomixer  Eppendorf 
UV-transluminator Bachofer 
Vortex Scientific Industries 
Water bath VWR 
Product Source 
Conical tubes (15 ml, 50 ml, 200 ml) BD Falcon Corning 
Cryovials (1.8 ml) Thermo Fisher Scientific 
Electroporation cuvettes (0.4 cm, 0.1 cm) Bio-Rad 
Filter (0.2 µm, 0.45 µm) BD Falcon 
LS Column Miltenyi Biotec 
Needles Surflo® winged infusion sets BD Falcon Termuno 
Non-tissue culture plates (6-well, 24-well) Thermo Fisher Scientific 
Nunc-Immuno™ 96 Well Plate Thermo Fisher Scientific 
Nunclon™ Delta flasks  Thermo Fisher Scientific 
Parafilm® Pechiney Plastic Packaging 
Pasteur pipettes Copan 
Petri dishes  Thermo Fisher Scientific 
Pipettes (5 ml, 10 ml, 25 ml, 50 ml) Sigma-Aldrich 
Round bottom tubes (5 ml) BD Falcon Corning 
Snap-cap tubes (14 ml) BD Falcon 
Syringes (1 ml, 10 ml, 50 ml) BD Falcon 
TipOne® Filter Tips (1-10 µl, 10 -200 µl, 200-1000 µl) Star Lab 
Tips without filter (1-10 µl, 10 -200 µl, 200-1000 µl) Thermo Fisher Scientific 
Tissue culture flasks CellStar 
TPP® tissue culture plates  Sigma-Aldrich  
TPP® unit filter (250 ml, 500 ml) Sigma-Aldrich 
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2.3 Enzyme, cytokines, reagents 
Table 3. Restriction enzymes 
Product Source 
AgeI-HF® New England BioLabs 
EcoRI-HF® New England BioLabs 
NotI-HF® New England BioLabs 
SpeI-HF® New England BioLabs 
XbaI New England BioLabs 
HF®: high-fidelity restriction enzyme 
 
 
Table 4. Cytokines and TLR-ligands 
Product Source 
GM-CSF, human Berlex 
Interferon-γ (IFN-γ), human Boehringer Ingelheim 
Interleukin-15 (IL-15), human PeproTech 
Interleukin-1β (IL-1β), human R&D Systems 
Interleukin-2 (IL-2), human Novartis 
Interleukin-4 (IL-4), human R&D Systems 
Interleukin-6 (IL-6), human R&D Systems 
Interleukin-7 (IL-7), human PeproTech 
Prostaglandin E2 (PGE2) , human Sigma-Aldrich 




Tube with Cell Strainer Cap BD Falcon Corning 
Tubes (0.5 ml, 1.5 ml, 2 ml, 5 ml) Eppendorf 
Tubes with filter blue cap BD Falcon Corning 
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Table 5. Enzymes and reagents 
Product Source 
100 bp DNA Ladder Thermo Fischer Scientific 
1kb-plus DNA Ladder Thermo Fischer Scientific 
2-Mercaptoethanol Thermo Fischer Scientific 
2-Propanol Sigma-Aldrich 
Agarose Ultra Pure Thermo Fischer Scientific 
Ampicillin Merck 
Bovine serum albumin (BSA) Sigma-Aldrich 
Cyclosporin A (CSA) Sigma-Aldrich 
CutSmart Buffer® New England BioLabs 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich 
Dimethylsulfoxide (DMSO) Merck 
DNA gel loading buffer Thermo Fischer Scientific 
DNA primers Sigma-Aldrich 
Dulbecco's phosphate-buffered saline (DPBS) 1X 
without calcium and magnesium 
Thermo Fischer Scientific 
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fischer Scientific 
EDTA (0,5 M) Thermo Fischer Scientific 
Ethanol  Merck 
Ethidium bromide 0.025% Carl Roth 
FACS™ Flow and Rinse BD Bioscience 
FcR Blocking Reagent, human Miltenyi Biotec 
Fetal Bovine Serum (FBS) Thermo Fischer Scientific 
Ficoll® Biochrom 
Glucose 40% Braun 
Glycerol Merck 
Heparin-Natrium  Braun 
HEPES (1M) Thermo Fischer Scientific 
Human serum (HS) Medigene Immunotherpies GmbH 
Human serum albumin (HSA) Baxalta 
IncuCyte® Annexin V Red Reagent Essen Bioscience 
IncuCyte® NucLight Red Lentivirus Reagent Essen Bioscience 
Iscove's Modified Dulbecco's Medium (IMDM) Thermo Fischer Scientific 




Luria Broth Base (Miller's LB Broth Base) powder Thermo Fischer Scientific 
Minimum Essential Medium Non-Essential Amino 
Acids (MEM NEAA)  
Thermo Fischer Scientific 
OKT-3 (anti-CD3 antibody)  Helmholtz Zentrum München 
OptEIA™ TMB Substrate BD bioscience 
Paraformaldehyde solution (PFA) 4% Thermo Fischer Scientific 
PBS very low endotoxin (VLE) 1X 
without calcium and magnesium 
Biochrom 
Penicillin/Streptomycin Thermo Fischer Scientific 
Phosphoric acid 85% Merck 




RiboRuler™ High Range RNA Ladder Thermo Fischer Scientific 
RPMI 1640  Thermo Fischer Scientific 
RPMI 1640 very low endotoxin (VLE) Biochrom  
Select Agar Thermo Fischer Scientific 
Skim milk powder Sigma-Aldrich 
SOC Medium Thermo Fischer Scientific 
Sodium acetate (C2H3NaO2) Thermo Fischer Scientific 
Sodium bicarbonate (NaHCO3) Merck 
Sodium carbonate (Na2CO3) Sigma-Aldrich 
Sodium pyruvtae Thermo Fischer Scientific 
T4 DNA Ligase New England BioLabs 
T4 DNA Ligase Reaction Buffer New England BioLabs 
TAE 50X buffer (Tris Acetate EDTA) Thermo Fischer Scientific 
TransIT®-LT1 Transfection Reagent Mirus 
TRI-Reagent® Sigma-Aldrich 
Trypan blue solution 0.4% Thermo Fischer Scientific 
Trypsin-EDTA 0,05%  Thermo Fischer Scientific 





2.4 Commercial Analytic systems 
Table 6. Commercial Analytic systems 
Product Source 
Advantage® 2 PCR Kit Clontech 
CD8+ T cell Isolation Kit Miltenyi Biotec 
Dynabeads® Human T-Activator CD3/CD28 Thermo Fischer Scientific 
JETstar Plasmid Purification Kit (Maxi and Mini) Genomed 
mMESSAGE mMACHINE™ T7 Kit Thermo Fischer Scientific 
OptEIA™ Human IFN-γ ELISA Set BD Biosciences 
QIAquick® Gel Extraction Kit Qiagen 
RNeasy Mini Kit Qiagen 
SMARTer™ RACE cDNA Amplification Kit Clontech 
TMB Substrate Reagent Set BD Bioscience 
UltraComp eBeads® eBioscience 
2.5 Cell culture media 
Table 7. Cell culture media 
Medium Components Concentration 
DC medium 

































Luria Broth Base 
 
25 g/l 






Medium Components Concentration 





































* containing 1% Penicillin/Streptomycin when used for cell culture after sorting 
2.6 Buffers and solutions 
Table 8. Buffers and solutions 






ELISA blocking buffer 
DPBS 1X 
Skim milk powder 
 
1% 







ELISA stop solution 
dH2O 
Phosphoric acid 85% 
93.2 ml 
6.8 ml 
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2.7 Cell lines, primary cells and bacteria 












transformed with the 































T2 Lymphoblast  







Table 10. Human tumor cell lines 





AMO-1 Ascitic fluid Plasmacytoma 
Suspension 
RPMI IV 20 
ATCC 
EJM Peritoneal fluid  Multiple myeloma 
Adherent/ 
suspension 
IMDM IV 20 
DSMZ 




























KMS-12-BM Bone marrow  Multiple myeloma 
Suspension 
RPMI IV 20 
ATCC 
KMS-12-PE Peripheral blood  Multiple myeloma 
Suspension 









Mel624.38 Skin Melanoma 
Adherent 
RPMI IV 
M. Panelli NCI 
















MOLP-8 Peripheral blood Multiple myeloma 
Suspension 




































CD8+ T cells 
Derived from either PBMC or 
PBL of healthy donors by MACS 
enrichment  
Suspension 
T cell medium 
Longinotti G. 
Clone 10/24 
CD8+ T cell clone HLA-A2-
restricted HA-1H-specific 
Suspension 
T cell medium 
Sommermeyer D. 
Clone 234 
CD4+ T cell clone HLA-A24-
reactive 
Suspension 
T cell medium 
Schendel D. 
DCs 
Derived from monocytes of a 





Derived from PBMC of healthy 
donors by monocyte plate 
adherence 
Suspension 
T cell medium 
Longinotti G. 
PBMC 
Derived from human peripheral 
blood of healthy donors by 
density gradient centrifugation 
Suspension 






Table 12. Bacteria 






F' proA+B+ lacIq ∆lacZM15/ 
fhuA2  ∆(lac-proAB)  glnV galK16 
galE15  R(zgb-210::Tn10)TetS  









F- mcrA Δ( mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 
Δ lacX74 recA1 araD139 
Δ( araleu)7697 galU galK rpsL 








recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIq 
Z∆M15 Tn10 (Tetr) 
Agilent 
Technologies 
2.8 Plasmids, primers, probes 
Table 13. Plasmids characteristics 
Name Characteristics Source 
pES12.6 
 
Retroviral self-inactivating (SIN) vector for transduction 
Elongation factor 1-α (EF1α) internal promoter, 
cytomegalovirus (CMV) enhancer, 5’ LTR of moloney 
murine leukemia virus (MoMuLV), psi/psi+ packaging 
signal of MoMuLV, woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE), self-
inactivating (SIN) 3’ long terminal repeat (LTR) of 











Plasmid for ivtRNA production 




Retroviral vector for transduction [102] 
Myeloproliferative sarcoma virus (MPSV)-LTR promoter-
enhancer sequences and improved UTR derived from 
the murine embryonic stem cell virus (MESV), MCS, 







Table 14. Plasmid generated in this project 
Name Cloning strategy* 
pGEM_NY-ESO-1  Traditional cloning 
pGEM_NY-ESO-1-pco  Traditional cloning  
pGEM_NY-ESO-1-ORF2  Seamless cloning  
pGEM_NY-ESO-1-ORF3  Seamless cloning  
pGEM_NY-ESO-1-ORF4  Seamless cloning  
pGEM_NY-ESO-1-ORF2_1-20 aa_eGFP  Seamless cloning  
pGEM_NY-ESO-1-ORF2_11-30 aa_eGFP  Seamless cloning  
pGEM_NY-ESO-1-ORF2_21-40 aa_eGFP  Seamless cloning  
pGEM_NY-ESO-1-ORF2_31-50 aa_eGFP  Seamless cloning  
pGEM_NY-ESO-1-ORF2_41-58 aa_eGFP  Seamless cloning  
pGEM_LAGE-1a  Traditional cloning  
pGEM_LAGE-1a-pco  Traditional cloning  
pGEM_CAMEL  Seamless cloning  
pGEM_TCR 1G4-α95:LY  Traditional cloning  
pGEM_TCR 5-271  Traditional cloning  
pES12.6_TCR 1G4-α95:LY Traditional cloning  
pES12.6_TCR 5-271 Traditional cloning  
*Cloning strategies are described in section 3.4.5 
 
 
Table 15. Plasmids kindly provided by collaborators 
Name Source 
pMP71_HLA-A*02:01 Wehner C. 
pGEM_HLA-A*02:01 Wehner C. 
pMP71_CD86 Milosevic S. 
pGEM_HA-1H Sommermeyer D. 






Table 16. Plasmids for retroviral transduction 
Name Characteristics Source 
pALF _env 10A1 
cDNA encoding the envelope derived 




cDNA encoding envelope derived 






cDNA encoding gag/pol polyprotein 




Table 17. Primers RACE-PCR 
Primer Sequence 5’ – 3’ 
5’ TRAC CGGCCACTTTCAGGAGGAGGATTCGGAAC 
5’ TRBC CCGTAGAACTGGACTTGACAGCGGAAGTGG 
5’ nTRAC CCACAGCACTGTTGCTCTTGAAGTC 
5’ nTRBC GCTCAGGCAGTATCTGGAGTCATTGA 
 
 
Table 18. Primers sequencing 
Primer Sequence 5’ – 3’ 
pGEM FW TATTACGACTCACTATAGGG 
pMP71 FW GCTCCGCCACTGTCCGAG 
pES12.6 FW CGCAACGGGTTTGCCGCCA 
P2A FW CTGCTGAAACAGGCCGGCG 
5’ TRAC CGGCCACTTTCAGGAGGAGGATTCGGAAC 
5’ TRBC CCGTAGAACTGGACTTGACAGCGGAAGTGG 
 
 
Table 19. Probes nanostring nCounter 

















2.9 TCR sequences 
Table 20. TCR 1G4-α95:LY 
 V region J region  CDR3  
TCRα chain TRAV21*01 TRAJ6*01 CAVRPLYGGSYIPTF 
TCRβ chain TRBV6-5*01 TRBJ2-2*01 CASSYVGNTGELF 
HLA-A2-restricted NY-ESO-1/LAGE-1a157-165-specific TCR. 
Sequence derived from patent WO 2005/113595 A2. 
 
 
Table 21. TCR 5-271 
 V region J region  CDR3  
TCRα chain TRAV21*01 TRAJ6*01 CAVSPQWGGSYIPTF 
TCRβ chain TRBV6-5*01 TRBJ2-7*01 CASSYLRGGGYEQYF 
HLA-A2-restricted NY-ESO-1-ORF2/CAMEL11-18-specific TCR. 
Sequence identified in this project. 
 
The variable and junctional gene segments are indicated in IMGT nomenclature. TRAV, TCR alpha 
variable segment; TRAJ, TCR alpha joining segment; TRBV, TCR beta variable segment; TRBJ, 
TCR beta joining segment.  
2.10  Peptides 
Table 22. Peptides 
Sequence (aa) X-mer Antigen/protein Position Source 
MLMAQEALAFLM 12 NY-ESO-1-ORF2 1-12 Peps4LS GmbH 
MLMAQEALAFL 11 NY-ESO-1-ORF2 1-11 Peps4LS GmbH 
MLMAQEALA 9 NY-ESO-1-ORF2 1-9 Peps4LS GmbH 
MLMAQEAL 8 NY-ESO-1-ORF2 1-8 Peps4LS GmbH 
LMAQEALAFL 10 NY-ESO-1-ORF2 2-11 Peps4LS GmbH 
FLMAQGAMLAA 11 NY-ESO-1-ORF2 10-20 Peps4LS GmbH 
FLMAQGAMLA 10 NY-ESO-1-ORF2 10-19 Peps4LS GmbH 
FLMAQGAML 9 NY-ESO-1-ORF2 10-28 Peps4LS GmbH 
FLMAQGAM 8 NY-ESO-1-ORF2 10-17 Peps4LS GmbH 
LMAQGAML 8 NY-ESO-1-ORF2 11-18 Peps4LS GmbH 
LMAQGAMLAA 10 NY-ESO-1-ORF2 11-20 Peps4LS GmbH 
ALAFLMAQGAML 12 NY-ESO-1-ORF2 7-18 Peps4LS GmbH 
AQGAMLAA 8 NY-ESO-1-ORF2 13-20 Peps4LS GmbH 
MAQGAMLAA 9 NY-ESO-1-ORF2 12-20 Peps4LS GmbH 
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Sequence (aa) X-mer Antigen/protein Position Source 
GLAFLMAQGAML 12 NY-ESO-1-ORF2 7-18 (F7G) Peps4LS GmbH 
AAAFLMAQGAML 12 NY-ESO-1-ORF2 7-18 (L8A) Peps4LS GmbH 
ALGFLMAQGAML 12 NY-ESO-1-ORF2 7-18 (A9G) Peps4LS GmbH 
ALAALMAQGAML 12 NY-ESO-1-ORF2 7-18 (F10A) Peps4LS GmbH 
ALAFAMAQGAML 12 NY-ESO-1-ORF2 7-18 (L11A) Peps4LS GmbH 
ALAFLAAQGAML 12 NY-ESO-1-ORF2 7-18 (M12A) Peps4LS GmbH 
ALAFLMGQGAML 12 NY-ESO-1-ORF2 7-18 (A13G) Peps4LS GmbH 
ALAFLMAAGAML 12 NY-ESO-1-ORF2 7-18 (Q14A) Peps4LS GmbH 
ALAFLMAQAAML 12 NY-ESO-1-ORF2 7-18 (G15A) Peps4LS GmbH 
ALAFLMAQGGML 12 NY-ESO-1-ORF2 7-18 (A16G) Peps4LS GmbH 
ALAFLMAQGAAL 12 NY-ESO-1-ORF2 7-18 (M17A) Peps4LS GmbH 
ALAFLMAQGAMA 12 NY-ESO-1-ORF2 7-18 (L18A) Peps4LS GmbH 
ALMAQGAMLAA 11 NY-ESO-1-ORF2 10-20 (F10A) Peps4LS GmbH 
FAMAQGAMLAA 11 NY-ESO-1-ORF2 10-20 (L11A) Peps4LS GmbH 
FLAAQGAMLAA 11 NY-ESO-1-ORF2 10-20 (M12A) Peps4LS GmbH 
FLMGQGAMLAA 11 NY-ESO-1-ORF2 10-20 (A13G) Peps4LS GmbH 
FLMAAGAMLAA 11 NY-ESO-1-ORF2 10-20 (Q14A) Peps4LS GmbH 
FLMAQAAMLAA 11 NY-ESO-1-ORF2 10-20 (G15A) Peps4LS GmbH 
FLMAQGGMLAA 11 NY-ESO-1-ORF2 10-20 (A16G) Peps4LS GmbH 
FLMAQGAALAA 11 NY-ESO-1-ORF2 10-20 (M17A) Peps4LS GmbH 
FLMAQGAMAAA 11 NY-ESO-1-ORF2 10-20 (A18G) Peps4LS GmbH 
FLMAQGAMLGA 11 NY-ESO-1-ORF2 10-20 (A19G) Peps4LS GmbH 
FLMAQGAMLAG 11 NY-ESO-1-ORF2 10-20 (A20G) Peps4LS GmbH 
ALMAQGAML 9 NY-ESO-1-ORF2 10-18 (F10A) Peps4LS GmbH 
FAMAQGAML 9 NY-ESO-1-ORF2 10-18 (L11A) Peps4LS GmbH 
FLAAQGAML 9 NY-ESO-1-ORF2 10-18 (M12A) Peps4LS GmbH 
FLMGQGAML 9 NY-ESO-1-ORF2 10-18 (A13G) Peps4LS GmbH 
FLMAAGAML 9 NY-ESO-1-ORF2 10-18 (Q14A) Peps4LS GmbH 
FLMAQAAML 9 NY-ESO-1-ORF2 10-18 (G15A) Peps4LS GmbH 
FLMAQGGML 9 NY-ESO-1-ORF2 10-18 (A16G) Peps4LS GmbH 
FLMAQGAAL 9 NY-ESO-1-ORF2 10-18 (M17A) Peps4LS GmbH 
FLMAQGAMA 9 NY-ESO-1-ORF2 10-18 (L18A) Peps4LS GmbH 
SLLMWITQV 9 NY-ESO-1 157-165 ProteoGenix 
KVLEYVIKV 9 MAGE-A1 278-286 ProteoGenix 
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2.11  Antibodies 
Table 23. Antibodies 
Sequence (aa) X-mer Antigen/protein Position Source 
YMDGTMSQV 9 Tyrosinase 369-377 Peps4LS GmbH 
VLHDDLLEA 9 HA-1H 137-145 (H139) ProteoGenix 





Isotype Clone Source 
CD4 APC Mouse IgG1κ RPA-T4 BD 
CD8 PB Mouse IgG1κ RPA-T8 BD 
CD137 PE Mouse BALB/c IgG1κ 4B4-1 BD 
CD86 FITC Mouse BALB/c IgG1κ 2331(FUN-1) BD 
HLA-A2 APC Mouse IgG2b, κ BB7.2 BD 
CD4 FITC  Mouse BALB/c IgG1κ SK3 BD 
CD3 PercP  Mouse BALB/c IgG1κ SK7 BD 
CD56 PE Mouse IgG1κ CMSSB eBioscience 
CD80 APC-Cy7 Mouse C3H/Bi IgG1κ L307.4 BD 
CD19 PE-Cy7 Mouse IgG1κ HIB19 eBioscience 
CD3 BUV Mouse IgG1κ UCHT1 BD 
CD14 PB Mouse IgG2a M5E2 BD 
CD83 APC Mouse IgG1κ HB15e BD 
CD86 Alexa700 Mouse BALB/c IgG1κ 2331(FUN-1) BD 
CCR7 PE-vio770 Recombinant human IgG1 REA108 MiltenyiBiotec 
HLA-DR PercP Mouse BALB/c IgG2a κ L243 BD 
CD274 FITC Mouse IgG1κ MIH1 BD 
TRBV6-5 PE Mouse IgG2b IMMU222 Beckman Coulter 
*Anti-human     
     
     




Table 24. Softwares 
Task Software/online tool 
Cloning simulation Clone Manager 
Data analyses 
Microsoft Excel 
Graph Pad Prism 









2.13  Collaborators 
Table 25. Collaborators 
Name Company/Institute 
Milosevic S. Medigene Immunotherapies GmbH, Germany 
Moosmann A. Helmholtz Zentrum München, Germany 
Schendel D. Medigene Immunotherapies GmbH, Germany 
Sommermeyer D. Medigene Immunotherapies GmbH, Germany 
Uckert W. Max Delbrück Center, Berlin, Germany 
Wehner C. Medigene Immunotherapies GmbH, Germany 
- BioNTech Innovative Manufacturing Services, Germany 
- Medigene Immunotherapies GmbH, Germany 






3.1 Cell-biological methods 
To avoid contamination with bacteria, fungi or other organisms, cell cultures were 
performed under sterile conditions and sterile material, solutions and media were used. 
Cells were grown in incubators at 37°C, 6.5% CO2 and 95% humidity in laboratories of S2 
standard. 
3.1.1 Cell counting 
Cell numbers were determined using Neubauer counting chambers. Trypan blue staining 
was used to allow discrimination of viable and dead cells. Trypan blue is not taken up by 
viable cell, but passes the cell membrane of dead cells. An aliquot of the cell suspension 
(10µl) was diluted with trypan blue at a ratio of either 1:2 for samples at low cell 
concentration or 1:10 for samples at high cell concentration. Using an inverted microscope, 
the number of viable cells (unstained with trypan blue) in the four big quadrants was 
counted. The following formula was applied to determine the cell concentration per ml: cell 
number/ml = mean of cells counted in four big quadrants x dilution factor x chamber factor 
(104). 
3.1.2 Cryopreservation of cells 
Cells were collected and centrifuged at 350 g for 5 minutes at room temperature. Cell pellets 
were re-suspended in ice-cold cell freezing medium and frozen in 1 ml aliquots in cryovials. 
Peripheral blood mononuclear cells (PBMC) and peripheral blood lymphocytes (PBL) were 
frozen at the cell concentration of 5×107 cell/ml, while all the other cells were frozen at cell 
concentrations ranging between 4×106 and 1×107 cell/ml. Cryovials were placed into 
CoolCell® Cell Freezing Containers and stored at -80°C overnight. The following day, the 
cryovials were transferred into a -150°C freezer for long-term storage. 
3.1.3 Cell thawing 
Cryovials containing frozen cells were thawed at room temperature. The suspension of 
each cryovial was transferred to a 15 ml tube containing 10 ml of RPMI VI medium and 
centrifuged at 350 g for five minutes at room temperature. The supernatant was discarded 
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and cell pellet resuspended in the appropriate pre-warmed medium. Cells were counted 
and used for the required applications. 
3.1.4 Cultivation of adherent cell lines 
Adherent cell lines were cultivated in T25 - T75 cm2 tissue culture flasks adding 10 - 25 ml 
of appropriate medium. Approximately every three to four days, confluent cells were 
passaged either 1:5 or 1:10 depending on the growth rate of the cell line by detaching 
adherent cells with trypsin/EDTA. Therefore, the medium was removed, cells were washed 
once with 10 ml of warm DPBS and then incubated with 1 - 3 ml of trypsin/EDTA for three 
minutes at 37°C. Fresh medium was added into the flask to inactivate trypsin. The desired 
number of detached cells was resuspended in fresh medium to a final volume of 10 - 25 ml 
and distributed in new tissue culture flasks 
3.1.5 Cultivation of suspension cell lines 
Suspension cell lines were cultivated in T25 - T75 cm2 tissue culture flasks adding 15 - 50 
ml of the appropriate medium. Approximately every three to four days, cells were passaged 
1:3 or 1:5 depending on the growth rate of the cell line and fresh medium was added. 
3.1.6 Cell irradiation 
Cells were counted and resuspended at 3 x 106 cells/ml in the appropriate medium. 
According to the total number of cells and the corresponding total volume of medium, cells 
were seeded into either tissue culture plates or flasks (table 26). After sealing the vessel 
with Parafilm®, cells were placed into the RS225 irradiation device. For each cell type, 
irradiation was performed according to the specific protocol shown in table 27.  







 Cell type Gray 
(Gy) 
24-well  1 ml T25 12.5 ml  K562 cells 100 
12-well 2 ml T75 37.5 ml  LCL 100 
6-well  5 ml T150 50 ml  LAZ 388 100 





3.1.7 T cell clone stimulation and expansion 
The CD8+ T cell clone 10/24 and CD4+ T cell clone 234 were (re-)stimulated and expanded 
according to the following protocols. 
The CD8+ T cell clone 10/24 was seeded in a 24-well tissue culture plate (1 x 106 cells/well) 
and mixed with an irradiated PBL pool composed of cells of several donors (1 x 106 
cells/well) as well as with irradiated HLA-A2-positive LCL P8 that were loaded with the 
peptide recognized by the clone 10/24 (1 x 105 cells/well). The final volume per well was 2 
ml of T cell medium containing IL-2 (50 IU/ml). Either phytohemagglutinin (PHA 250 ng/ml) 
or anti-CD3 antibody (OKT-3, 30 ng/ml) was added to the medium. PHA was removed from 
T cell culture after four days due to its toxicity. 
The CD4+ T cell clone 234 was seeded in 24-well tissue culture plates (1 x 106 cells/well) 
and mixed with irradiated HLA-A24-positive LCL BW (3 x 105 cells/well) in T cell medium 
containing IL-2 (50 IU/ml) (2 ml final volume/well). 
For both clones, half of the medium was substituted with fresh T cell medium containing IL-
2 (50 IU/ml) every two days. When cells were confluent, they were split either in a ratio of 
1:2 or 1:3 and fresh T cell medium containing IL-2 (50 IU/ml) was added. T cell clones were 
restimulated every 2 weeks.  
3.1.8 Isolation of human PBMC  
Fresh blood from healthy donors was collected after informed consent. PBMC were isolated 
from blood samples by density gradient centrifugation using a separating solution 
containing the synthetic copolymer Ficoll®. Syringes for collecting blood were supplemented 
with 10 IU heparin-sodium/ml of blood. Blood samples were diluted 1:2 with PBS VLE and 
35 ml of diluted blood were layered over 15 ml Ficoll® in 50 ml tubes. After centrifugation at 
840 x g for 18 minutes without brake, 15 ml of the upper phase were removed and the 
centrifugation step was repeated. PBMC located in the interphase between plasma and 
Ficoll® were collected and transferred in new 50 ml tubes (two interphases/50 ml tube). PBS 
VLE was added to each tube to a final volume of 50 ml. Tubes were centrifuged at 470 x g 
for ten minutes with brake. Supernatants were discarded and cell pellets were mixed (two 
cell pellets/50 ml tube) and resuspended in PBS VLE to a final volume of 50 ml. Tubes were 
centrifuged at 470 x g for ten minutes with brake. Supernatants were discarded and cell 
pellets were mixed (two cell pellets/50 ml tube) and resuspended in PBS VLE with 0.5% 
human serum to a final volume of 40 ml. After centrifugation at 130 x g for 15 minutes 
without brake, the step was repeated. The final cell pellet was resuspended in T cell 
medium, counted and used freshly in experiments or frozen for long-term storage. 
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3.1.9 Generation of lymphoblastoid cell lines  
The immortalization of human B cells can be achieved in vitro by infection with Epstein-
Barr-Virus (EBV) which can lead to a transformation of these cells [103]. The lines 
generated by EBV infection of B cells are called lymphoblastoid cell lines (LCL). For this 
project, LCL were generated starting from PBMC derived from a HLA-A2-positive healthy 
donor (see section 3.1.8 for PBMC isolation). The infection was performed using the B95.8 
EBV virion-containing supernatant kindly provided by Dr. Moosmann. Freshy isolated 
PBMC were seeded into a 96-well flat-bottom plate at 5 x 105 cells per well in 100 µl of 
RPMI IV medium containing 1 µg/ml of cyclosporin A (CSA). B95.8 EBV virion-containing 
supernatant was added to each well (100 µl/well). Only RPMI IV medium containing 1 µg/ml 
of CSA was added into the negative control wells (100 µl/well). The plate was incubated at 
37°C overnight. The following day, half of the medium of each well (100 µl) was exchanged 
by fresh RPMI IV medium containing CSA (1 µg/ml). The plate was kept in the incubator for 
the following days. The procedure was repeated every four days.  About two or three weeks 
after infection, each well was inspected for outgrowth of LCL showing spherical aggregates 
compared to negative control wells. Within the following six weeks, LCL were expanded 
and finally analyzed by flow cytometry for their purity and quality (staining for B cell marker 
CD19, T cell marker CD3 and live/dead staining). 
3.1.10 Generation of mDCs 
To stimulate and expand HLA-A2-allo-restricted NY-ESO-1-specific T cells, mDCs were 
used as APCs during the priming procedure. Therefore, mDCs were generated in vitro using 
an 8-day protocol and the Jonuleit maturation cocktail [104]. Monocytes were derived from 
freshly isolated PBMC by plastic adherence. Hence, PBMC were isolated from a healthy 
HLA-A2-negative donor as previously described (see section 3.1.8). Subsequently, 75 x 
106 PBMC were resuspended in 15 ml of DC medium and transferred into an 80cm2 
Nunclon® Δ surface cell culture flask. After 25 minutes of incubation at 37°C, the flask was 
gently shaken and incubated for additional 25 minutes at 37°C. Non-adherent cells were 
carefully washed away by two washing steps using 15 ml of fresh DC medium. These non-
adherent cells represented the ‘PBL fraction’. PBL were collected and frozen for other 
applications. Adherent monocytes were kept in culture overnight adding 15 ml of DC 
medium into the flask. In order to mature immature DCs (iDCs), on the following day (day 
1) as well as after three days (day 3), 100 ng/ml GM-CSF and 20 ng/ml IL-4 were added to 
the cells. Finally, on day 6, the Jonuleit maturation cocktail was added (table 28). mDCs 
were harvest on day 8 and used for further experiments. The quality and the purity of the 
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generated mDCs was evaluated by analyzing the surface expression of typical DC 
maturation markers by flow cytometry (see section 3.2.1 for staining of cell surface marker). 
Table 28. Jonuleit maturation cocktail 
Components Amount  
GM-CSF 100 ng/ml 
IL-4 20 ng/ml 
IL-1β 10 ng/ml 
IL-6 15 ng/ml 
TNF-α 10 ng/ml 
PGE2 1000 ng/ml 
3.1.11 ivtRNA electroporation into APCs 
APCs were harvested, counted and washed once with RPMI1640 medium without serum 
(VLE RPMI 1640 in case of mDCs). Cell were adjusted at 2 – 3 × 106 cells/200 µl in 
RPMI1640 medium without serum (VLE RPMI 1640 in case of mDCs) and 200 µl of the cell 
suspension were transferred into a 0.4 cm pre-cooled electroporation cuvette. 
Subsequently, either 20 µg of ivtRNA or 20 µl of water (negative control) were added into 
the cuvette (see section 3.4.10 for ivtRNA production). The suspension was shortly mixed 
by pipetting and then quickly electroporated using the Gene Pulser Xcell™ device. 
Electroporation for each cell type was performed according to the specific conditions shown 
in table 29. Immediately after electroporation, cells were transferred into the appropriate 
fresh medium and placed into the incubator. After three hours, cells were counted and 
resuspended at the adequate concentrations for further applications. 
Table 29. Electroporation conditions 
Cell type Protocol Voltage (volt) Capacitance (µF)  Time 
mDCs Exponential 150 150 ∞ 
K562 cells  Exponential 300 300 ∞ 
Tumor cell lines Exponential 300 150 ∞ 
T cells Time constant 400 - 5ms 
3.1.12 Loading of T2 cells with small synthetic peptides 
T2 cells were harvested, counted and adjusted to 1 x 106 cells/ml using appropriate medium 
in a 15 ml tube. Subsequently, the required amount of peptide was added to the cells. T2 
cells were loaded with either 10-5 M or with titrated amounts (ranging from 10-5 M to 10-12 
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M) of the peptide of interest. Cells were incubated for 1h and 30 minutes at 37°C. After 
incubation, the appropriate medium was added to a final volume of 15 ml. Cells were 
centrifuged (350 x g for five minutes) and the supernatant was discarded to remove 
unbound peptides. Cells were resuspended in fresh medium at the required concentration 
for the subsequent applications. 
3.1.13 Isolation of CD8+ T cells 
CD8+ T cells were enriched starting either from PBMC or from PBL by the MACS® 
technology. The CD8+ T cell Isolation kit was selected as means to isolate untouched CD8+ 
T cells, avoiding direct labeling of CD8+ T cell surface molecules that could interfere with 
subsequent applications. The MACS separation was performed according to the 
manufacturer’s protocol. Either PBMC or PBL were counted and resuspended in 40 µl of 
DPBS - 0.5% human serum per 1 x 107 total cells into a 15 ml tube. A biotin-antibody cocktail 
was added to the cells (10 µl per 1 x 107 total cells) and well mixed in order to label CD8-
negative cells. After incubation of five minutes at 4°C, 30 µl of DPBS - 0.5% human serum 
and 20 µl of anti-biotin MicroBeads per 1 x 107 total cells were added into the tube. The 
reaction mix was incubated for ten minutes at 4°C. Meanwhile, LS columns were placed 
into the magnetic MACS separator and rinsed with 3 ml of DPBS - 0.5% human serum. 
Subsequently, the cell suspension was applied to LS columns. The flow-through containing 
unlabeled cells represented the enriched CD8+ T cells that were collected into 50 ml tubes. 
LS columns were washed with 3 ml of DPBS - 0.5% human serum and the flow-through 
was mixed with the previously collected cells. Enriched CD8+ T cells were counted and 
resuspended in T cell medium at the required cell concentration for stimulation. Samples 
before and after enrichment were analyzed by flow cytometry to evaluate the purity of the 
enriched cell population and the efficiency of the separation process. 
3.1.14 Stimulation and expansion of T cells 
PBL and CD8-enriched T cells were (re-)stimulated and expanded using Dynabeads® 
Human T-Activator CD3/CD28. T cells were seeded at 1 x 106 cells/ml in a 24-well tissue 
culture plate in T cell medium with 50 U/ml IL-2. Dynabeads® were resuspended and the 
desired volume was transferred to a 15 ml tube (25 µl Dynabeads®/1 x 106 T cells). An 
equal volume of DPBS with 0.1 % human serum or at least 1 ml was added. After mixing, 
the tube was placed on a magnet for one minute and the supernatant was discarded. The 
tube was removed from the magnet and the washed Dynabeads® were resuspended in T 
cell medium. The washed Dynabeads® were added to the T cells and the plate was placed 
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into the incubator. After three or four days, Dynabeads® were removed from the culture. 
Therefore, T cells were transferred in a 15 ml tube and the tube was placed on the magnet 
for two minutes. The supernatant containing the cells was collected in a new tube. The 
remaining Dynabeads® were washed with fresh T cell medium and the procedure on the 
magnet was repeated. T cells were counted and placed into either a suitable tissue culture 
plate or into a tissue culture flask at 5 x 105 cells/ml. T cells were passaged 1:2 or 1:3 and 
fresh T cell medium containing IL-2 (50 IU/ml) was added every two days. Restimulation of 
the cells was performed every 2 weeks. 
3.1.15 De novo induction of CD8+ T cells using ivtRNA-transfected mDCs 
mDCs generated in vitro from an HLA-A2-negative donor were electroporated 
simultaneously with ivtRNA encoding the foreign HLA-A2 molecule and the full-length NY-
ESO-1 antigen (20 µg each ivtRNA) to utilize them as APCs for stimulation and expansion 
of autologous CD8-enriched T cells. As control, ivtRNA encoding full-length eGFP was 
transfected in combination with HLA-A2 ivtRNA into mDCs (20 µg each ivtRNA). 
Electroporation was performed as described in section 3.1.11. The expression of HLA-A2 
molecules and eGFP was evaluated by flow cytometry 3h after electroporation. On the 
same day, autologous CD8+ T cells were enriched from freshly isolated PBMC according to 
the protocol described in section 3.1.13. Co-cultures were initiated 3h after electroporation 
in 24-well tissue culture plates. The cells were seeded at an effector to target ratio of 10:1 
(1 x 106 CD8+ T cells and 1 x 105 mDCs) in T cell medium containing 5 ng/ml IL-7. Addition 
of IL-2 (50 IU/ml) was delayed for two days and then added every two days. Cells were 
expanded for 14 days and subsequently NY-ESO-1-specific T cells were selectively 
separated using the double sorting strategy (see section 3.2.2.2). 
3.1.16 Stimulation and expansion of single-cell-sorted T cells 
Single-cell-sorted T cells were stimulated immediately after the double-sorting procedure. 
Anti-CD3 antibody (30 ng/ml OKT-3), 1 x 104 irradiated LAZ 388 cells and 1 x 105 irradiated 
PBL pooled from different donors were added to each well. The final volume per well was 
200 µl of T cell medium supplemented with 50 IU/ml IL-2. After 14 days, plates were 
screened for expanded clones. The expanded clones were tested in the first screening for 
antigen specificity. Moreover, a fraction of the cells was resuspended in TRI Reagent® for 
subsequent TCR sequence analysis. A fraction of the cells was restimulated for further 
expansion according to standard CD8+ T cell clone stimulation and expansion. 
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3.1.17 Plasmid-DNA transfection into 293FT cells for retrovirus production 
Retroviruses needed for subsequent retroviral-mediated transduction were produced by 
triple plasmid DNA transfection of the packaging 293FT cells. The transgene-encoding DNA 
retroviral vector and the plasmids encoding the gag/pol and the env viral genes were 
introduced into the packaging cells using the TransIT®-LT1 transfection reagent. Therefore, 
293FT cells were seeded at 1.5 x 106 cells per 100 mm petri dish in 10 ml DMEM IV medium 
and placed into the incubator overnight. The following day, 470 µl of DMEM medium without 
serum were mixed with 30 µl of TransIT®-LT1 transfection reagent and incubated for five 
minutes at room temperature. Subsequently, plasmid DNA was added to the transfection 
mixture (see table 30). The transfection mix was incubated for 15 minutes at room 
temperature. The medium of the seeded 293FT cells was replaced by RPMI IV and the 
transfection mix was added dropwise to the 293FT cells. Petri dishes were incubated at 
37°C. After three days, the virus-containing medium was harvested and centrifuged at 200 
g for 10 minutes at 32°C. The retroviral supernatant was either used freshly or frozen at -
80°C for long-term storage. 
Table 30. Amount of plasmid DNA for transfection of 293FT cells 




3.1.18 Retroviral-mediated transduction 
Retroviral-mediated transduction of T cells and K562 cells was performed using a 
RetroNectin® reagent to co-localize the virus with the cells in order to enhance the viral 
transduction efficiency. Transduction was done in two subsequent rounds (infection hits). 
Therefore, non-tissue culture treated 24-well plates were coated with 10 µg/ml RetroNectin® 
in 1ml DPBS per well. Plates for the first and the second infection hit were prepared in 
parallel. Plates were sealed with Parafilm® and kept at 4°C until the next day. The following 
day, RetroNectin® was replaced with DPBS containing 2% BSA. After incubation for 30 
minutes at room temperature, the solution was removed from each well. Retroviral 
supernatant (either frozen or fresh, see section 3.1.17) was added to the RetroNectin®-
coated plates (1 ml/well). If two different retroviral supernatants were used for simultaneous 
transduction, 1 ml of each retroviral supernatant was added into the well (final volume per 
well 2 ml). As negative control, only RPMI VI medium was added into RetroNectin®-coated 
wells. Plates were sealed with Parafilm® and centrifuged for 90 minutes at 3200 g at 32°C. 
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After centrifugation, the plate for the second infection hit was stored at 4°C until the next 
day. In contrast, supernatants were removed from the plate for the first infection hit and 
cells in proliferating phase were seeded into the retrovirus-coated wells (0.5 - 1 x 106 T 
cells/well in 1 ml of T cell medium with 50 IU/ml IL-2, 0.3 – 0.5 x 106 K562 cells/well in 1 ml 
of RPMI IV medium). Cells were also seeded into the negative-control wells. These cells 
were designated as untransduced cells. The plate was incubated at 37°C. The following 
day, supernatants were removed from the plate for the second infection hit. Cells were 
transferred from the plate for the first infection hit to the plate for the second infection hit. 
Fresh T cell medium was added to the cells (1 ml/well).  After three or four days, cells were 
harvested and seeded at an adequate cell concentration (0.5 x 106 T cells/ml; 0.3 x 106 
K562 cells/ml) either into tissue culture plates or into cell culture flasks in fresh medium 
(containing 50 IU/ml IL-2 in case of T cells). Transduction rate was verified by flow 
cytometry, evaluating the surface expression of the introduced molecules. After adequate 
expansion, cells were harvested, counted and used for further applications.   
3.1.19 Lentiviral-mediated transduction 
IncuCyte® NucLight Lentivirus Reagent was used for nuclear labelling of T2 cells by 
homogenous expression of the mKate2 protein (red fluorescent protein). This reagent 
enabled the generation of stable transduced cell populations using puromycin selection. T2 
cells were collected, counted and resuspended at 2 x 105 cells/ml in fresh RPMI IV medium. 
Subsequently, 500 µl of cell suspension were transferred into a 1.5 ml tube. Polybrene (8 
µg/ml) and IncuCyte® NucLight Lentivirus Reagent (multiplicity of infection, MOI 3) were 
added to the cells. The volume of lentiviral supernatant corresponding to MOI 3 was 
calculated according to the virus titer listed in the manufacturer’s datasheet. The sample 
was incubated for 1h at 37°C and then centrifuged at 400 g for 1h at room temperature. 
The pellet was resuspended in 2 - 3 ml of fresh RPMI IV medium. Cells were transferred 
into a 6-well tissue culture plate and placed into the IncuCyte® ZOOM device to monitor the 
fluorescence expression. Puromycin (1 µg/ml) was added to the plate to select the 
transduced cells five days after transduction. Red-labelled T2 cells were expanded and kept 
in culture in RPMI IV medium containing 0.5 µg/ml puromycin. Before performing the 




3.2 Flow cytometry 
3.2.1 Staining of cell surface markers 
For each staining condition 0.2 – 1 x 106 cells were transferred into a 5 ml tube. In case of 
DC staining, FcR blocking reagent was added to the samples prior the staining to block 
unwanted binding of antibodies to human Fc receptor-expressing cells. Cells were washed 
with 1 ml DPBS - 1% FBS buffer and the supernatant removed leaving 100 µl in the tube. 
To stain the desired surface markers, appropriate antibodies were added and incubated for 
30 minutes at 4°C in the dark. After incubation, the tubes were filled with DPBS - 1% FBS 
ad 1ml, centrifuged (300 g for five minutes) and the supernatants discarded. Cells were 
resuspended in DPBS - 1% PFA for fixation and stored at 4°C until the flow cytometric 
analysis was performed using the analyzer BD LSRFortessaTM. UltraComp eBeads® were 
used for fluorescence compensation in case of multicolor flow cytometric analyses. The 
beads preparation was performed according to manufacturer's instructions. 
3.2.2 Fluorescence-activated cell sorting (FACS) 
Cell suspensions were stained with fluorochrome-conjugated antibodies as previously 
described and analyzed for fluorochrome signals. Once the photons emitted by the 
fluorochromes have been detected, cells were selected according to marker expression. 
After passing the laser beam, cells were separated using BD FACSAriaTM Fusion cell sorter. 
Cells were sorted applying either “purity” (highest cell yield) or “single cell” (highest purity) 
mode. 
3.2.2.1 Sorting of K562 cells 
To generate appropriate APCs for the double sorting procedure and for the screening 
assays, K562 cells were stably transduced with the HLA-A2 molecule and the CD86 co-
stimulatory molecule (see section 3.1.18 for retroviral-mediated transduction). After 
transduction, the expression of HLA-A2 and CD86 surface molecules was evaluated by 
surface marker staining with specific antibodies and analyzed by flow cytometry. 
Subsequently, HLA-A2-positive CD86-positive K562 cells (designated as tgK562) were 
sorted by FACS to obtain a high purity cell population.  
3.2.2.2 CD137-based double-sorting strategy 
A 2-step-sorting procedure based on the CD137 activation marker and K562 cells as target 
cells was performed to selectively separate NY-ESO-1-specific T cells after de novo T cell 
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induction and expansion. In the first step a NY-ESO-1-unspecific stimulation of primed T 
cells was performed using irradiated water-electroporated tgK562 cells at an E:T ratio of 
2:1. Stimulated T cells were stained for CD137 and CD8 cell surface expression 12 h after 
activation and the CD137-negative CD8-positive fraction was sorted by FACS (CD137-
negative cell sorting). In the second step, NY-ESO-1-specific stimulation of the sorted T 
cells was performed using irradiated NY-ESO-1 ivtRNA-transfected tgK562 cells at an E:T 
ratio of 5:1. After 12 h, stimulated T cells were stained for CD137 and CD8 cell surface 
expression and the CD137-positive CD8-positive fraction was sorted (CD137-positive cell 
sorting) as single cells into tissue culture 96-well U-bottom plates by FACS. Single-cell-
sorted T cells were stimulated and expanded as described in section 3.1.16. 
3.3 Assays for functional analyses 
3.3.1 Co-culture of T cells and APCs 
The functionality of either TCR-transgenic T cells or T cell clones was investigated by 
evaluating IFN-γ release after target antigen-specific stimulation as well as by testing the 
capacity to mediate killing of cells expressing the target antigen. T cells and T cell clones 
were harvested, counted and used for functional analyses between 10 and 14 days after 
restimulation. 
3.3.1.1 Evaluation of IFN-γ release by T cells 
Effector cells and target cells were counted and adjusted according to the desired cell 
concentration for the co-culture (30000 effector cells/100µl/well, 10000-30000 target 
cells/100µl/well). The co-cultures for each test condition were performed in duplicates. The 
effector cells were co-cultured with target cells for 24h at 37°C. After incubation, the co-
culture supernatants were harvested and the amount of secreted interferon-gamma (IFN-
γ) was assessed by enzyme-linked immunosorbent assay (ELISA) (see section 3.3.2). The 
residual supernatants were frozen at -20°C for long-term storage. 
3.3.1.2 Evaluation of killing mediated by T cells 
Killing capacity mediated by TCR-transgenic T cells was evaluated by setting up co-culture 
experiments with different types of target cells and dyes for live-cell imaging using 
IncuCyte® ZOOM - Live Cell Analysis System. 
In the first approach, red-labelled T2 cells generated as described in section 3.1.19 were 
used as target cells. Thus, peptides of interest were loaded on red-labelled T2 cells 
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according to the protocol previously described (see section 3.1.12). Subsequently, loaded 
red-labelled T2 cells were seeded into 96-well round bottom plates (1 x 103 cells/well). The 
effector cells were added into each well at an effector to target (E:T) ratio of 20:1. The co-
cultures for each test condition were performed in triplicates. After setting up the co-
cultures, the plates were incubated at room temperature for 30 minutes and then placed 
into the IncuCyte® ZOOM device. The cells were monitored over 48h by live-cell imaging 
using IncuCyte® ZOOM - Live Cell Analysis System to evaluate the decrease of the red 
fluorescence intensity showing T2 cell killing mediated by TCR-transgenic T cells. 
In the second approach, tumor cell lines transfected with target antigen ivtRNA were used 
as target cells. The electroporation was performed as described in section see 3.1.11. 
Tumor cell lines were resuspended in fresh medium and seeded in 96-well flat-bottom-
plates (1.5 x 104 cells/well) 3h after transfection. After seeding, the cells were incubated at 
room temperature for 30 minutes to allow an even distribution and settling of the cells and 
subsequently incubated at 37°C. The following day, half of the medium was removed from 
the plates. Each well was refilled with 50 µl of the red fluorescent annexin V apoptosis dye 
(resuspended and pre-diluted according to manufacturer’s instructions) and 50 µl of 
medium containing 5 x 104 effector cells. The co-cultures for each test condition were 
performed in duplicates. After adding the effector cells, the plates were incubated at room 
temperature for 30 minutes and then placed into the IncuCyte® ZOOM device. To evaluate 
apoptosis in the co-cultures, the cells were monitored over 48h by live-cell imaging using 
IncuCyte® ZOOM - Live Cell Analysis System. 
3.3.2 IFN-γ ELISA 
The measurement of IFN-γ in co-culture supernatants was performed by a sandwich ELISA 
using the OptEIA™ Human ELISA Set IFN-γ. IFN-γ ELISA was performed according to the 
manufacturer’s protocol. Nunc-Immuno™ MicroWell™ 96-well plates were coated with 50 
µl/well capture antibody diluted 1:250 in ELISA coating buffer and incubated at 4°C 
overnight. The plates were washed five times with 300 µl/well ELISA washing buffer, 
blocked with 300 µl/well ELISA blocking buffer for 1h at room temperature and washed 
again three times. Co-culture supernatants as well as serially diluted standard were 
incubated on the plates for 1h at room temperature (50 µl/well each sample). The plates 
were washed five times and 100 µl of detection antibody plus peroxidase-conjugated avidin 
(both diluted 1:250 in blocking buffer) were added into the plates for 1h at room 
temperature. To remove unbound enzyme, the plates were washed five times. The enzyme 
substrate was added to the plates (100 µl/well) and incubated for five minutes at room 
temperature. The reaction was stopped by adding 50 µl/well of ELISA stop solution. The 
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optical density of the products, that is proportional to the bound cytokines, was detected by 
a spectrophotometer at 450 nm and 620 nm. The standard curve was calculated according 
to standard IFN-γ concentration and respective detected optical density. The IFN-γ 
concentration of the samples tested was interpolated. 
3.4 Molecular biological methods 
3.4.1 Plasmid DNA digestion 
Plasmid DNA was digested with restriction enzymes to enable the cloning of the desired 
DNA fragments into corresponding expression vectors. The digestion of the plasmid DNA 
was performed in 1.5 ml tubes in a final volume of 100 µl containing 20 µg of DNA, 10X 
CutSmart buffer and 40U of the required restriction enzymes. The samples were incubated 
for 1h at 37°C. The resulting DNA fragments were separated by agarose gel electrophoresis 
and extracted from the gel as described in section 3.4.2. 
3.4.2 Agarose gel electrophoresis and extraction of DNA fragments  
The separation of DNA fragments was performed in 1% agarose electrophoresis gels with 
0.4 µg/mL of ethidium bromide. A DNA ladder (either 1 kb or 100 bp) was included as a 
size standard during electrophoresis. After 45 minutes at 80 V, DNA bands were exposed 
to a UV transilluminator and cut from the gels. Subsequently, the QIAquick® Gel Extraction 
Kit was used for the extraction of DNA fragments from agarose gel according to 
manufacturer´s instructions. 
3.4.3 Ligation of DNA fragments 
Digested DNA fragments and linearized recipient plasmids were mixed in 0.5 ml tubes (2 
µl linearized recipient plasmid and 6 µl insert). Subsequently, 1µl of T4 ligase buffer (10X) 
and 1µl of T4 ligase (1 IU) were added into the tubes. The reactions were incubated 
overnight at 16 °C. 
3.4.4 Seamless cloning 
The GENEART® Seamless Cloning and Assembly Kit exploits homologous recombination 
to fuse DNA fragments that share terminal end-homology in an in vitro cloning reaction. 
Briefly, the DNA fragment including the required end sequence homology (20 – 80 ng) was 
mixed with the linearized recipient plasmid (100 ng), 4 µl of reaction buffer (5X) and water 
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to a final volume of 18 µl. Subsequently, 2 µl of enzyme mix (10X) were added to the 
reaction mix. After incubation of 30 minutes at room temperature, the reaction mix was 
placed on ice and used for bacteria transformation. 
3.4.5 Generation of plasmids 
Plasmids containing the transgenes of interest were generated using either traditional 
cloning methods (figure 1A) or using the seamless cloning technology (figure 1B) according 
to the protocols described in more detail in previous sections. The cloning strategy to 




Figure 1. Cloning strategies to generate plasmids containing the transgenes of interest. (A) 
Traditional cloning procedure. The transgene of interest was synthesized and cloned into a shuttle 
plasmid by Thermo Fisher Scientific. The shuttle plasmid and the appropriate recipient plasmid 
(either pGEM or pES12.6) were digested with the same combination of restriction enzymes (NotI-
HF® and EcoRI-HF®) and subsequently ligated by a T4 Ligase. (B) Seamless cloning procedure. The 
transgene of interest was produced as DNA string fragment by Thermo Fisher Scientific. The 
recipient pGEM plasmid was linearized using XbaI and Not I-HF® restriction enzymes. Subsequently, 
the GENEART® Seamless Cloning and Assembly Kit was used to fuse the DNA string fragment and 




3.4.6 Bacterial culture conditions 
Three different types of bacteria were transformed: electrocompetent XL1-blue E.coli, 
chemically competent One Shot™ TOP10 E. coli and chemically competent NEB® Turbo 
Turbo E. coli. Bacteria were cultivated in an incubator at 37°C. For long-term storage, 
bacterial suspensions were supplemented with glycerol (20%) and stored at -80 °C. Since 
all the plasmids used for transformation contained an ampicillin resistance cassette, 
ampicillin was added to the LB medium and to the agar plates (50 µg/ml) for selection of 
the plasmid-expressing bacteria. 
3.4.7 Bacterial transformation 
In order to obtain larger amounts of plasmid DNA, competent bacteria had to be 
transformed with the plasmid DNA of interest and expanded. According to the type of 
competent bacteria, either chemical transformation or electroporation was performed. 
3.4.7.1 Chemical transformation 
Chemically competent bacteria were slowly thawed on ice (30 µl bacteria/each 
transformation). Plasmid DNA was added and mixed with bacteria by tapping gently (3 µl 
DNA/vial). Cells were incubated on ice for 30 minutes. A heat-shock step was performed 
by transferring the cells in a water bath at 42°C for 30 seconds. Heat-shock caused the 
uptake of the DNA by the bacteria. Subsequently, the cells were placed on ice for two 
minutes. SOC medium was added to the transformation mix. The cells were gently shaken 
at 37°C for 1h. After incubation, transformation mix was diluted (1:10) in SOC medium, 
added to the agar plates containing ampicillin and distributed homogeneously. Plates were 
incubated at 37°C overnight. 
3.4.7.2 Electroporation 
Electrocompetent bacteria were slowly thawed on ice and transferred in pre-cooled 0.1 cm 
cuvettes (25 µl bacteria/cuvette). Plasmid DNA was added to the bacteria (1 µl 
DNA/cuvette) and mixed by tapping gently. The cuvettes were placed into the Gene Pulser 
Xcell™ device. Electroporation was performed using pre-set protocol for bacteria (1 mm 
cuvette and 1.8kV). After electroporation, SOC medium was added (1 ml/cuvette) and the 
samples were incubated at 37°C for 1h in new 1.5 ml tubes. The tubes were centrifuged at 
5000 g for ten minutes at room temperature. The supernatants were discarded and the 
pellets were resuspended in 200 µl of SOC medium. Transformed bacteria were added to 
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the agar plates with ampicillin and distributed homogeneously. Plates were incubated at 
37°C overnight. 
3.4.8 Selection and expansion of transformed bacteria 
Only bacteria transformed with plasmid DNA encoding resistance to the antibiotic were able 
to grow and form colonies on selection agar plates containing ampicillin. After overnight 
growth, colonies were picked from the plates. Each individual colony was inoculated into 5 
ml of LB medium containing ampicillin in a 5 ml tube. The tubes were incubated overnight 
at 37°C with vigorous shaking for efficient growth of transformed bacteria. An aliquot of the 
transformed bacteria (1 - 2 ml) was used for the isolation of plasmid DNA using JetStar™ 
2.0 Plasmid Miniprep Kit according to the manufacturer’s instructions. An additional step of 
bacteria expansion was performed for subsequent DNA isolation using JetStar™ 2.0 
Plasmid Maxiprep Kit. An aliquot of the transformed bacteria (200 – 300 µl) was transferred 
into 200 ml of LB medium with ampicillin and the sample was incubated at 37°C overnight 
with vigorous shaking for efficient growth of transformed bacteria. 
3.4.9 Plasmid DNA extraction from transformed bacteria 
For the isolation of high amount of plasmid DNA, the JetStar™ 2.0 Plasmid Purification 
MaxiPrep Kit was used according to manufacturer´s instructions. The bacteria cultures were 
centrifuged at 3400 g for ten minutes at room temperature. The supernatant was discarded 
and the pellet resuspended in 10 ml buffer E1 and transferred to a 50 ml tube. Lysis buffer 
E2 was added (10 ml) and the collection tube inverted ten times. Thereafter 10 ml 
precipitation buffer E3 was added and the tube inverted again for ten times. The suspension 
was centrifuged at 5000 g for ten minutes at room temperature and the supernatant applied 
to a 70 µm filter onto an equilibrated column. The column was filled up with washing buffer 
E5 and the flow-through was discarded. The column was placed on top of a 50 ml collection 
tube and the DNA eluted by adding 15 ml of elution buffer E6. lsopropanol was added (10.5 
ml) to the DNA, mixed and centrifuged at 5000 g for 45 minutes at 4°C. The supernatant 
was discarded and the pellet dehydrated with 1 ml 75% ethanol, air-dried and resuspended 
in nuclease-free water. The DNA concentration was determined with the Nanodrop. 
3.4.10 In vitro transcription of single-species cDNA into mRNA 
For in vitro transcription of single-species cDNA into mRNA (designated as in vitro 
transcribed RNA, ivtRNA) the mMESSAGE mMACHINE™ T7 kit was used. For this 
purpose, 20 µg of pGEM-plasmid DNA containing the T7 promoter were linearized with the 
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restriction enzyme SpeI-HF® overnight at 37°C. The SpeI-HF® recognition site is located 
downstream of a poly-A tail consisting of about 116 adenines. This poly-A tail is meant to 
increase the stability of ivtRNA. The following day, the reaction was stopped and purified 
by adding 5 µl EDTA (0.5 M), 10 µl sodium acetate (3 M) and 200 µl 100% ethanol. The 
reaction was incubated at -20 °C for 45 minutes. After centrifugation (15000 x g at 4 °C for 
15 minutes), the supernatant was discarded and the DNA pellet was resuspended in 40 µl 
nuclease-free water. The concentration of the linearized DNA was determined with the 
Nanodrop. The production of ivtRNA was performed using the mMESSAGE mMACHINE™ 
T7 kit according to the manufacturer's instructions. Briefly, linearized DNA (2 - 3 µg) was 
mixed with 20 µl NTP/CAP (7-methyl guanosine cap and nucletotides), 4µl Reaction Buffer 
(10X) and 4µl T7 polymerase. Nuclease-free water was added to a final volume of 40 µl. 
The reaction mix was incubated for 2h at 37°C. DNAse was added (2 µl/sample) and 
incubated for 30 minutes at 37°C. Subsequently, the RNeasy® Mini Kit was used to purify 
the ivtRNA according to the manufacturer's instructions. Purified ivtRNA was eluted in 40 
µl nuclease-free water. The RNA concentration was determined by the Nanodrop and 
ivtRNA was stored at -20°C. 
3.4.11 Total RNA isolation 
Total RNA was isolated from either T cell clones for TCR sequence analyses by RACE-
PCR (see section 3.4.16.1) or from tumor cell lines to evaluate NY-ESO-1 expression by 
Nanostring nCounter technology (see section 3.4.17). Cells were collected and the pellet 
was resuspended vigorously in TRI Reagent® to disrupt plasma membranes, inactivate 
released RNases and homogenize the suspension (1 x 106 cells/200 µl of TRI Reagent®). 
Incubation at room temperature for five minutes allowed the dissociation of nucleoprotein-
complexes. Linear acrylamide was added to the sample (10 µl/sample). Subsequently, 40 
µl of chloroform were added, the suspensions were vortexed for 15 seconds, incubated at 
room temperature for ten minutes and then centrifuged at 12000 g for 15 minutes at 4°C. 
The upper colorless aqueous phase was transferred into a new 1.5 ml tube and 100 µl of 
isopropanol were added to the sample. The tube was vortexed, incubated at 4°C for ten 
minutes and then centrifuged at 12000 g for 15 minutes at 4°C. Supernatant was removed 
and 500 µl of 75% ethanol were added. After centrifugation at 12000 g for ten minutes at 
4°C, supernatant was removed and the RNA pellet was air-dried at room temperature for 
five minutes. Finally, RNA was resuspended in 20 µl of nuclease-free water. 
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3.4.12 RNA denaturing-agarose gel electrophoresis 
To verify the success and the quality of the ivtRNA production, an aliquot of the produced 
ivtRNA was loaded on 1% agarose gel (0.4% ethidium bromide, 1X TAE buffer in DEPC-
treated water).  Therefore, 0.5 μl ivtRNA were mixed with 5µl RNA loading buffer (2X) and 
4.5 μl nuclease-free water and subsequently heated up to 70 °C for 10 minutes to destroy 
secondary structures. After incubation, the sample was loaded into the gel. A RNA ladder 
was included as a size standard for the electrophoresis. After 45 minutes at 80 V, RNA 
bands were analyzed using an UV transilluminator. 
3.4.13 DNA sequencing 
The sequencing of double-stranded DNA was performed in collaboration with the external 
partner MWG Eurofins (Martinsried, Germany). Primers used for sequencing are listed in 
section 2.8 table 18. The software Chromas lite was used for bioinformatic evaluation of the 
electropherograms. 
3.4.14 Measurement of DNA and RNA concentration 
DNA and RNA concentrations were determined using the Nanodrop photometer. The ratio 
of absorbance at 260 nm and 280 nm was used to assess the purity of the samples. A ratio 
of 2.0 or higher was acceptable for RNA, whereas a ratio of 1.8 or higher was acceptable 
for DNA. 
3.4.15 HLA typing 
Fresh blood (3 ml EDTA-blood sample) collected from healthy donors after informed 
consent were sent to the facility IMGM (Martinsried, Germany) for fine HLA-typing analyses 
in an anonymous format. 
3.4.16 TCR sequence analysis 
3.4.16.1 cDNA synthesis and RACE-PCR 
The rapid amplification of cDNA ends PCR (RACE-PCR) was used to analyze TCR 
sequences of single-cell-sorted T cell clones. The ‘RACE-ready’ cDNA was synthetized 
starting from total RNA using the SMARTer™ RACE cDNA Amplification Kit according to 
the manufacturer’s protocol (see section 3.4.11 for total RNA isolation). 
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This kit is based on the joint action of the SMARTScribe Reverse Transcriptase (RT) and 
SMARTer II A Oligonucleotide. The SMARTScribe RT exhibits terminal transferase activity 
upon reaching the end of the RNA template, adding 3–5 residues to the 3’ end of the first-
strand cDNA. The SMARTer oligo contains a terminal stretch of modified bases that anneal 
to the extended cDNA tail, allowing the oligonucleotide to serve as a template for the 
SMARTScribe RT. The SMARTScribe RT switches templates from the mRNA molecule to 
the SMARTer oligo, generating a complete cDNA copy of the original RNA with the 
additional SMARTer sequence at the end. 
The generated first-strand cDNA was used directly for 5’ RACE-PCR reactions using the 
Advantage® 2 PCR kit according to the manufacturer’s instructions. To amplify the cDNA 
encoding TCRα and TCRβ chains, two gene-specific 5’ primers were designed to bind the 
constant region of each TCR chain (5’ TRAC and 5’ TRBC primers). All TCRα chains have 
the same constant region, while there are two possible constant regions for the TCRβ chain 
(Cβ1 or Cβ2). Cβ1 or Cβ2 are very similar, therefore the gene-specific 5’ primer for the C 
region of the TCRβ chain was designed to detect both Cβ1 and Cβ2. Primer sequences are 
listed in material section 2.8 table 17. Two separated 5’ RACE PCR were performed for 
each sample to identify both TCRα and TCRβ chain sequences (see table 31 for 5’ RACE 
PCR program). One reaction included the 5’ primer TRAC and the other included the 5’ 
primer TRBC. The universal primer mix (UPM) binding to the SMARTer sequence at the 
end of the cDNA was used as 3’ primer for both reactions. A second round of amplification 
was performed (5’ nested RACE-PCR) using "nested" 5’ primers (see table 32 for 5’ nested 
RACE-PCR program). PCR products were loaded into a 1% agarose gel and separated by 
electrophoresis. Subsequently, QIAquick® Gel Extraction Kit was used for the extraction of 
DNA fragments from agarose gel according to manufacturer´s instructions (see section 
3.4.2). DNA fragments were sequenced using 5’ primer TRAC and 5’ primer TRBC. 
Table 31. 5’ RACE-PCR program 

























Table 32. Nested 5’ RACE-PCR program 
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3.4.16.2 TCR reconstruction 
Isolated TCRα and TCRβ sequences were reconstructed in adequate plasmids to allow 
TCR transgenic expression in recipient cells. Therefore, a two-gene expression cassette 
was designed (figure 2). The TCRβ chain was linked to the TCRα chain by a "self-cleaving" 
2A peptide (P2A element) and subsequently the construct was cloned using a traditional 
cloning procedure into pGEM and pES12.6 recipient plasmids as described in section 3.4.5. 
The IMGT database was used to identify the specific V regions (TRAV and TRBV) and the 
joining (J) regions (TRAVJ and TRBVJ) of the TCRα and TCRβ chains. 
 
Figure 2. Two-gene cassette designed for TCR reconstruction. The TCRβ chain (TRBV, CDR3β, 
TRBVJ, TRBC) was linked to the TCRα chain (TRAV, CDR3α, TRAVJ, TRAC) by a P2A element. 
The TCR construct was synthesized and cloned into a shuttle plasmid by Thermo Fisher Scientific. 
The shuttle plasmid containing the reconstructed TCR and the appropriate recipient plasmid (pGEM 
or pES12.6) were digested with the same combination of restriction enzymes (Not I-HF and EcoRI-
HF) and subsequently ligated by T4 Ligase. 
3.4.17 Nanostring nCounter  
Nanostring nCounter technology is based on digital detection and direct molecular 
barcoding of target molecules through the use of colour-coded probe pair. The nCounter 
gene expression assay is designed to provide an ultra-sensitive, reproducible and highly 
multiplexed method for gene expression profiling. This assay provides a method for direct 
detection of mRNA molecules without the use of reverse transcription or amplification. The 
target-specific probe (100 nt) includes a reporter probe (50 nt) and capture probe (50 nt) 
that hybridize to the target sequences of interest, forming a tripartite complex. The report 
probe is linked to the colour code signal for digital detection, while the capture probe 
includes a biotin moiety on the 3’ end for target/probe complex immobilization.  
First, the probes and the target molecules hybridize in solution forming target/probe 
complexes. Wash steps are performed for removing excess probes and non-target cellular 
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transcripts. Second, after washing, the target/probe complexes are insert in a cartridge and 
immobilized for data collection. 
Nanostring nCounter analyses were performed by Nanostring Headquarters facility 
(Seattle, USA). This technology was utilized to investigate NY-ESO-1/LAGE-1 mRNA 
expression in several tumor cell lines. Total RNA was isolated from tumor cell lines and 
utilized as starting material (see section 3.4.11 for total RNA isolation). Two target-specific 
probes were designed to detect NY-ESO-1 mRNA (see section 2.8 table 19 for probe 
sequences). The first probe (probe 1) was designed to target a sequence present in NY-
ESO-1, but not included in any isoform of the highly homologous tumor antigen LAGE-1 
(LAGE-1a and LAGE-1b). In contrast, the second probe (probe 2) was designed to target a 
region that included the sequence encoding the known immunogenic epitope NY-ESO-
1/LAGE-1a157-165. Therefore, NY-ESO-1 and LAGE-1a mRNA transcripts comprising the 







4.1 Isolation of NY-ESO-1-specific CD8+ T cells  
As an overview, the following steps were performed to induce, expand and separate NY-
ESO-1-specific CD8+ T cells and corresponding TCRs using an HLA-A2-allogeneic priming 
approach (figure 3). Mature DCs (mDCs) from an HLA-A2-negative healthy donor were 
generated in vitro within eight days following the Jonuleit maturation protocol [104]. mDCs 
were transfected with ivtRNA encoding the allogeneic HLA-A2 molecule (HLA-A*02:01 
allele) and the full-length NY-ESO-1 antigen in order to induce and expand autologous CD8-
enriched T cells specific for NY-ESO-1. Subsequently, NY-ESO-1-specific T cells were 
separated as single cells by FACS using an innovative sorting strategy based on the 
activation-induced cell surface marker CD137. Two weeks later, the first functional 
screening was performed to evaluate antigen specificity of expanded T cell clones. TCR 
sequence of a confirmed NY-ESO-1-specific T cell clone was analyzed and reconstructed 
for transgenic expression in recipient cells to allow characterization of the properties of the 
identified TCR. In the following chapters, each step is described in more detail.  
 
Figure 3. Schematic depiction of the procedure performed to isolate NY-ESO-1-specific T 
cells and corresponding TCRs. The isolation of NY-ESO-1-specific T cells using an HLA-A2-
allogeneic priming approach comprised several steps: mDC generation, de novo induction of CD8+ 
T cells, separation of NY-ESO-1-specific T cells, identification of NY-ESO-1-specific T cells, TCR 





4.1.1 Generation of mDCs in vitro  
mDCs are the most potent APCs for the stimulation of naïve T cells [105]. To generate 
mDCs in vitro, monocytes derived from an HLA-A2-negative healthy donor were obtained 
by plate adherence of freshly isolated PBMC, cultured in vitro for eight days and matured 
by using the Jonuleit cocktail [104]. The mDC phenotype required for efficient T cell 
stimulation was analyzed by flow cytometry. As shown in figure 4, mDCs showed no 
expression of the monocyte marker CD14, but high expression of the DC maturation marker 
CD83. The analyzed B7 family ligands (CD86 and CD80) were highly expressed on mDCs, 
as well as the inhibitory molecule CD274. The chemokine receptor CCR7 and HLA-DR, 
stained as representative marker for MHC class II molecules, showed high expression after 
in vitro maturation. CD3 as a marker of T lymphocytes was not detected, confirming that 
there were not residual autologous T cells in the DC population. 
 
Figure 4. Phenotype of mDCs generated in vitro. Cell surface expression of CD14, CD83, CD86, 
CD80, CD274, CCR7, HLA-DR and CD3 molecules was analyzed by flow cytometry on mDCs 
generated in vitro within eight days using the Jonuleit maturation cocktail. Stained samples are 
shown in black and corresponding unstained samples in grey. Populations shown are pre-gated on 
live single cells. 
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4.1.2 De novo induction of CD8+ T cells  
mDCs were transfected simultaneously with two ivtRNA, one encoding the foreign HLA-A2 
molecule and one encoding the full-length NY-ESO-1 antigen. These ivtRNA-transfected 
mDCs were utilized as APCs for induction and expansion of autologous CD8-enriched T 
cells. As control, ivtRNA encoding full-length GFP was transfected in combination with 
ivtRNA encoding the HLA-A2 molecule into the mDCs. Since there were no specific 
antibodies available for intracellular flow cytometry staining of the NY-ESO-1 protein, HLA-
A2- and GFP-transfected mDCs served as an internal control to verify the efficient 
transfection of two ivtRNA simultaneously. Expression of the transgenic HLA-A2 molecules 
and GFP was analyzed by flow cytometry. As shown in figure 5A, 99.0% of mDCs were 
positive for HLA-A2 after electroporation with HLA-A2 and NY-ESO-1, proving a good 
transfection rate. In the control sample, 100% of mDCs were positive for HLA-A2 and 75.0% 
were double-positive for HLA-A2 and GFP, showing the feasibility of transfecting two 
ivtRNA simultaneously. 
 
Figure 5. Evaluation of HLA-A2 and NY-ESO-1 expression in ivtRNA-transfected mDCs. (A) 
HLA-A2 and GFP expression was detected by flow cytometry after either HLA-A2 and NY-ESO-1 or 
HLA-A2 and GFP ivtRNA electroporation into mDCs generated from an HLA-A2-negative donor. 
mDCs without electroporation were also stained with anti-HLA-A2 antibody and used as background 
control. Populations shown are pre-gated on live single cells. (B) HLA-A2- and NY-ESO-1-
transfected mDCs and HLA-A2- and GFP-transfected mDCs were tested in a co-culture assay to 
verify their capacity to stimulate NY-ESO-1-specific T cells to release IFN-γ. T cells expressing either 
TCR 1G4-α95:LY (HLA-A2-restricted NY-ESO-1/LAGE-1a157-165-specific TCR) or an irrelevant TCR 
(negative control) were used as effector cells. IFN-γ release was measured 24h after setting up the 





The stimulatory capacity of transfected mDCs and their ability to translate, process and 
present peptides derived from the introduced NY-ESO-1 ivtRNA on foreign HLA-A2 
molecules by internal cellular pathways was verified by testing their recognition by T cells. 
Therefore, ivtRNA-transfected mDCs were co-cultured with either transgenic T cells 
expressing an HLA-A2-restricted NY-ESO-1/LAGE-1a157-165-specific TCR (TCR 1G4-
α95:LY) or transgenic T cells expressing an HLA-A2-restricted irrelevant TCR serving as 
negative control [58], [90]. After 24h of incubation, IFN-γ release was analyzed by ELISA 
(figure 5B). TCR 1G4-α95:LY-transgenic T cells recognized mDCs transfected with HLA-
A2 and NY-ESO-1, but not mDCs transfected with HLA-A2 and GFP. T cells expressing the 
irrelevant TCR were not activated after incubation with any mDCs. These results showed 
that mDCs generated in vitro were able to process and presented a peptide derived from 
the introduced NY-ESO-1 ivtRNA on the HLA-A2 molecules and to stimulate T cells 
expressing a HLA-A2-restricted NY-ESO-1-specific TCR to release IFN-γ. 
The priming was started with as many CD8+ T cells as possible in order to enlarge the 
starting CD8+ T cell repertoire for the induction of NY-ESO-1 specific T cells. Therefore, 
autologous CD8+ T cells were enriched by depleting other cell populations in freshly isolated 
PBMC. To assess the purity of the enriched CD8+ T cell population and the efficiency of the 
separation process, the expression of CD3 and CD8 molecules was evaluated and 
compared before and after CD8-enrichment. As shown in figure 6, the sample prior to 
separation included 20.1% of CD3+CD8+ cells, while after enrichment the population was 
composed of an increased number of CD3+CD8+ cells (76.1%), confirming a CD3+CD8+ cell 
enrichment. Subsequently, CD8-enriched T cells were induced and expanded using NY-
ESO-1 and HLA-A2 ivtRNA-transfected mDCs as stimulator cells for 14 days. 
 
Figure 6. Frequency of CD3+CD8+ cells before and after CD8-enrichment. CD8+ T cells were 
enriched by depleting other cell populations in freshly PBMC isolated from the HLA-A2-negative 
healthy donor that was selected for performing the priming procedure. The ratio of CD3+CD8+ cells 




4.1.3 Separation of NY-ESO-1-specific T cells  
NY-ESO-1-specific T cells needed to be selectively separated as single cell and further 
expanded before performing the first functional screening in order to enable the 
identification of T cells expressing TCRs specific for NY-ESO-1 within the primed 
lymphocyte culture. Thus, a sorting method based on the cell surface marker CD137 
expressed on T cells upon antigen-specific stimulation was selected to separate NY-ESO-
1-specific T cells. CD137-mediated sorting has been shown to be an effective technique for 
the isolation of CD8+ T cells specific for various tumor antigens [99]–[101]. This strategy 
allows the isolation of antigen-specific T cells irrespective of known immunogenic epitopes 
and facilitates the isolation of T cells recognizing all potential immunogenic peptides derived 
from a selected tumor antigen. Therefore, it represented the best choice to fully exploit the 
potential of using ivtRNA encoding the full-length NY-ESO-1 protein for T cell induction. 
However, two critical aspects needed to be considered for setting up a CD137-based 
sorting strategy in the context of an allogeneic priming. 
One aspect was the selection of appropriate APCs to be used for NY-ESO-1-specific 
stimulation to induce CD137 expression on T cells. To address this issue, K562 cells, a 
tumor cell line endogenously negative for MHC class I and II molecules and for NY-ESO-1, 
were stably transduced with HLA-A2 molecule and the CD86 co-stimulatory molecule and 
subsequently transfected with ivtRNA encoding the full-length NY-ESO-1. K562 cells 
expressing CD86 molecules were used to enhance and sustain T cell clone survival after 
single cell sorting. The advantage of using K562 cells was that these cells allowed the 
stimulation and consequently isolation of T cells restricted only to the transduced allogeneic 
HLA-A2 molecules and specific for NY-ESO-1 peptides naturally processed and presented 
by a tumor cell line. Moreover, being negative for endogenous MHC class I and II 
molecules, no activation of allo-reactive T cells recognizing foreign MHC molecules other 
than the introduced HLA-A2 molecules was expected. 
The second critical aspect to be considered was that the primed T cell culture contained, 
as an unavoidable consequence of the HLA-A2-allogeneic priming, a high number of HLA-
A2-allo-reactive T cells. These T cells recognize the HLA-A2 molecules independently of 
NY-ESO-1-derived peptides. Thus, K562 cells expressing HLA-A2 and NY-ESO-1, required 
for stimulation of the desired NY-ESO-1-specific T cells, will also stimulate the large portion 
of HLA-A2-allo-reactive T cells to express CD137. An innovative sorting approach, called 
‘double-sorting’, based on the CD137 activation marker and K562 stimulator cells, was 
developed and tested for the first time in this project to reduce the stimulation of HLA-A2-




4.1.3.1 Generation and evaluation of K562 cells as artificial APCs 
K562 cells were stably transduced with the HLA-A2 molecule and the CD86 co-stimulatory 
molecule to generate artificial APCs (aAPCs) to be used as stimulator cells for CD137-
mediated sorting. As shown in figure 7A, the transduction rate of K562 cells was evaluated 
by flow cytometry and 20.1% of the cells were positive for HLA-A2 and CD86. Transduced 
K562 cells were sorted by FACS to obtain an HLA-A2+ CD86+ high purity cell population. 
After one week of in vitro expansion, sorted K562 cells were analyzed again for HLA-A2 
and CD86 expression that resulted in 95.5% of double-positive cells. These cells are 
hereafter designated as transgenic K562 cells (tgK562). 
To verify the stimulatory capacity of tgK562 cells and to investigate their ability to translate, 
process and present peptides by internal cellular pathways on transgenic HLA-A2 
molecules after electroporation with tumor antigen ivtRNA, tgK562 cells were transfected 
with ivtRNA encoding either the full-length NY-ESO-1 or GFP and tested in a co-culture 
assay. TCR 1G4-α95:LY-transgenic T cells and untransduced T cells were used as 
effectors. Autologous LCL transfected with ivtRNA encoding NY-ESO-1 and T2 cells loaded 
with the peptide NY-ESO-1/LAGE-1a157-165, which is the epitope recognized by TCR 1G4-
α95:LY, were used as positive target controls. Autologous LCL transfected with ivtRNA 
encoding GFP and T2 cells loaded with the irrelevant peptide Tyrosinase369-377 were used 
as negative target controls. IFN-γ secretion by T cells was evaluated after 24h of incubation 
with target cells by ELISA. As shown in figure 7B, NY-ESO-1-transfected tgK562 cells 
efficiently stimulated TCR 1G4-α95:LY-transgenic T cells to release IFN-γ, demonstrating 
the capacity of tgK562 cells to process and present peptides for T cell recognition. IFN-γ 
secretion by TCR 1G4-α95:LY-expressing T cells was also observed after incubation with 
the positive target controls, whereas no IFN-γ was detected in response to the negative 
target controls. Untransduced T cells were not activated by any targets used in the assay. 






Figure 7. Evaluation of transduction rate and presentation capacity of tgK562 cells. (A) K562 
cells were transduced with HLA-A2 molecule and CD86 co-stimulatory molecule to generate aAPCs. 
The transduction rate was analyzed by flow cytometry and subsequently K562 cells which were 
double-positive for HLA-A2 and CD86 were sorted by FACS to increase the purity of this population. 
Untransduced K562 cells were stained with anti-CD86 and anti-HLA-A2 antibodies and used as 
background control. Populations shown are pre-gated on live single cells. (B) After sorting, HLA-A2+ 
CD86+ K562 cells (tgK562) were transfected with ivtRNA encoding either the full-length NY-ESO-1 
or GFP and tested in a co-culture assay. TCR 1G4-α95:LY-transduced T cells (HLA-A2-restricted 
NY-ESO-1/LAGE-1a157-165-specific TCR) and untransduced T cells were used as effectors. 
Autologous LCL transfected with NY-ESO-1 ivtRNA and T2 cells loaded with peptide NY-ESO-
1/LAGE-1a157-165 (epitope recognized by TCR 1G4-α95:LY, relevant peptide) were used as positive 
target controls, while autologous LCL transfected with GFP ivtRNA and T2 cells loaded with an 
irrelevant peptide (Tyrosinase369-377) served as negative target controls. IFN-γ secretion of T cells 
was evaluated after 24h of incubation with target cells by ELISA. Shown is the mean value of 





4.1.3.2 Double sorting: 2-step-sorting procedure based on CD137 marker 
An innovative 2-step-sorting procedure (‘double-sorting’) was developed based on the 
CD137 activation-induced marker and tgK562 cell stimulation in order to isolate NY-ESO-
1-specific T cells. This new approach combined the sorting of T cells expressing CD137 
upon NY-ESO-1-specific stimulation with a previous step to reduce the isolation of HLA-A2-
allo-reactive T cells. As shown in figure 8, in the first step a NY-ESO-1-unspecific 
stimulation of the primed T cells was performed using irradiated water-electroporated 
tgK562 cells at an effector to target (E:T) ratio of 2:1 (NY-ESO-1-unspecific stimulation). 
Kinetic experiments showed that the maximal CD137 expression on T cells was obtained 
between 12h and 20h after stimulation with tgK562 cells (data not shown). Accordingly, 
stimulated T cells were stained for CD137 and CD8 cell surface expression 12h after 
activation and the CD137-negative CD8-positive fraction (44.8%) was sorted by FACS 
(CD137-negative cell sorting). The aim of the NY-ESO-1-unspecific stimulation and of the 
CD137-negative cell sorting step was to remove those unwanted T cells which react 
towards the HLA-A2 molecule independently of the chosen target antigen on tgK562 cells 
by enriching the CD137-negative fraction including NY-ESO-1-specific T cells. The 
unwanted CD137-positive fraction was discarded, whereas the CD137-negative fraction 
was subjected to a second stimulation, this time using irradiated NY-ESO-1 ivtRNA-
transfected tgK562 cells at an E:T ratio of 5:1 (NY-ESO-1-specific stimulation). After 12h, 
stimulated T cells were stained for CD137 and CD8 cell surface expression and the CD137-
positive CD8-positive fraction was sorted (1.3%) by FACS as single cells and immediately 
seeded into 96-well culture plates (CD137-positive cell sorting). Single-cell-sorted T cells 







Figure 8. Double-sorting strategy based on the CD137 activation marker and tgK562 
stimulator cells. Primed T cells were stimulated using irradiated water-electroporated tgK562 cells 
at an E:T ratio of 2:1 (NY-ESO-1-unspecific stimulation) and stained after 12h for CD137 and CD8 
surface expression. The CD137-negative CD8-positive fraction was sorted by FACS (CD137-
negative cell sorting) and subsequently stimulated using irradiated NY-ESO-1 ivtRNA-transfected 
tgK562 cells at an E:T ratio of 5:1 (NY-ESO-1-specific stimulation). CD137 and CD8 staining was 
performed 12h after stimulation and CD137-positive CD8-positive T cells were sorted by FACS as 





4.1.4 Identification of NY-ESO-1-specific T cell clones 
Expanded T cell clones (301 expanded clones out of 600 sorted cells) were assessed for 
IFN-γ release upon stimulation with tgK562 cells transfected with ivtRNA encoding either 
NY-ESO-1 (positive target) or GFP (negative target) to identify HLA-A2-restricted NY-ESO-
1-specific T cells. Screening results for 15 exemplary clones are shown in figure 9. T cell 
clones were divided in three groups according to their reaction patterns: clones showing no 
recognition of any target cell (152 non-reactive clones), clones recognizing HLA-A2 
molecules independently of NY-ESO-1 (144 HLA-A2-allo-reactive clones) and clones 
releasing IFN-γ only after NY-ESO-1-specific stimulation (5 NY-ESO-1-reactive clones). 
Among the NY-ESO-1-specific clones, T cell clone 5-271 showed the highest amounts of 
IFN-γ secretion in the presence of NY-ESO-1-presenting tgK562 cells, but no activation 
after GFP-transfected tgK562 cell stimulation. 
 
Figure 9. Screening results of expanded clones to identify T cells with NY-ESO-1 specificity. 
Screening results of 15 exemplary clones sorted by FACS using the CD137-mediated double sorting 
approach. IFN-γ release by T cell clones was assessed by ELISA after 24h co-culture with tgK562 
cells transfected with ivtRNA encoding either NY-ESO-1 (positive target) or GFP (negative target). 
T cell clones were divided in three groups according to their reactivity patterns: non-reactive, HLA-





4.1.5 TCR 5-271 sequence analysis and reconstruction 
The antigen specificity of each T cell clone is defined by its individual TCR. Thus, TCR 
sequences of the five NY-ESO-1-specific T cell clones were analyzed by RACE-PCR. 
Unfortunately, due to limited amounts of starting material, the unique TCR sequence was 
successfully obtained only for the clone 5-271. Sequencing results of TCRα and TCRβ 
chains are summarized in table 33.  
Table 33. TCR sequence analysis of NYESO-1-specific T cell clone 5-271. 
 
 
In order to evaluate the expression and the functionality of the identified TCR 5-271 in a 
transgenic setting and to fully characterize the properties of the TCR, the TCRα and TCRβ 
sequences were reconstructed in expression vectors (pGEM and pES12.6). For the TCR 
5-271 reconstruction, the codon usage in the TCR encoding nucleotide sequences was 
optimized to enhance protein translation [106]. For both the TCRα and TCRβ chain, critical 
amino acids of the human constant (C) regions were exchanged for corresponding murine 
C region counterparts to enforce the pairing of the transgenic TCRα and TCRβ chains over 
the mixed pairing with the T cell’s endogenous TCR [107]. Moreover, one cysteine was 
introduced into the C regions of each TCR 5-271 chain to allow the formation of an 
additional disulfide bond between the C regions of the TCR 5-271 α and β chains, aiming 
to further reduce mixed pairing between endogenous and exogenous TCR chains [108]. To 
obtain simultaneous and equal expression of TCRα and TCRβ chains, both TCR sequences 
were inserted into the same vector whereby the TCRβ chain was linked to the TCRα chain 
by a "self-cleaving" 2A peptide (P2A element) [109]. Subsequently, the construct was 
cloned into the pGEM and pES12.6 plasmids to achieve transgenic TCR expression in 





4.2 Functional characterization of TCR 5-271-expressing T cells 
An extensive in vitro characterization in terms of specificity and functionality was performed 
for the isolated and reconstructed HLA-A2-restricted NY-ESO-1-specific TCR 5-271 in a 
transgenic setting. As a positive control, TCR 1G4-α95:LY was used for all characterization 
assays. TCR 1G4-α95:LY is a melanoma patient-derived affinity-enhanced TCR that 
recognizes the peptide NY-ESO-1/LAGE-1a157-165 in complex with HLA-A2 molecules. This 
TCR has been well-characterized by in vitro and in vivo studies and already tested in clinical 
trials for synovial cell sarcoma, melanoma, multiple myeloma, ovarian cancer and non-small 
cell lung cancer with promising results [56]–[58], [90] 
4.2.1 TCR 5-271 expression in recipient T cells 
Transfer of TCRs into recipient T cells not only serves to fully characterize potential 
candidate TCRs when the original clone is not available, but also to prove transgenic TCR 
expression and functionality required for later clinical applicability. The TCR 5-271 and the 
positive control TCR 1G4-α95:LY were expressed in different types of recipient cells, i.e. 
effector T cells and CD8-enriched effector T cells. Well-established retroviral transduction 
and ivtRNA electroporation approaches were selected as TCR transfer methods. To assess 
the successful TCR transfer, the percentage of T cells expressing either TCR 5-271 or TCR 
1G4-α95:LY was analyzed by flow cytometry. As both TCRs included the same TRBV 
chain, the TRBV6-5-specific antibody was used to evaluate the expression of both TCRs. 
Unmodified T cells were used as control for the endogenous TRBV6-5 chain expression. 
An example of one representative flow cytometry analysis is shown in figure 10. By 
subtracting the fraction of endogenously TRBV6-5-expressing T cells (2.9%, untransduced 
T cells), the percentage of effector cells expressing the transgenic TCR resulted in 43.1% 
for TCR 5-271 and in 43.6% for TCR 1G4-α95:LY. These data showed that both TCRs were 





Figure 10. TCR 5-271 surface expression after transfer into recipient T cells. TCR 5-271 and 
the control TCR 1G4-95α:LY were introduced into recipient T cells by either ivtRNA electroporation 
or retroviral transduction. After TCR transfer, the expression level of the transgenic TCR was 
determined by FACS using the TRBV6-5 specific antibody. Unmodified recipient T cells were used 
as control for the endogenous expression of the TRBV6-5 chain. One representative experiment of 
TCR transfer by retroviral transduction into CD8-enriched T cells is shown. Populations shown are 
pre-gated on live single cells. 
4.2.2 Evaluation of antigen specificity 
After TCR transfer and evaluation of TCR expression in recipient T cells, the first step in 
the TCR evaluation process was to confirm the antigen specificity of TCR 5-271 in the 
transgenic expression setting. ivtRNA encoding TCR 5-271 was introduced into effector T 
cells derived from a healthy donor. In addition, T cells were also electroporated with ivtRNA 
encoding either TCR 1G4-α95:LY (positive control) or an HLA-A2-allo-reactive TCR (TCR 
3-9), the latter was included to assess the expression of the HLA-A2 molecule on targets 
cells. T cells electroporated with water served as the negative control. Autologous LCL and 
tgK562 cells transfected with ivtRNA encoding either NY-ESO-1 or GFP were used as 
target cells. T2 cells loaded with the TCR 1G4-α95:LY-specific peptide NY-ESO-1/LAGE-
1a157-165 or the irrelevant peptide MAGE-A1278-286 were used as internal target controls for 
the assay. Moreover, K562 cells untransduced were included as negative target to control 
the reactivity of the TCR 3-9. After 24h of effector/target co-culture, an ELISA was 
performed to evaluate IFN-γ secretion by T cells (figure 11). TCR 5-271-transfected T cells 
recognized LCL and tgK562 cells only when transfected with NY-ESO-1 ivtRNA. These 
findings confirmed the NY-ESO-1 specificity of TCR 5-271 and proved correct TCR 5-271 
heterodimer pairing and functionality of the TCRα and TCRβ transgenes in recipient T cells. 
Interestingly, TCR 5-271 showed a different peptide specificity compared to TCR 1G4-
α95:LY because it did not recognize T2 cells loaded with the peptide NY-ESO-1/LAGE-
1a157-165. TCR 1G4-α95:LY-transfected T cells also recognized LCL and tgK562 cells when 
they were transfected with NY-ESO-1 ivtRNA. Moreover, T2 cells loaded with peptide NY-
Results 
67 
ESO-1/LAGE-1a157-165 led to the activation of TCR 1G4-α95:LY-transfected T cells. TCR 3-
9-transfected T cells secreted IFN-γ after stimulation with all HLA-A2-positive targets used 
in the assay, confirming the HLA-A2 expression on these cells, whereas they were not 
activated by wild-type K562 cells that are not expressing HLA-A2 molecules. Water 
electroporated T cells were not activated in response to any target cells. 
 
Figure 11. Antigen specificity of TCR 5-271-transgenic T cells. T cells derived from a healthy 
donor were transfected with ivtRNA encoding either TCR 5-271 or TCR 1G4-α95:LY or an HLA-A2-
allo-reactive TCR (TCR 3-9). Water-electroporated T cells served as the negative control. 
Electroporated T cells were incubated with either autologous LCL or tgK562 cells that were 
transfected with ivtRNA encoding either NY-ESO-1 or GFP. Further target cells were T2 cells loaded 
with either TCR 1G4-α95:LY-specific peptide NY-ESO-1/LAGE-1a157-165 (N 157-165) or irrelevant 
peptide MAGE-A1278-286 (M 278-286) and K652 cells not-expressing HLA-A2 molecules (K562). Co-
cultures were set-up 3h after electroporation. IFN-γ release of transfected T cells was assessed by 
ELISA after 24h co-culture. Shown is the mean value of duplicates with standard deviations. This 
experiment was performed with two different donors. Shown is one representative experiment.  
4.2.3 Tumor cell line recognition 
To be potentially useful in a clinical setting, it is essential that T cells expressing the 
candidate TCR are able to specifically recognize tumor cells. In order to select tumor cell 
lines for testing the recognition mediated by T cells expressing TCR 5-271, the Nanostring 
nCounter® technology was used to investigate NY-ESO-1 mRNA expression in several 
tumor cell lines. To note, LAGE-1 is a tumor antigen showing high homology to NY-ESO-1 
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that comprises two alternatively spliced isoforms (figure 12A). The first isoform is 
designated as LAGE-1a and encodes a protein of 180 amino acids (aa), while the second 
one is designated as LAGE-1b and encodes a protein of 210 aa [110]. NY-ESO-1, LAGE-
1a and LAGE-1b mRNA transcripts and the corresponding proteins differ in parts of their 
sequences and in other parts they are identical (identical sequences are shown with an 
identical pattern in figure 12A). Importantly, the sequence encoding the epitope recognized 
by TCR 1G4-α95:LY is included both in NY-ESO-1 and in LAGE-1a (NY-ESO-1/LAGE-
1a157-165). To detect NY-ESO-1 mRNA expression by Nanostring nCounter® technology, 
two probes were designed. The first probe was designed to target a sequence present in 
NY-ESO-1, but not included in any isoform of LAGE-1 (probe 1, shown in black in figure 
12A). In contrast, the second probe was designed to target a region that included the 
sequence encoding the immunogenic epitope NY-ESO-1/LAGE-1a157-165 (probe 2, shown 
in grey in figure 12A). Therefore, NY-ESO-1 and LAGE-1a mRNA transcripts comprising 
the NY-ESO-1/LAGE-1a157-165-encoding sequence were both detected by the second 
probe. Nanostring results for the tumor cell lines showing the highest level of expression for 
either probe 1 or probe 2 are shown in figure 12B. The analyzed cell lines were all positive 
for probe 2, while they were either slightly positive or negative for probe 1. Consequently, 
the tumor cell lines were all positive for LAGE-1a, while only seven out of 15 were also 
positive for NY-ESO-1 (MelA375, U266, FM6, MOLP-8, EJM, RPMI-8226 and KMS-12-
BM). As LAGE-1a is highly homologous to NY-ESO-1 and the exact location of the epitope 
recognized by TCR 5-271 was unknown, the 15 tumor cell lines were all included in the 
assay to evaluate tumor recognition mediated by TCR 5-271. According to data derived 
from the TRON database (data were confirmed by flow cytometry analyses as shown in 
figure 13B), within the selected tumor cell lines, nine were endogenously positive for HLA-
A2, whereas six did not express HLA-A2 molecules. 
T cells derived from a healthy donor were transfected with ivtRNA encoding either TCR 5-
271 or TCR 1G4-α95:LY or TCR 3-9 and used as effector cells in the co-culture assays to 
assess tumor cell recognition. Additionally, water was electroporated into T cells as the 
negative control. The tumor cell line SK-Mel23 (endogenously HLA-A2-positive and NY-
ESO-1/LAGE-1a-negative) and K562 cells (endogenously HLA-A2-negative and NY-ESO-
1/LAGE-1a-negative) were used as the negative controls. To confirm the capacity of TCR-
transfected T cells to secrete IFN-γ after specific stimulation, tgK562 cells transfected with 
either NY-ESO-1 or GFP ivtRNA were included as internal target controls. IFN-γ release 




Figure 12. NY-ESO-1/LAGE-1a mRNA expression evaluated by Nanostring nCounter® 
technology. (A) Schematic depiction of NY-ESO-1 and LAGE-1 mRNA transcripts and of the two 
probes designed to perform Nanostring nCounter® analyses. Probe 1 (shown in black) targeted a 
sequence included in NY-ESO-1, but not in any isoform of the highly homologous tumor antigen 
LAGE-1 (LAGE-1a and LAGE-1b). In contrast, probe 2 (shown in grey) detected a region including 
the sequence encoding the epitope recognized by TCR 1G4-α95:LY (NY-ESO-1/LAGE-1a157-165, 
shown in blue) which is present in NY-ESO-1 as well as in LAGE-1a transcripts. Identical sequences 
in mRNA transcripts are shown with an identical pattern. (B) Results of NY-ESO-1/LAGE-1a mRNA 
expression analyses for 15 tumor cell lines (nine HLA-A2+, six HLA-A2-) selected to assess tumor 
recognition by TCR 5-271-transfected T cells. SK-Mel23 cell line and tgK562 cells (HLA-A2+, NY-
ESO-1/LAGE-1-) were included as negative controls. Data obtained using probe 1 (black bars) and 
probe 2 (grey bars) are shown. Data provided by Nanostring Headquarters facility (Seattle, USA). 
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As shown in figure 13A (top graph), IFN-γ release of transfected T cells was evaluated after 
incubation with the nine HLA-A2-positive tumor cell lines. TCR 5-271-transfected T cells did 
not recognize any tested tumor cell line. Although a slight IFN-γ release was detected after 
incubation with U266 and IM9 cells, this was due to the reactivity mediated by endogenous 
TCRs of the T cells and was not related to TCR 5-271-specific recognition since the same 
level of IFN-γ secretion was detected for T cells electroporated with water. However, TCR 
5-271 recognized tgK562 cells expressing NY-ESO-1, proving the capacity of these 
transfected T cells to release IFN-γ after specific stimulation. In contrast, TCR 1G4-α95:LY-
expressing T cells recognized all tested tumor cell lines except for the negative controls. 
TCR 3-9-transfected T cells released IFN-γ after stimulation with HLA-A2-expressing target 
cells (FM6, FM3, FM3.29 and MM415 were not analyzed), confirming HLA-A2 expression 
for the target cell lines. 
Since six tumor cell lines were HLA-A2-negative, ivtRNA encoding the HLA-A2 molecule 
was electroporated into these target cells. To verify the capacity of the tumor cell lines to 
process and present the unknown NY-ESO-1 peptide recognized by TCR 5-271, the same 
cell lines were also electroporated with ivtRNA encoding HLA-A2 in combination with NY-
ESO-1. As shown in figure 13A (bottom graph), TCR 5-271-transfected T cells did not 
recognize any of the HLA-A2-transfected tumor cell line, although they were endogenously 
positive for NY-ESO-1/LAGE-1a. A slight IFN-γ release was detected after incubation with 
RPMI-8226 and KM-12-PE cells, which was again due to the reactivity mediated by 
endogenous TCRs of the T cells and was not related to TCR 5-271-specific recognition 
since the same IFN-γ secretion was detected for T cells electroporated with water. 
However, IFN-γ secretion was detected in response to all tumor cell lines electroporated 
with ivtRNA encoding HLA-A2 plus NY-ESO-1, proving that the epitope recognized by TCR 
5-271 was efficiently processed and presented by the tested tumor cell lines. In contrast, 
TCR 1G4-α95:LY-expressing T cells recognized all HLA-A2-transfected tumor cell lines 
independently of NY-ESO-1 ivtRNA transfection and TCR 3-9-transfected T cells released 
IFN-γ after stimulation with all transfected target cells, confirming HLA-A2 expression after 
transfection for all samples. 
Surface expression of HLA-A2 molecules was analyzed by flow cytometry for all tumor cell 
lines used in the assays. As shown in figure 13B, the endogenously positive as well as the 






Figure 13. Tumor cell line recognition by TCR 5-271-expressing T cells. (A) T cells derived from 
a healthy donor were transfected with ivtRNA encoding either TCR 5-271 or TCR 1G4-α95:LY or an 
HLA-A2-allo-reactive TCR (TCR 3-9). T cells electroporated with water were used as a negative 
control. Electroporated T cells were used as effectors in co-culture assays with 15 tumor cell lines 
endogenously positive for NY-ESO-1/LAGE-1a according to NanoString data (see figure 12B). 
Figure legend continues on page 72. 
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Figure 13. Of the selected lines, nine were endogenously positive for HLA-A2 (top graph), while six 
were endogenously HLA-A2-negative (bottom graph). Thus, these six cell lines were tested after 
transfection with ivtRNA encoding either HLA-A2 alone (left graph) or in combination with ivtRNA 
encoding NY-ESO-1 (right graph) to verify the capacity of the tumor cell lines to process and present 
the unknown NY-ESO-1 peptide recognized by TCR 5-271. The SK-Mel23 cell line (HLA-A2+, NY-
ESO-1/LAGE-1a-) was used as the negative control. Moreover, tgK562 cells transfected with ivtRNA 
encoding either NY-ESO-1 or GFP were included as internal target controls. IFN-γ release of 
transgenic TCR-expressing T cells was measured by ELISA after 24h co-culture. Shown is the mean 
value of duplicates with standard deviations. This experiment was performed with two different 
donors. Shown is one representative experiment. FM6, FM3, FM3.29 and MM415 cell lines were not 
analyzed (n.a.) for recognition by TCR 3-9-transfected T cells. (B) HLA-A2 surface expression was 
detected by flow cytometry for all tested tumor cell lines. Endogenous expression is shown in green, 
expression after electroporation (EP) with ivtRNA encoding HLA-A2 is shown in black, HLA-A2 
expression after EP with ivtRNA encoding HLA-A2 and NY-ESO-1 is shown in blue and the negative 
control (HLA class I-negative K562 cells stained with the HLA-A2-specific antibody) is shown in grey. 
Populations shown are pre-gated on live single cells. 
4.2.4 NY-ESO-1-ORF2 recognition 
The wild-type NY-ESO-1 sequence (NY-ESO-1_wt) includes the ORF encoding the full-
length NY-ESO-1 protein consisting of 180 aa in the first reading frame (designated as NY-
ESO-1-ORF1) and three alternative ORFs in the second and third reading frame encoding 
proteins consisting of 58 aa, 50 aa and 14 aa (designated as NY-ESO-1-ORF2, -ORF3 and 
-ORF4, respectively) (figure 14A, left panel). Since the alternative ORFs are located in 
alternative reading frames compared to NY-ESO-1-ORF1, the corresponding proteins 
present completely different amino acid sequences compared to the NY-ESO-1-ORF1-
encoded protein. After electroporation with ivtRNA encoding NY-ESO-1_wt into mDCs, 
these alternative ORFs might have been translated and the corresponding proteins 
processed and presented in addition to the full-length NY-ESO-1-ORF1 protein. 
Consequently, T cells against peptides derived from these alternative NY-ESO-1 proteins 
might have been induced during the priming process. To verify the antigen specificity of 
TCR 5-271, a partial-codon-optimized version of NY-ESO-1 (NY-ESO-1_pco) was 
designed to exclude the alternative ORFs (NY-ESO-1-ORF2, -ORF3 and -ORF4) other than 
NY-ESO-1-ORF1 and cloned into the pGEM vector (figure 14A, right panel). Additionally, 
the three alternative NY-ESO-1-ORFs were cloned separately into the pGEM vector. 
ivtRNA was produced for NY-ESO-1-ORF2, -ORF3, -ORF4, NY-ESO-1_pco and NY-ESO-
1_wt and then transfected into tgK562 cells. These cells were used to stimulate CD8+ T 
cells transduced with either TCR 5-271 or TCR 1G4-α95:LY. Untransduced T cells were 
used as a negative control. IFN-γ release was evaluated by ELISA 24h after setting up the 





Figure 14. NY-ESO-1-ORF2 recognition by TCR 5-271-transgenic T cells. (A) Schematic 
depiction of the proteins encoded by alternative ORFs of NY-ESO-1. The wild-type NY-ESO-1 
sequence (NY-ESO-1_wt, left panel) includes four different ORFs in the three reading frames 
encoding proteins of 180 aa (ORF1, 5’3’ frame 1), 58 aa (ORF2, 5’3’ frame 2), 50 aa (ORF3, 5’3’ 
frame 2) and 14 aa (ORF4, 5’3’ frame 3) (ORFs are shown in blue). A partial-codon-optimized (pco) 
version of NY-ESO-1 (NY-ESO-1_pco, right panel) was designed to eliminate alternative ORFs 
(ORF2, ORF3 and ORF4) other than ORF1 encoding the full-length NY-ESO-1 protein consisting of 
180 aa. Figure wasadapted from the online translate tool ExPASy. (B) CD8+ T cells were isolated 
from a healthy donor and transduced with either TCR 5-271 or TCR 1G4-α95:LY. Untransduced T 
cells served as a negative control. IFN-γ release of TCR-transgenic CD8+ T cells was evaluated after 
24h co-culture with tgK562 cells transfected with ivtRNA encoding either NY-ESO-1_wt, NY-ESO-
1_pco, NY-ESO-1-ORF2, -ORF3 or -ORF4. Electroporation of tgK562 cells with water was 
performed as a negative target control. Shown is the mean value of duplicates with standard 





Interestingly, TCR 5-271-transduced T cells showed IFN-γ secretion after stimulation with 
tgK562 cells expressing either NY-ESO-1_wt or NY-ESO-1-ORF2, but they were not 
activated by tgK562 cells transfected with NY-ESO-1_pco or any other NY-ESO-1-ORFs. 
On the other hand, TCR 1G4-α95:LY-transgenic T cells recognized tgK652 cells transfected 
with ivtRNA encoding NY-ESO-1_wt as well as NY-ESO-1_pco. These results 
demonstrated that TCR 5-271 was not specific for a peptide derived from the full-length NY-
ESO-1-ORF1 protein, but for an epitope present in the 58 aa NY-ESO-1-ORF2 protein. 
Moreover, they showed that after electroporation with ivtRNA encoding NY-ESO-1_wt into 
tgK562 cells, NY-ESO-1-ORF2 was translated and the corresponding protein processed 
and presented in addition to the full-length NY-ESO-1-ORF1 protein. 
4.2.5 Epitope identification 
In order to narrow down the region recognized within the NY-ESO-1-ORF2 protein by TCR 
5-271, five constructs were designed encoding 20-mer peptides derived from the NY-ESO-
1-ORF2 protein, overlapping by ten aa and linked to GFP (1-20 aa, 11-30 aa, 21-40 aa, 31-
50 aa, 41-58 aa) (figure 15A). ivtRNA was produced for each construct and used to transfect 
tgK562 cells. As shown in figure 15B, GFP expression in transfected tgK562 cells was 
detected for all five constructs, proving successful transfection. A co-culture assay was set 
up using the transfected tgK562 cells to stimulate CD8+ T cells expressing either TCR 5-
271 or TCR 1G4-α95:LY. Untransduced T cells served as a negative control. Additionally, 
ivtRNA encoding either NY-ESO-1_wt or NY-ESO-1-ORF2 full-length protein were 
transfected into tgK562 cells as internal positive controls for the assay and tgK562 cells 
were electroporated with water as the negative control. IFN-γ ELISA was performed 24h 
after setting up the co-culture (figure 15C). TCR 5-271-transduced T cells released IFN-γ 
after incubation with tgK562 cells transfected with ivtRNA encoding the 20-mer peptide 1-
20 aa of the NY-ESO-1-ORF2 protein, showing that the TCR 5-271 epitope was located in 
the first 20 aa. ivtRNA encoding the other 20-mer peptides of NY-ESO-1-ORF2 (11-30 aa, 
21-40 aa, 41-58 aa) did not lead to any activation of TCR 5-271-transduced T cells. As 
expected, TCR 1G4-α95:LY-transgenic T cells recognized only tgK652 cells transfected 




Figure 15. TCR 5-271 epitope identification: NYESO-1-ORF2 first 20 aa. (A) Schematic 
representation of the five constructs designed to produce ivtRNA encoding 20-mer peptides derived 
from NY-ESO-1-ORF2 protein overlapping by ten aa and linked to GFP (1-20 aa, 11-30 aa, 21-40 
aa, 31-50 aa, 41-58 aa). Figure legend continues on page 76. 
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Figure 15. (B) GFP expression for each construct was detected by flow cytometry after ivtRNA 
electroporation (EP) into tgK562 cells (shown in green). Water-electroporated tgK562 cells were 
used as the background control (shown in grey). Populations shown are pre-gated on live single 
cells. (C) TCR 5-271- or TCR 1G4-α95:LY-transduced T cells were incubated with tgK562 cells 
transfected with ivtRNA encoding 1-20 aa, 11-30 aa, 21-40 aa, 31-50 aa, 41-58 aa peptides derived 
from NY-ESO-1-ORF2 protein. In addition, tgK562 cells transfected with ivtRNA encoding either NY-
ESO-1_wt or NY-ESO-1-ORF2 full-length protein were included as positive controls. Water 
electroporation into tgK562 cells served as a negative control. IFN-γ ELISA was performed after 24h 
of co-culture. Shown is the mean value of duplicates with standard deviations. This experiment was 
performed with two different donors. Shown is one representative experiment. 
A group of 14 peptides that bound to HLA-A2 molecules, ranging from 8-mer to 12-mer and 
covering the first 20 aa of NY-ESO-1-ORF2 protein were selected and subsequently used 
to assess the core epitope recognized by TCR 5-271 (figure 16A). T2 cells loaded with 
either these 14 peptides or with an irrelevant peptide (MAGE-A1278-286) served as stimulator 
cells for CD8+ T cells transduced with TCR-5-271 and for untransduced T cells. IFN-γ 
secretion was determined 24h after setting up the co-cultures by ELISA. To note, whenever 
no IFN-γ release was observed it was not possible to verify whether the tested peptide 
sufficiently bound to the HLA-A2 molecules. Therefore, the absence of T cell activation 
could be due either to the abrogation of the peptide:MHC binding or to the disability of the 
TCR to interact properly with the peptide:MHC complex in order to lead to T cell activation. 
TCR 5-271-transduced T cells released IFN-γ in response to T2 cells loaded with six out of 
the 14 tested peptides (figure 16B). Peptides from 8- to 12-mer mapping from position 7 to 
position 20 of the NY-ESO-1-ORF2 protein were recognized by TCR 5-271-expressing T 
cells. As shown in figure 16A, the recognized peptides showed an identical sequence of 
eight aa, representing the minimum sequence needed for recognition by TCR 5-271 (NY-






Figure 16. TCR 5-271 core epitope identification: NY-ESO-1-ORF211-18, LMAQGAML. (A) 
Position in the NYESO-1-ORF2-protein (start - end), peptide length (X-mer) and peptide sequence 
are shown for the 14 peptides selected for the identification of the TCR 5-271 epitope. The six 
peptides recognized by TCR 5-271-transgenic T cells in the IFN-γ ELISA assay (data shown in figure. 
16B) comprised an identical sequence of eight aa (NYESO-1-ORF211-18, LMAQGAML) shown in blue. 
(B) CD8+ T cells transduced with TCR 5-271 and untransduced cells were stimulated with T2 cells 
loaded with either the 14 selected peptides or with irrelevant peptide MAGE-A1278-286. IFN-γ release 
was evaluated 24h after setting up the co-cultures by ELISA. Shown is the mean value of duplicates 
with standard deviations. This experiment was performed using two different donors. Shown is one 
representative experiment.  
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4.2.6 Fine typing of the recognized epitope  
The fine typing of an identified epitope is needed to subsequently investigate potential TCR 
cross-recognition of alternative peptides that contain amino acid exchanges compared to 
the known epitope sequence [68]. These alternative peptides can be expressed in healthy 
tissues, presented on corresponding MHC molecules and recognized equally by the 
transgenic TCR, leading to potential unwanted side effects in clinical applications 
(designated as off-target toxicity). Therefore, alanine scanning assays were performed to 
determine the contribution of each aa of the HLA-A2-bound epitope to the interaction with 
the TCR 5-271. The amino acids included in the 12-mer NY-ESO-1-ORF27-18, 11-mer NY-
ESO-1-ORF210-20 and 9-mer NY-ESO-1-ORF210-18 peptides, recognized by TCR 5-271-
transgenic T cells in previous experiments, were consecutively replaced by an alanine (or 
by a glycine where an alanine was already present in the original sequence) (figure 17). T2 
cells were loaded with these modified peptides and used as APCs to induce IFN-γ release 
of either TCR 5-271-transduced T cells or untransduced T cells. The three wild-type 
peptides were included in the assays as positive controls and the irrelevant peptide MAGE-
A1278-286 served as the negative control. To note, as discussed before, whenever no IFN-γ 
release was observed it was impossible to verify whether the tested peptide sufficiently 
bound to the HLA-A2 molecules. Therefore, the absence of T cell activation could be due 
either to the abrogation of the peptide:MHC binding or to the disability of the TCR to interact 
properly with the peptide:MHC complex in order to lead to T cell activation. Replaced amino 
acids that led to the abrogation of IFN-γ release by T cells were defined as “non-
exchangeable amino acids” within the epitope sequence. As shown in figure 17, the 
phenylalanine (F) at position 4 (P4) in the 12-mer and at P1 in the 11- and 9-mer, as well 
as the leucine (L) at P5 in the 12-mer and at P2 in the 11- and 9-mer, were identified to be 
non-exchangeable in the three peptides tested. The substitution of the glycine (G) at P9 in 
the 12-mer and at P6 in the 11- and 9-mer only affected TCR 5-271 recognition of the 9-
mer peptide. All the other aa of the peptides tested could be replaced either by alanine or 






Figure 17. Fine typing of the epitope recognized by TCR 5-271. Alanine scanning analyses were 
performed for the 12-mer NY-ESO-1-ORF27-18, 11-mer NY-ESO-1-ORF210-20 and 9-mer NY-ESO-1-
ORF210-18 peptides recognized by TCR 5-271-transgenic T cells. The amino acids included in these 
peptides were consecutively replaced by an alanine or by a glycine when an alanine was already 
present in the original sequence. Peptide tables include the original peptide sequence (first line) and 
the alanine/glycine scanning peptide panel (exchanged aa are shown in bold). The identical 
sequence included in the tested peptides is shown in blue. T2 cells were loaded with the modified 
peptides and used in the co-cultures with either T cells expressing TCR 5-271 or with untransduced 
T cells to assess IFN-γ release by ELISA after 24h of incubation. The irrelevant MAGE-A1278-286 
peptide was included as the negative control. Shown is the mean value of duplicates with standard 
deviations. Each experiment was performed with two different donors. Representatively shown are 




4.2.7 Recognition of LAGE-1 and CAMEL 
Both isoforms of the tumor antigen LAGE-1 (highly homologous to NY-ESO-1) include not 
only the primary ORF in the first reading frame encoding the full-length protein (designated 
as LAGE-1a-ORF1 and LAGE-1b-ORF1), but also an alternative ORF in the second 
reading frame (figure 18). This alternative ORF is called LAGE-1-ORF2 and is identical in 
LAGE-1a and in LAGE-1b. The AUG start codon of the LAGE-1-ORF2 is located 40 base 
pairs (bp) downstream of the AUG of LAGE-1-ORF1. Translation of LAGE-1-ORF2 leads 
to the production of a 109 aa protein called CAMEL [111]. Importantly, the N-terminal 54 aa 
of CAMEL are identical to the N-terminal 54 aa of NY-ESO-1-ORF2 protein. Since the 
epitope recognized by TCR 5-271 (NY-ESO-1-ORF211 -18) was located in the region shared 
by NY-ESO-1-ORF2 and CAMEL, the recognition of LAGE-1 and CAMEL by TCR 5-271-
transgenic T cells was evaluated. CAMEL, LAGE-1a wild-type (LAGE-1a_wt) and a partial-
codon-optimized version of LAGE-1a including only the LAGE-1-ORF1 (LAGE-1a_pco) 
were cloned into the pGEM vector (figure 19A). ivtRNA encoding CAMEL, LAGE-1a_wt or 
LAGE-1a_pco were transfected into tgK562 cells. In addition, ivtRNA encoding NY-ESO-
1_wt, NY-ESO-1_pco or NY-ESO-1-ORF2 were transfected into tgK562 cells as positive 
controls for the assay. Water electroporation of tgK562 cells served as the negative control. 
Electroporated tgK562 cells were used as stimulator cells for CD8+ T cells transduced with 
either TCR 5-271 or TCR 1G4-α 95:LY in order to induce IFN-γ release. Untransduced 
CD8+ T cells were included as a negative control. As shown in figure 19B, T cells expressing 
TCR 5-271 recognized tgK562 cells transfected with ivtRNA encoding NY-ESO-1_wt or NY-
ESO-1-ORF2 as well as LAGE-1a_wt or CAMEL. In contrast, they did not release IFN-γ 
after incubation with NY-ESO-1_pco- and LAGE-1a_pco-transfected tgK562 cells. These 
results confirmed that the TCR 5-271 was specific for a peptide derived from the proteins 
encoded by ORF2 of NY-ESO-1 as well as by ORF2 of LAGE-1a. As expected, TCR 1G4-
α95:LY-transgenic T cells were activated only in response to tgK562 cells expressing the 
wt or pco versions of both NY-ESO-1 and LAGE-1a, confirming that TCR 1G4-α95:LY was 
specific for a peptide derived from proteins encoded by ORF1 of NY-ESO-1 and LAGE-1a. 
Furthermore, these findings showed that after electroporation with ivtRNA encoding LAGE-
1_wt into tgK562 cells, LAGE-1-ORF2 was translated and the corresponding CAMEL 
protein was processed and presented in addition to the full-length LAGE-1a-ORF1 protein. 
Interestingly, TCR 5-271-transgenic T cells showed better recognition of tgK562 cells 
expressing NY-ESO-1_wt compared to LAGE-1a_wt-transfected tgK562 cells, whereas 
TCR 1G4-α95:LY-transgenic T cells were equally activated by tgK562 cells expressing NY-
ESO-1_wt or LAGE-1a_wt. This observation could not be explained by differences in 
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transfection efficiency of NY-ESO-1 and LAGE-1a, and hence one hypothesis was that 
ORF2 of NY-ESO-1 was more efficiently translated than ORF2 of LAGE-1a. 
 
Figure 18. Schematic representation of NY-ESO-1 and LAGE-1 mRNA transcripts and protein 
products. LAGE-1 mRNA (both isoforms, LAGE-1a and LAGE-1b), as described for NY-ESO-1, 
comprises not only the ORF in the first frame (LAGE-1-ORF1) encoding the full-length protein (180 
aa LAGE-1a and 210 aa LAGE-1b), but also an alternative ORF in the second reading frame (LAGE-
1-ORF2, identical for the two LAGE-1 isoforms). Translation of LAGE-1-ORF2 leads to the 
production of a 109 aa protein called CAMEL. The N-terminal 54 aa of CAMEL are identical to the 
N-terminal 54 aa of NY-ESO-1-ORF2 protein. Identical sequences in the proteins are shown by 
identical patterns. The locations of the NY-ESO-1/LAGE-1157-165 epitope recognized by TCR 




Figure 19. Recognition of LAGE-1 and CAMEL by TCR 5-271-transgenic T cells. (A) Schematic 
depiction of NY-ESO-1_wt, NY-ESO-1_pco, NY-ESO-1-ORF2, LAGE-1a_wt, LAGE-1a_pco and 
CAMEL mRNA transcripts and corresponding protein products. Identical sequences in the proteins 
are shown by identical patterns. The locations of the NY-ESO-1/LAGE-1a 157-165 epitope recognized 
by TCR 1G4:95:LY and the NY-ESO-1-ORF2/CAMEL11-18 epitope recognized by TCR 5-271 are 
shown. (B) tgK562 cells were transfected with ivtRNA encoding NY-ESO-1_wt, NY_ESO-1_pco, NY-
ESO-1-ORF2, LAGE-1a_wt, LAGE-1a_pco or CAMEL. tgK562 cells electroporated with water 
served as negative target controls. Electroporated tgK562 cells were co-cultured with T cells 
transduced with either TCR 5-271 or TCR 1G4-α95:LY. Untransduced T cells were included as 
negative controls. IFN-γ release was evaluated 24h after T cell stimulation. Shown is the mean value 
of duplicates with standard deviations. This experiment was performed with two different donors. 
Shown is one representative experiment. 
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4.2.8 Recognition of target antigen-transfected tumor cell lines  
 To further investigate the hypothesis that ORF2 of NY-ESO-1 was more efficiently 
translated than ORF2 of LAGE-1a, ivtRNA encoding either NY-ESO-1_wt or LAGE-1a_wt 
was transfected in tumor cell lines and the recognition by TCR 5-271-transgenic T cells was 
evaluated. The NY-ESO-1/LAGE-1a-positive cell lines FM6, MM415, Mel624.38, MelA375 
and the NY-ESO-1/LAGE-1a-negative tumor cell lines MM127, SK-Mel23 and gK562 were 
selected as target cells (see Nanostring analyses for NY-ESO-1/LAGE-1a mRNA 
expression, figure 12B. Data not shown for the tumor cell line MM127). All the selected 
tumor cell lines expressed HLA-A2 molecules on the cell surface as confirmed by flow 
cytometry analysis (figure 20A). In previous experiments, it was shown that the four 
selected tumor cell lines, endogenously positive for NY-ESO-1/LAGE-1a, were recognized 
by T cells expressing TCR 1G4-α95:LY. Therefore, an additional internal control was 
needed to prove that the expected lack or reduction of LAGE-1a recognition by TCR 5-271 
was due to reduced ORF2 translation and not due to inefficient transfection. Since selected 
tumor cell lines did not express the minor histocompatibility antigen HA-1H, a CD8+ T cell 
clone specific for HA-1H (HA-1137-145(H139)) and restricted to HLA-A2 (clone 10/24) was used 
as an internal control. The tumor cell lines were transfected simultaneously with ivtRNA 
encoding either NY-ESO-1_wt or LAGE-1a_wt in combination with ivtRNA encoding HA-
1H. Untransfected and ivtRNA-transfected tumor cell lines were used to stimulate IFN-γ 
release of T cells expressing either TCR 5-271 or TCR 1G4-α95:LY. Untransduced T cells 
served as the negative control.  IFN-γ ELISA was performed 24h after setting up the co-
culture (figure 20B). As already observed, TCR 5-271-transduced T cells did not recognize 
any tumor cell lines even if they were endogenously NY-ESO-1/LAGE-1a-positive. 
However, they secreted IFN-γ when incubated with the same cell lines transfected with NY-
ESO-1_wt ivtRNA. After incubation with LAGE-1a_wt-transfected cell lines, TCR 5-271-
trangenic T cells released either lower amounts of IFN-γ compared to the amount detected 
by stimulation with NY-ESO-1-transfected cells (FM6, MM415) or did not secrete IFN-γ at 
all (Mel624.38, MelA375). TCR 1G4-α95:LY-transgenic T cells recognized all tumor cell 
lines that were endogenously positive for NY-ESO-1/LAGE-1a without the need of 
additional ivtRNA electroporation. Clone 10/24 did not release IFN-γ in response to any of 
the tested tumor cell lines without ivtRNA transfection. On the other hand, T cell activation 
was observed when clone 10/24 was co-cultured with HA-1H-transfected cell lines in 
combination with NY-ESO-1 as well as with LAGE-1a, showing efficient transfections in 




Figure 20. Tumor cell line recognition after either NY-ESO-1_wt- or LAGE-1a_wt ivtRNA 
transfection by TCR 5-271-transgenic T cells. Figure legend continues on page 85. 
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Figure 20. (A) HLA-A2 expression in FM6, MM415, Mel624.38, MelA375, MM127, SK-Mel23 and 
tgK562 cell lines was evaluated by flow cytometry. Stained tumor cell lines are shown in black and 
the negative control (HLA class I-negative K562 cells stained with the HLA-A2-specific antibody) is 
shown in grey. Populations shown are pre-gated on live single cells. (B) The NY-ESO-1/LAGE-1a-
positive cell lines FM6, MM415, Mel624.38, MelA375 and the NY-ESO-1/LAGE-1a-negative tumor 
cell lines MM127, SK-Mel23 and tgK562 were transfected with ivtRNA encoding either NY-ESO-
1_wt or LAGE-1a_wt in combination with HA-1H antigen. Untransfected and transfected tumor cell 
lines were used as target cells in co-culture assays. TCR 5-271-, TCR 1G4-α95:LY-transduced T 
cells and untransduced T cells served as effector cells. The clone 10/24 was included as an internal 
effector control recognizing HA-1H peptide (HA-1137-145(H139)) on HLA-A2 molecules. IFN-γ release 
was measured by ELISA 24h after setting up the co-cultures. Shown is the mean value of duplicates 
with standard deviations.  
The tumor cell lines MM127, SK-Mel23 and tgK562, endogenously NY-ESO-1/LAGE-1a-
negative and HA-1H-negative, were recognized by TCR 5-271-transduced T cells, by TCR 
1G4-α95:LY-transduced T cells and by clone 10/24 only after ivtRNA transfection. 
Interestingly, TCR 1G4-α95:LY-transgenic T cells and clone 10/24 released similar 
amounts of IFN-γ in response to NY-ESO-1/HA-1H and to LAGE-1a/HA-1H stimulation. In 
contrast, TCR 5-271-transduced T cells showed better recognition when the three cell lines 
were transfected with NY-ESO-1/HA-1H compared to LAGE-1a/HA-1H. All together these 
results supported the hypothesis that ORF2 of NY-ESO-1 was more efficiently translated 
than ORF2 of LAGE-1a in tgK562 cells and also in the tested tumor cell lines. 
4.2.9 Killing of target epitope-loaded cells  
Functionality of TCR-transgenic T cells can be addressed by evaluating IFN-γ release upon 
target antigen-specific stimulation as well as by testing their capacity to mediate killing of 
cells expressing the target tumor antigen. Therefore, the killing capacity of TCR 5-271-
transgenic T cells was assessed by live-cell imaging. The first experiment was performed 
to assess the killing of T2 cells after specific peptide loading. T2 cells were stably 
transduced with a lentiviral vector that enabled nuclear labelling by homogenous expression 
of the mKate2 protein (red fluorescent protein) without altering cell function and with minimal 
toxicity. After transduction, T2 cells were analyzed by flow cytometry and 92.1% of the cells 
expressed mKate2 protein resulting in the red-label (figure 21A). These red-labelled T2 




Figure 21. Analyses of T2 cells transduced with a red fluorescent reagent. T2 cells were stably 
transduced with a red fluorescent reagent for nuclear labelling. (A) The transduction rate was 
analyzed by flow cytometry. Transduced T2 cells are shown in red, while untransduced cells are 
shown in grey. Populations shown are pre-gated on live single cells. (B) Exemplary image of red-
labelled T2 cells detected by live-cell imaging. 
Red-labelled T2 cells were loaded with either peptide NY-ESO-1-ORF-211-18 (specific 
peptide for TCR 5-271, irrelevant peptide for TCR 1G4-α95:LY) or with NY-ESO-1/LAGE-
1a157-165 peptide (specific peptide for TCR 1G4-α95:LY, irrelevant peptide for TCR 5-271). 
After peptide loading, red-labelled T2 cells were incubated with T cells expressing TCR 5-
271 or TCR 1G4-α95:LY. Untransduced T cells served as the negative control. The cells 
were monitored over 48h by live-cell imaging to evaluate the decrease of the red 
fluorescence intensity showing T2 cell killing mediated by TCR-transgenic T cells. Images 
acquired at time point zero (0h) and 24h as well as 48h after setting up the co-cultures are 
shown in figure 22. A decrease of the red fluorescence intensity was observed only when 
TCR 5-271-transduced T cells were incubated with peptide NY-ESO-1-ORF-2/CAMEL11-18-
loaded T2 cells and when TCR 1G4-α95:LY-transduced T cells were added in the co-culture 
with peptide NY-ESO-1/LAGE-1a157-165-loaded T2 cells. In contrast, an increase of the red 
fluorescence intensity due to proliferation of the labelled T2 cells was detected when TCR 
5-271- and TCR 1G4-α95:LY-transduced T cells were incubated with irrelevant peptide-
loaded T2 cells. The red fluorescence intensity increased also when untransduced T cells 









Figure 22. Killing of red-labelled T2 cells loaded with specific peptide by TCR 5-271-transgenic 
T cells. Red-labelled T2 cells were loaded with either peptide NY-ESO-1-ORF-211-18 (specific peptide 
for TCR 5-271, irrelevant peptide for TCR 1G4-α95:LY) or with peptide NY-ESO-1/LAGE-1a157-165 
(specific peptide for TCR 1G4-α95:LY, irrelevant peptide for TCR 5-271). After peptide loading, red-
labelled T2 cells were incubated with T cells expressing either TCR 5-271 or TCR 1G4-α95:LY and 
with untransduced T cells served as negative control (E:T ratio of 40:1). The cells were monitored 
over a time of 48h using a live-cell imaging system to evaluate the decrease of the red fluorescence 
intensity showing T2 cell killing mediated by TCR-transgenic T cells. Images acquired at time point 
zero (0h) and 24h as well as 48h after setting up the co-cultures are shown. 
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In a second experiment, MM415, Mel624.38 and tgK562 cell lines were selected as target 
cells and transfected with ivtRNA encoding NY-ESO-1_wt to assess the capacity of T cells 
expressing TCR 5-271 to kill tumor cell lines that processed and presented the TCR 5-271 
epitope by internal cellular pathways. T cells transduced with either TCR 5-271 or TCR 
1G4-α95:LY were used as effector cells and untransduced T cells were used as the 
negative control. To evaluate apoptosis in the co-cultures, the Annexin V red reagent was 
added to the medium and the cells were monitored by live-cell imaging over 48h. Images 
acquired at time point zero (0h) and 24h as well as 48h after setting up the co-cultures are 
shown in figure 23. Apoptotic red cells as well as clusters of T cells and target cells were 
detected for all NY-ESO-1-transfected tumor cell lines after incubation with T cells 
expressing either TCR 5-271 or TCR 1G4-α95:LY. To note, TCR 1G4-α95:LY-transduced 
CD8+ T cell seemed to mediate killing with a better efficiency compared to TCR 5-271-
transduced T cells. In contrast, growing target cells were observed for all tumor cell lines 
when untransduced T cells were used as effectors. 
In conclusion, these data showed that TCR 5-271-transduced T cells were able to mediate 










Figure 23. Killing of NY-ESO-1-transfected tumor cell lines by TCR 5-271-transgenic T cells. 
MM415 (A), Mel624.38 (B) and tgK562 (C) cell lines were transfected with ivtRNA encoding NY-
ESO-1_wt. T cells transduced with either TCR 5-271 or TCR 1G4-α95:LY and untransduced T cells 
were incubated with transfected tumor cell lines 24h after transfection (TF) (E:T ratio of 40:1). 
Annexin V red reagent was added to the medium for evaluation of the apoptosis over a time of 48h 
by live-cell imaging. Images acquired at time point zero (0h) and 24h as well as 48h after setting up 
the co-cultures are shown. 
4.2.10 Evaluation of T cell peptide sensitivity 
In principle, a therapeutic TCR needs to have high specificity as well as optimal sensitivity 
for its peptide:MHC complex in order to efficiently mediate tumor killing and to discriminate 
between tumor cells and normal cells to avoid unwanted side effects. TCR affinity is defined 
as strength of the monomeric interaction between the TCR and a peptide:MHC complex. 
Since T cells express more than one TCR molecule, the overall binding strength of all 
available TCR molecules, called avidity, has to be considered for accurate evaluation in a 
physiological context. Evaluation of T cell peptide sensitivity, by analyzing IFN-γ secretion 
by T cells in response to APCs loaded with graded amounts of the target epitope, 
represents one method commonly used to validate the so called functional avidity of TCR-
transgenic T cells. Serial dilutions are used to calculate effective epitope concentrations 
which induce half-maximal T cell responses, measured by IFN-γ amounts. The lower the 
amount of specific peptide that is required for half-maximal activation of the T cells, the 
Results 
91 
higher is the functional avidity and the peptide sensitivity. Importantly, using this method a 
direct comparison of peptide sensitivity for T cells expressing transgenic TCRs specific for 
different peptides is impossible because the outcome of the assay is influenced by the 
stability of the specific target peptide in solution and by the peptide MHC binding affinity. 
Here, peptide sensitivity of TCR 5-271-expressing CD8+ T cells was assessed by using 
serial dilutions of either the 9-mer peptide NY-ESO-1-ORF2/CAMEL10-18 or of the 8-mer 
peptide NY-ESO-1-ORF2/CAMEL11-18 loaded on T2 cells. Untransduced CD8+ T cells were 
used as the negative control. IFN-γ release by CD8+ T cells was evaluated 24h after setting 
up the co-cultures by ELISA (figure 24). Peptide sensitivity of TCR 5-271-expressing T cells 
were similar in response to titrated amounts of the 8-mer and 9-mer target peptides. TCR 
5-271-expressing T cells showed half-maximal IFN-γ release at approximately 10-6 M, 
requiring very high amounts of peptides for activation.  
 
Figure 24. Peptide sensitivity of TCR 5-271-transduced T cells. T2 cells were loaded with titrated 
amounts of either the peptide NY-ESO-1-ORF2/CAMEL 10-18 (9-mer) or of the peptide NY-ESO-1-
ORF2/CAMEL 11-18 (8-mer). Loaded T2 cells were co-cultured with TCR 5-271-expressing CD8+ T 
cells. Untransduced CD8+ T cells served as the negative controls for all conditions. An ELISA was 
performed after 24h to evaluate IFN-γ release by CD8+ T cells. Dashed lines indicate the peptide 
concentrations needed to induce the half-maximal IFN-γ secretion. This experiment was performed 




4.2.11 Evaluation of CD8-dependency 
The CD8 co-receptor is known to directly bind to MHC class I molecules and to be critical 
for the development of CD8+ T cells. CD8 stabilizes the binding of a TCR to the MHC-
peptide complex and facilitates early events of the TCR signaling cascade [112]. 
Nevertheless, it has been shown that some TCRs restricted to MHC class I molecules can 
induce T cell activation upon antigen encounter without the need of CD8-costimulation 
[113]. To evaluate the impact of CD8 co-receptor on the functionality of the identified TCR, 
TCR 5-271 was transferred into a CD8+ T cell clone (clone 10/24) and into a CD4+ T cell 
clone (clone 234) by retroviral transduction. The same clones were transduced also with 
TCR 1G4-α95:LY and used as positive controls since it has been shown that this TCR is 
CD8-independent and functions efficiently in CD4+ T cells [58]. Untransduced T cell clones 
served as negative controls. As shown in figure 25A, the transduction rates were analyzed 
by flow cytometry. Transduction was efficient for both TCRs in the CD8+ clone as well in 
the CD4+ clone. In particular, 29.0% of CD8+ cells expressed TCR 5-271 and 36.0% were 
TCR 1G4-α95:LY-positive, while 40.5% of CD4+ cells showed TCR 5-271 expression and 
42.4% expressed TCR 1G4-α95:LY. Transduced clones were tested in a co-culture assay 
using tgK562 cells electroporated with either NY-ESO-1_wt ivtRNA or with water as target 
cells and IFN-γ secretion was evaluated after 24h by ELISA. To verify the functionality in 
terms of IFN-γ release for the CD8+ and CD4+ clones, specific targets recognized by their 
endogenous TCRs were included in the assay. T2 cells loaded with either the specific 
peptide recognized by clone 10/24 (HA-1137-145(H139)) or with an irrelevant peptide (HA-1137-
145(R139)) were used as target controls for the CD8+ clones. HLA-A24-positive and HLA-A24-
negative LCL served as control targets for the CD4+ clones since the clone 234 was shown 
to be HLA-A24-reactive (data unpublished). As shown in figure 25B, CD8+ clone T cells as 
well as CD4+ clone T cells expressing TCR 5-271 recognized NY-ESO-1-transfected 
tgK562 cells, showing that the functionality of the transgenic TCR was not dependent on 
the presence of the CD8 co-receptor. TCR 1G4-α95:LY worked efficiently after transduction 
in CD8+ clone T cells and in CD4+ clone T cells, confirming its CD8-independency. The 
functionality of TCR-transduced and untransduced clones was shown by their activation 





Figure 25. Functionality of TCR 5-271 in CD8+ and in CD4+ T cells. (A) TCR 5-271 and TCR 1G4-
α95:LY were transferred into a CD8+ T cell clone (clone 10/24) and into a CD4+ T cell clone (clone 
234) by retroviral transduction. Transduction rates were analyzed by flow cytometry. Untransduced 
T cell clones were used as background controls. Populations shown are pre-gated on live single 
cells. (B) Transduced T cell clones were tested in a co-culture assay with tgK562 cells electroporated 
with either NY-ESO-1_wt ivtRNA or water to evaluate the role of the CD8 co-receptor for the 
functionality of TCR 5-271 and of TCR 1G4-α95:LY. Untransduced clones served as negative 
controls. T2 cells loaded with the specific peptide recognized by clone 10/24 (HA-1H137-145(H139), HA-
1 H139) or with an irrelevant peptide (HA-1R137-145(R139), HA-1 R139) were used as target controls for 
the CD8+ clones. HLA-A24-positive and -negative LCL were included as control targets for the CD4+ 
clones since the clone 234 was shown to be HLA-A24-reactive. IFN-γ release was measured 24h 




In this project, a CD8+ T cell clone and the corresponding TCR specific for a new 
unconventional epitope derived from NY-ESO-1 and LAGE-1 were isolated and 
characterized. NY-ESO-1-specific T cells were induced using an in vitro allogeneic priming 
approach. An innovative sorting strategy based on the activation-induced T cell marker 
CD137 and K562 as stimulating cells was developed and tested for the first time in order to 
enable the isolation of T cells specific for unknown epitopes of NY-ESO-1. The TCR 
sequence of the isolated NY-ESO-1-reactive clone 5-271 was analyzed and reconstructed 
for transgenic expression in recipient cells to allow the characterization of the properties of 
the identified TCR. Interestingly, the recognized epitope turned out to be a peptide derived 
from the second ORF of NY-ESO-1 and LAGE-1. Tumor cell recognition was observed only 
in response to antigen-loaded or antigen-transfected tumor cell lines. TCR 5-271-
transduced T cells showed low peptide sensitivity, but a CD8-independent functionality. 
5.1 Experimental procedure for the isolation of NY-ESO-1-
specific CD8+ T cells 
5.1.1 Priming approach 
In this project, an in vitro allogeneic priming approach was performed to stimulate and 
expand HLA-A2-restricted NY-ESO-1-specific CD8+ T cells. mDCs derived from an HLA-
A2-negative healthy donor were transfected with one ivtRNA encoding the foreign HLA-A2 
molecule and one encoding the full-length NY-ESO-1 antigen and used to stimulate 
autologous CD8-enriched T cells. 
Unlike strategies in autologous settings, the allogeneic priming approach enables the 
access to the non-tolerant high-affinity allo-reactive TCR repertoire, allowing the potential 
isolation of high-avidity T cells that recognize peptides derived from the TAA of interest [79]. 
Due to the excellent capacity of mDCs to induce (prime) antigen-specific T cells from the 
naïve lymphocyte repertoire, priming procedures including in vitro mDCs have been 
successfully established [80], [84]. Accordingly, in vitro mDCs were selected as APCs for 
the priming procedure performed in this project. Protocols using other types of APCs to 
stimulate tumor antigen-specific T cells from the non-tolerant allo-reactive T cell repertoire 
of healthy donors have also been utilized by several research groups. Approaches including 
the T2 cell line (T and B cell hybrid), that has defects in the antigen-processing pathway but 
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expresses HLA-A2 molecules on its surface, have been developed to isolate tumor antigen-
specific HLA-A2-allo-restricted T cells from healthy donors [81], [83], [114]. However, many 
T cell clones isolated using these non-professional APCs were not able to efficiently 
recognize tumor cells endogenously positive for the antigen of choice. Other groups have 
utilized B cells as APCs after they coupled MHC-peptide monomers to the CD20 molecules 
on the surface [115]. This approach exploits the professional APC capacity of B cells, albeit 
it is a quite laborious procedure requiring the generation of MHC-peptide monomers for 
each tumor antigen of interest.  
In this thesis, ivtRNA transfection was chosen as method to express the desired HLA 
molecules and tumor antigen into mDCs in order to enable the induction of HLA-A2-
restricted NY-ESO-1-specific T cells. In general, MHC epitope loading can be achieved 
either by external loading of pre-defined peptides or by cell-intrinsic presentation of 
endogenous peptides by classical MHC presentation pathways [116], [117]. External 
loading of small synthetic peptides allows only the isolation of T cells with pre-defined 
specificities. The selection of peptides requires the knowledge of immunogenic epitopes 
derived from the antigen of interest. Importantly, externally loaded peptides are not subject 
to post-translational modifications. Therefore, this loading strategy includes the risk of 
isolating T cells only able to recognize synthetic peptides and not physiologically processed 
and presented epitopes. In addition, externally loaded peptide:MHC complexes frequently 
exhibit short half-lives which may hamper successful priming of T cells. All these limitations 
led to the exclusion of the usage of short peptides to load mDCs as antigen delivery strategy 
for the isolation of T cells specific for unknown epitopes derived from NY-ESO-1. 
Electroporation of ivtRNA encoding the selected tumor antigen is a strategy for antigen 
delivery that circumvents most of the disadvantages of peptide loading. Following 
transfection, ivtRNA molecules serve as the template for cell intrinsic translation, adding 
new antigens to the pool of endogenous proteins. Subsequently, full-length proteins are 
processed and presented following internal cellular pathways. The use of ivtRNA as the 
antigen source for T cell activation allows any DNA sequence to be used as a transcription 
template and facilitates the isolation of T cells specific for all potential immunogenic 
epitopes derived from the tumor antigen of interest. The electroporation of ivtRNA leads to 
a longer presentation of the selected antigen on the cell surface of mDCs, increasing the 
probability of a successful T cell induction [118], [119]. It has been shown previously that 
electroporation of mDCs with ivtRNA is effective and that mDCs retain their mature 
phenotype as well as their migratory capacities after electroporation [120], [121]. Moreover, 
simultaneous transfection of ivtRNA encoding MHC class I molecules and TAA into mDCs 
has been shown to be a reliable method for obtaining co-expression of both proteins [122].  
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For priming, a high-purity CD8+ enriched T cell population was used from autologous PBMC 
to enlarge the starting CD8+ T cell repertoire for the induction of NY-ESO-1-specific T cells. 
Although it is well-known that CD4+ T cells have a pivotal role for T cell priming and for the 
survival of CD8+ T cells in vivo, previous experiments in our group have shown that the 
presence of CD4+ T cells is not necessary for in vitro CD8+ T cell priming and expansion 
when cytokines, such as IL-7 and IL-2, are added to the priming co-culture (data 
unpublished). A CD8-untouched cell isolation procedure was used to avoid any unwanted 
activation of CD8+ T cells mediated by antibody-binding prior to priming procedure. 
CD8-enriched T cells were co-cultured with ivtRNA-transfected mDCs in the presence of 
IL-7 and IL-2 in order to sustain the proliferation of CD8+ T cells during the priming 
procedure. These cytokines are commonly used as supplements for in vitro cultivation of T 
cells to support cell survival and proliferation [123]. Importantly, IL-2 was added to the 
medium two days after setting up the co-cultures according to the findings of previous 
studies, where it was observed that T cells reactive to irrelevant antigens can be transiently 
activated and start to proliferate immediately after induction, leading to a dilution of target-
specific T cells [124]. Delaying cytokine addition was shown to help reducing the expansion 
of these unwanted T cells. Previous reports further showed that high antigen concentrations 
and repeated stimulations with mDCs could result in the deletion of high-avidity tumor 
antigen-specific T cells by activation-induced cell death (AICD), affecting the quality of the 
induced T cells [125], [126]. An effector to target ratio of 10:1 was defined and tested in 
previous allogeneic priming experiments in our group [84]. This ratio resulted in an efficient 
induction of high-avidity tumor antigen-specific T cells without causing over-stimulation and 
death of the desired T cells. Therefore, T cells and mDCs were co-cultured at this standard 
E:T ratio. In contrast to previous protocols, only one stimulation with mDCs was performed, 
aiming to improve and optimize the priming procedure. Additional stimulations might induce 
a massive growth of HLA-A2-allo-reactive T cells reducing the fraction of NY-ESO-1-
specific T cells present within the priming culture. Performing only one stimulation might 
further reduce the risk of AICD and favor survival of the desired NY-ESO-1-specific T cells. 
Moreover, the entire priming protocol was thereby simplified as the number of mDCs and 
the time required for the complete procedure were reduced. 
5.1.2 Sorting approach 
After de novo induction, NY-ESO-1-specific T cells needed to be selectively separated from 
the rest of primed T cells to enable functional characterization as well as isolation of 
individual TCR sequences. Here, it was established and tested in the context of an 
allogeneic priming a novel 2-step-sorting strategy independent of the knowledge of 
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immunogenic epitopes and based on the activation-induced CD137 marker and K562 cell 
stimulation. 
The technology based on multimers is the most common strategy used to selectively isolate 
tumor antigen-specific T cells [93], [94]. The applicability of multimer technology requires 
knowledge of immunogenic peptide sequences and corresponding MHC alleles. Therefore, 
this procedure allows the isolation of T cells only with defined peptide specificities, whereas 
it lacks the possibility to capture T cells recognizing other peptides generated by using 
ivtRNA encoding the full-length protein as the antigen source. For well-known immunogenic 
peptides, the multimer technology has been shown to be an efficient sorting method to use 
with patient samples as well as in combination with in vitro and in vivo priming protocols 
[127]–[129]. On the other hand, if less well-characterized antigens are used for T cell 
priming, peptides for multimer production need to be selected by using epitope prediction 
tools. Consequently, due to the low reliability of these tools previously discussed, multimers 
binding peptides that are not naturally processed and presented in tumor cells could be 
used for sorting, leading to isolation of T cells that are not relevant for clinical application 
[95], [96]. Furthermore, the availability of multimers is a limiting factor due to possible 
insufficient peptide:MHC complex stability and to sequence-dependent difficulties in MHC 
protein folding for some HLA molecules. Due to these limitations, an alternative method 
based on the analysis of the expression of an activation-induced marker was sought to 
isolate NY-ESO-1-specific T cells in this project. This strategy allowed to fully exploit the 
potential of the full-length tumor antigen ivtRNA used for T cell induction in the priming 
procedure. 
The sorting strategy required firstly, selecting an appropriate T cell marker which was 
upregulated strictly and strongly in response to TCR signaling, while the expression absent 
during the resting phase of T cells prior to stimulation. Accordingly, CD137 was selected as 
marker for the sorting procedure since it is one of the most promising activation-induced T 
cell marker described in the literature [99], [100]. CD137 is a member of the TNF receptor 
family that promotes proliferation and survival of activated T cells [130], [131]. In the clinical 
setting of allogeneic stem cell transplantation, the evaluation of CD137 expression on 
donor-derived T cells upon stimulation with allogeneic recipient APCs and the consequent 
depletion of CD137+ T cells prior to infusion has been proved to be an efficient procedure 
to reduce alloreactivity [132]. In previous studies, this marker has already been used to 
efficiently isolate CD8+ T cells specific for different tumor antigens from autologous T cell 
repertoires [99], [101]. Alternatively, protocols including the analysis of activation-induced 
cytokine secretion have also been developed by several research groups [97], [98]. 
Cytokine secretion by T cells upon specific activation is a tightly regulated process, 
therefore detection of cytokine secretion represents a suitable parameter for the isolation 
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of tumor antigen-specific T cells. However, such functional assays may reflect only a subset 
of specifically activated T cells. Due to very heterogeneous cytokine profiles of different T 
cell subpopulations, functionally diverse cells may not be identified by using a single 
cytokine, but have to be tracked by a multi-cytokine assays. These assays might result quite 
laborious and tedious as sorting of a high number of primed T cells need to be performed 
to meet the rare desired T cells within the population.  
Choosing efficient and appropriate APCs to induce CD137 expression on T cells was 
another crucial step for the sorting strategy. The human erythroleukemic cell line K562 
derived from a patient with chronic myelogenous leukemia in blastic crisis was chosen as 
the source of stimulating cells [133]. K562 cells represent ideal starting cell line to generate 
cell-based genetically engineered APCs and they have already been used in several 
protocols for in vitro T cell stimulation [134]. K562 cells do not express endogenous MHC 
class I and II molecules as well as costimulatory and co-inhibitory molecules, other than 
CD80 at a low level. By contrast, they express ICAM-1 (CD54) and LFA-3 (CD58), which 
are adhesion molecules required to form an effective immunological synapse [135]. Since 
they endogenously express β2-microglobulin, the introduction of MHC class I heavy chain 
molecules alone is sufficient for MHC class I surface expression [136]. Additionally, it has 
been shown that K562 cells possess fully functional antigen processing and MHC 
presentation machineries [137], [138]. There were several other advantages to use K562-
based aAPCs to induce CD137 expression on T cells compared to either standard APCs, 
such as autologous mDCs, B cells and LCL, or to other tumor cell lines. Compared to 
standard APCs, K562 cells enabled stimulation of T cells restricted to the solely desired 
allogeneic HLA-A2 molecules, excluding potential isolation of T cells restricted to self-MHC 
molecules which could be present in the priming culture. Additionally, using K652 cells it 
was possible to isolate T cells specific for NY-ESO-1 peptides that were naturally processed 
and presented by a tumor cell line, which might be different from the peptide repertoire of 
mDCs, B cells and LCL. Immune system cells, especially professional APCs, constitutively 
express immunoproteasome subunits while tumor cells contain nearly only standard 
proteasome subunits under basal conditions, albeit oxidative stress and proinflammatory 
cytokines can cause the upregulation of the immunoproteasome components. The standard 
proteasome and the immunoproteasome are different in their catalytic activity and peptide 
generation, leading to differences in the peptide repertoire of different cell types [139], [140]. 
Due to the lack of endogenous MHC molecules in K562 cells, there was no activation of T 
cells that were reactive to foreign MHC molecules other than the introduced HLA-A2. The 
activation of high numbers of allo-reactive T cells represented one of the major limitations 
to use other tumor cell lines expressing up to six different MHC class I molecules. In 
addition, compared to LCL, K562 cells lack EBV peptides and thus, activation of potentially 
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primed EBV-specific T cells during analysis of T cell samples was avoided utilizing K562 
cells as APCs. Priming of EBV-specific T cells is quite probable if the donor of the priming 
is EBV-positive, which is the case in about 95% of the world population  [141]. Having these 
advantages, K562 cells were used as a starting cell line to generate aAPCs by the 
introduction of HLA-A2 molecule and CD86 co-stimulatory molecule by retroviral 
transduction. Since in previous priming experiments in our group the survival of antigen-
specific CD8+ T clones after sorting was extremely low, CD86 co-stimulatory molecule was 
introduced into K562 cells with the final aim to enhance and sustain T cell clone survival 
(data unpublished). 
An additional critical aspect in developing the sorting strategy based on CD137 was related 
to the induction of a high number of HLA-A2-allo-reactive T cells within the culture in an 
HLA-A2-allogeneic priming approach. The T cell repertoire towards an allogeneic HLA 
molecule has not undergone negative selection. Hence, T cells recognizing allogeneic MHC 
molecules in combination with self-peptides are still present in the post-thymus selected T 
cell population [48], [49], [79]. As an unavoidable consequence of the HLA-A2-allogeneic 
priming, not only are HLA-A2-restricted tumor antigen-specific T cells induced, but also 
many unwanted HLA-A2-allo-reactive T cells. These HLA-A2-allo-reactive T cells will 
express CD137 in response to HLA-A2-positive APC stimulation, independently of the 
presence of the tumor antigen, and it is impossible to distinguish between the desired 
antigen-specific T cells and HLA-A2-allo-reactive T cells during sorting, but only in 
subsequent functional screenings at the clonal T cell level. The probability to isolate tumor 
antigen-specific T cells using an allogeneic priming approach in combination with a sorting 
method based on CD137 expression on T cells is therefore extremely low. Previous 
experiments in our group have shown that it is necessary to sort a very high number of 
clones to be able to catch a tumor antigen-specific clone, limiting the feasibility of the 
classical CD137-based sorting in combination with allogeneic priming approaches (data 
unpublished). An innovative 2-step-procedure called ‘double-sorting’ was developed and 
tested for the first time in this study in order to improve the CD137 based sorting strategy. 
The innovation within this approach was to perform an allogeneic HLA-A2 and NY-ESO-1-
unspecific stimulation of the primed T cells as first step and subsequently use the T cells 
that do not express CD137 in a next step for HLA-A2 and NY-ESO-1-specific stimulation. 
For the first NY-ESO-1-unspecific stimulation, irradiated water-electroporated tgK562 cells 
(endogenously negative for NY-ESO-1) were utilized at a high effector to target ratio of 2:1. 
The idea of using a high number of K562 cells was to provide sufficient numbers of APCs 
to activate as many HLA-A2-allo-reactive T cells as possible. At this step, the risk of 
inducing AICD was not relevant for NY-ESO-1-specific T cells since the activated T cells 
represented the unwanted cell fraction that was meant to be discarded. The final aim of the 
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first step was to enrich NY-ESO-1-specific T cells (CD137-negative fraction) by removing T 
cells that upregulated CD137 independently of NY-ESO-1. To note, the CD137-negative 
fraction sorted after NY-ESO-1-unspecific stimulation might include not only the desired 
NY-ESO-1-specific T cells, but also T cells that were either unreactive to HLA-A2 or were 
HLA-A2-allo-reactive but were not in the cell cycle phase to be activated at the time of 
sorting. In the second step, for antigen-specific stimulation of the previously sorted T cells, 
tgK562 cells transfected with ivtRNA encoding NY-ESO-1 were used at an effector to target 
ratio of 5:1. The ratio was higher compared to the number of mDCs used for de novo 
induction (E:T ratio of 10:1) since tgK562 cells are not professional APCs as mDCs.  
A high number of single-cell-sorted T cells expanded after 14 days, showing that, in general, 
T cells were able to survive and expand after two rounds of sorting by FACS. The evaluation 
of IFN-γ release of the expanded clones revealed T cell clones with different reaction 
patterns (152 non-reactive, 144 HLA-A2-allo-reactive and 5 NY-ESO-1-reactive). The 
observation of five potential NY-ESO-1-specific CD8+ T cell clones was the first proof-of-
principle for the double-sorting procedure based on CD137 and K562 cells as APCs, 
demonstrating the feasibility of this approach. However, still a lot of unwanted T cell clones 
were obtained, showing that the procedure needs to be further optimized. 
5.2 Characterization of the properties of the identified TCR 5-271  
5.2.1 Antigen specificity: unconventional epitopes 
The epitope recognized by the isolated TCR 5-271 was mapped to the protein encoded by 
ORF2 of NY-ESO-1 and the LAGE-1, supporting findings of previous studies showing the 
existence of unconventional epitopes encoded by non-primary ORFs for several tumor 
antigens [142]–[145]. Especially, NY-ESO-1-ORF2 and CAMEL proteins were already 
shown to contain epitopes recognized by both CD8+ and CD4+ T cells [111], [146]–[149]. 
Two different peptides derived from NY-ESO-1-ORF2/CAMEL and presented in the context 
of MHC class I molecules have been identified so far. Wang and colleagues have identified 
a CD8+ T cell clone derived from TILs of a melanoma patient specific for a peptide derived 
from NY-ESO-1-ORF2/CAMEL protein and presented on the HLA-A31 molecule (NY-ESO-
1-ORF2/CAMEL18-27) [149]. An HLA-A2-restricted NY-ESO-1-ORF2/CAMEL-specific (NY-
ESO-1-ORF2/CAMEL1-11) CD8+ T cell clone was obtained by Aarnoudse and colleagues 
from PBMC of a melanoma patient using autologous melanoma cells for in vitro stimulation 
in the presence of IL-2 [111]. The isolation of T cells specific for NY-ESO-1-ORF2/CAMEL 
from melanoma patients proved that epitopes derived from proteins encoded by the 
alterative ORFs can be naturally processed and presented by tumor cells eliciting T cell 
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responses. These findings together with the data regarding other antigens demonstrate the 
immunological significance of epitopes produced unconventionally [150], [151]. The 
mechanism by which proteins, derived from alternative ORFs, are translated is currently 
unclear. However, there are several potential explanations for the physiological production 
of alternative ORF-encoded proteins. One of them is that some ribosomes occasionally 
bypass the first AUG start codon with a weak kozak sequence (non-optimal adjacent 
sequences supporting the starting of the translation) and initiate translation at a 
downstream AUG. This mechanism is designated as leaky scanning [152], [153]. The leaky 
scanning enables the translation of two different ORFs and the consequent synthesis of 
two separately initiated proteins from one mRNA transcript. The derived alternative ORF-
encoded protein can either be a shorter version of the full-length ORF encoded-protein if 
the second AUG is in the same reading frame of the first AUG or a completely different 
protein if the second AUG is in an alternative reading frame. Both in NY-ESO-1 and in 
LAGE-1 mRNA transcripts, the sequences adjacent to the start codon of the primary ORF 
are not optimal for supporting the start of translation. Therefore, leaky scanning might 
happen leading to translation of primary and non-primary ORFs of NY-ESO-1 and LAGE-
1. As a consequence, NY-ESO-1-ORF2 and CAMEL proteins can be produced in addition 
to the full-length NY-ESO-1 and LAGE-1 proteins. Since NY-ESO-1-ORF2 and CAMEL 
proteins are encoded by ORFs included in alternative reading frames than the primary 
ORFs, the resulting proteins show a completely different amino acid sequence compared 
to the conventional ORF1-encoded proteins.  
In this project, the cDNA sequence used to generate NY-ESO-1 ivtRNA for the priming was 
not codon-optimized and no kozak sequence was introduced upstream of the tumor 
antigen. Codon-optimization and addition of a kozak sequence are the most common 
strategies to increase protein expression of a transgene [106], [152]. However, these 
strategies were not used in the NY-ESO-1 ivtRNA because high amounts of ivtRNA were 
introduced into mDCs to obtain adequate NY-ESO-1 protein expression to efficiently induce 
NY-ESO-1-specific T cells. Consequently, it was possible that the non-primary ORF was 
translated, the corresponding protein was processed and non-primary ORF-derived 
peptides were presented in addition to the primary ORF-derived peptides after NY-ESO-1 
ivtRNA transfection into mDCs, leading to the potential induction of T cells specific for 
unconventional peptides in the priming procedure.  
5.2.2 Low abundance of alternative ORF-encoded protein in tumor cells 
TCRs are only suitable for clinical development if they are able to recognize tumor cells 
endogenously expressing the target antigen and the MHC molecules. The recognition of 
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tumor cells by T cells expressing a transgenic tumor antigen-specific TCR requires efficient 
epitope presentation on MHC molecules by tumor cells. The latter depends on several 
factors, including the expression level of the tumor antigen in the target cells, the expression 
level of the MHC molecule on the tumor cell surface, the capacity of tumor cells to process 
and present the epitope of interest and the binding affinity of the peptide for the MHC 
molecule [154]. 
None of the tumor lines tested in the assay were recognized by the TCR 5-271, although 
NY-ESO-1/LAGE-1a mRNA expression was verified by Nanostring analyses and the 
surface expression of the HLA-A2 molecules was proved by flow cytometry. Unfortunately, 
no commercial antibodies were available to detect intracellular expression of the NY-ESO-
1-ORF2 and the CAMEL protein. Thus, no information regarding the endogenous 
expression of ORF2-encoded proteins were available. Nevertheless, the recognition of NY-
ESO-1 ivtRNA-transfected tgK562 cells and tumor cell lines by TCR 5-271-transgenic T 
cells showed that in principle ORF2 of NY-ESO-1 can be efficiently translated, the 
corresponding protein can be efficiently processed and the epitope recognized by TCR 5-
271 can be efficiently presented on HLA-A2 molecules by the tested tumor cell lines.  
Interestingly, during the characterization assays, it was hypothesized that translation of 
ORF2 of LAGE-1a was less efficient compared to the translation of ORF2 of NY-ESO-1 
after antigen ivtRNA electroporation both into tgK562 cells and into other tumor cell lines. 
According to Nanostring data, the analyzed tumor cell lines endogenously expressed 
mainly LAGE-1a, but rarely NY-ESO-1 mRNA transcripts. Consequently, the tested tumor 
cell lines might translate the LAGE-1a-ORF2 with very low efficiency and express very low 
amounts of the corresponding protein including the target epitope of TCR 5-271. Thus, 
these tumor cells might not represent the ideal targets to evaluate tumor recognition 
mediated by TCR 5-271-transgenic T cells. Tumor cell lines expressing endogenously high 
levels of NY-ESO-1 should be tested to further investigate this hypothesis.  
In general, the identification of unconventional epitopes processed and presented by tumor 
cells might enlarge the repertoire of potential targets for TCR gene therapy strategies. 
However, one potential limitation is the relatively low abundance with which alternative 
ORF-encoded products are usually naturally generated compared to primary ORF-derived 
proteins in tumor cells [150]. Consequently, TCRs specific for these unconventional 
epitopes might require a very high peptide sensitivity to efficiently recognize tumor cells 
expressing low amounts of their target peptides and to be considered as potential 
therapeutic TCRs for clinical use. 
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5.2.3 Low T cell peptide sensitivity and CD8-independent functionality 
The multistep process leading to efficient epitope presentation on MHC molecules by tumor 
cells is only one of the components that play a critical role in TCR-mediated tumor 
recognition. The other relevant element is the interaction between the TCR and its specific 
peptide:MHC complex. The strength and the stability of the interaction between TCR and 
peptide:MHC complex as well as the ensuing T cell peptide sensitivity are critical to trigger 
tumor target recognition and effective T cell responses [155], [156]. 
TCR 5-271-transduced T cells required very high amounts of peptides for activation as 
determined by the half-maximal IFN-γ secretion in response to titrated amounts of the target 
peptide. Thus, the isolated TCR 5-271 might not be a very potent TCR, albeit it was isolated 
using an allogeneic priming approach. This could explain the limited tumor cell recognition 
mediated by TCR 5-271-transgenic T cells, hence restricting its potential use in clinical 
application. Strategies to enhance TCR reactivity might be applied to TCR 5-271 with the 
final aim to improve its functionality without affecting the antigen specificity. Affinity-
enhanced TCRs can be obtained by introducing mutations in CDR regions of TCRα and 
TCRβ chains, aiming to increase the affinity of the TCR for its target peptide:MHC complex 
(strategy designated as in vitro affinity maturation) [71]–[74]. Besides in vitro affinity 
maturation, proximal TCR co-signaling pathways can be manipulated in order to increase 
TCR sensitivity for stimulation and activation [157]–[159]. 
Interestingly, the identified TCR 5-271 displayed independency of CD8 co-receptors, 
showing functionality after the transfer into CD8+ as well as CD4+ T cells. These findings 
were quite surprising since T cells expressing TCR 5-271 showed low peptide sensitivity. 
Indeed, functionality in a CD8-independent manner has mainly been observed as 
characteristic of TCRs showing high-affinity for their target MHC:peptide complex [113]. 
Nevertheless, each identified TCR needs to be evaluated individually for its CD8 
requirement in order to identify exceptions [160]. In principle, CD8-independency 
represents an advantageous property of a TCR used for T cell engineering, leading to the 
possibility to generate also tumor reactive MHC class I restricted CD4+ T cells. These 
modified CD4+ T cells can recognize MHC class I restricted peptides and provide help in 
anti-tumor reaction and support in terms of proliferation, differentiation and maintenance of 
CD8+ T cells directly at the tumor site [161], [162]. 
5.2.4 Fine typing of the recognized epitope 
A critical step in the TCR characterization process is the fine typing of the target epitope 
recognized by the candidate TCR [68]. In this project, the core epitope recognized by the 
isolated TCR 5-271 was identified and the contribution of each aa of the epitope to the TCR-
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mediated recognition was evaluated. Previous studies regarding epitopes presented on 
HLA-A2 molecules have shown that aa located at the N- and C-terminal end of the peptide 
are mainly responsible for the interaction with the MHC molecule (anchor residues). By 
contrast, the interaction with the TCR is principally governed by the central portion of the 
peptide [163]–[165]. 
During TCR 5-271 characterization, it was observed that the first and the last leucine (L) of 
the core epitope (P1 and P8 of the 8-mer peptide LMAQGAML) were essential in 
determining the target recognition mediated by the isolated TCR. Accordingly, these aa 
might be anchor residues critical for peptide binding to the HLA-A2 molecule and for the 
consequent efficient peptide presentation. 
The presence of the additional phenylalanine (F) at the N-terminal end of the core epitope 
might be crucial for further stabilizing the binding between HLA-A2 molecules and the 
peptide, enabling efficient epitope presentation, particularly under physiological conditions 
when the peptide is processed and presented by an internal cellular pathway.  
Interestingly, the substitution of the glycine (G) in the epitope affected TCR 5-271 
recognition in the context of the 9-mer peptide FLMAQGAML, but not in the extended 
versions of the peptide (11-mer and 12-mer). These results showed that the extended N-
terminal or C-terminal ends might alter the accommodation of the peptide in the MHC 
groove. Consequently, the position and the role of the G in the TCR 5-271-mediated 
recognition might be different in the extended versions of the peptide.  
In conclusion, these findings showed that the modification of single aa in the epitope 
sequence might either destroy the binding of the peptide with the TCR and/or the MHC 
molecule abrogating the recognition by the TCR or might not affect the epitope presentation 
and the TCR recognition. The possibility to modify single aa in the epitope sequence without 
altering TCR recognition is critical for the analysis of alternative peptides within the human 
proteome that show homology to the target epitope and might be potentially cross-
recognized by T cells expressing the transgenic TCR. In order to determine potentially 
cross-recognized peptides, N-terminal and C-terminal extended versions of the core 
epitope need to be also evaluated since they can also trigger T cell stimulation as shown in 
this study. Other than the alanine scanning assay, tests including combinatorial aa 
substitutions should be performed to gain more information for each single aa within the 
epitope. Three-dimensional structure models may also help to fully understand the 
interaction between peptide, MHC molecule and TCR. 
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5.3 Outlook  
The successful isolation of the T cell clone 5-271, recognizing a new epitope derived from 
NY-ESO-1-ORF2/CAMEL protein, was the first proof-of-principle study of the innovative 
double-sorting strategy based on CD137 and K562 cells combined with an HLA-A2-
allogeneic priming approach based on mDCs transfected with ivtRNA encoding the full-
length tumor antigen. Together these features enabled bypassing knowledge of pre-defined 
epitopes for tumor antigen-specific T cell isolation. However, further improvements can be 
developed to extend and increase the success and efficiency of the sorting strategy. One 
possibility could be to use K562 cells transduced only with HLA-A2 molecules without 
additional co-stimulatory molecules. CD86 was selected as co-stimulatory molecule to 
enhance and sustain T cell survival after sorting. However, its high expression on K562 
cells might also favor low-avidity T cells to upregulate CD137 which are not the desirable 
ones to be identified for clinical application. Since K562 cells can easily be genetically 
modified, it would be possible to transduce them with the tumor target antigen to obtain a 
stable and uniform antigen expression for T cell stimulation. The use of antigen-transduced 
K562 cells would simplify the double-sorting procedure and it would completely avoid any 
possible uncontrollable activation of genes in K562 cells due to the electroporation 
procedure. A ‘triple-sorting’ approach including two rounds of target antigen-unspecific 
stimulation might be tested, aiming to further reduce HLA-A2-allo-reactive T cells. 
Consequently, the entire procedure will take longer and will be even more stressful for the 
desired T cells. Hence, addition of very low doses of cytokines might be needed during the 
sorting period to assure T cell fitness and survival. Since studies in our group have shown 
that the probability to isolate the desired tumor antigen-specific T cells may differ 
substantially between donors and varies across different tumor target antigens, the double-
sorting approach should be tested in multiple priming approaches using several donors and 
different tumor target antigens to fully evaluate its feasibility and applicability in the context 
of allogeneic priming protocols. A test system using an established tumor antigen-specific 
T cell clone might be developed to evaluate the efficiency of the double-sorting procedure. 
In principle, the concept of ‘double-sorting’ could be applied to any T cell activation marker, 
other than CD137, showing expression on the surface of T cells only after TCR 
engagement. 
As observed in this project, the presence of alternative ORFs in alternative reading frames 
in the wild-type sequence of the selected tumor antigen may reduce the efficiency of the 
induction of T cells specific for peptides derived from primary ORF-encoded proteins during 
the priming procedures. Thus, alternative ORFs might be eliminated by partial-codon-
optimization of the cDNA sequence encoding the desired tumor target antigen without 
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altering the primary ORF encoding the protein of interest. Including this concept into the 
design of the tumor antigen sequences for priming protocols will abolish the induction of T 
cells specific for peptides derived from low abundant proteins encoded by alternative ORFs. 
Moreover, it will help to control the priming procedure and to increase its efficiency, allowing 






aa Amino acid 
ALL Acute lymphoblastic leukemia 
APC Allophycocyanin 
APC-Cy7 Allophycocyanin – cynine 7 
APCs Antigen presenting cells 
aAPCs Artificial antigen presenting cells 
ATLL Adult T cell leukemia/lymphoma 
BLAST Basic local alignment search tool 
bp Base pair 
BSA Bovines serum albumin 
BUV BD horizon brilliant™ ultraviolet 
C Cysteine 
CAMEL Cytotoxic T lymphocyte-recognized antigen on melanoma  
CAR Chimeric antigen receptor 
CCR7 C-C motif chemokine receptor 7 
CD Cluster of differentiation 
cDNA Complementary DNA 
CDR Complementarity determinig region  
CMV Cytomegalovirus 
C region  Constant region 
CSA Cyclosporin A 
CTAs Cancer-testis antigens 
CTLA-4 Cytotoxic T Lymphocyte Antigen-4 
D Aspartic acid 
DCs Dendritic cells 
DEPC Diethyl pyrocarbonate 
dH2O Distilled water 
DMEM Dulbecco's Modified Eagle's medium 
DLBCL Diffuse large B cell lymphoma 
DLI Donor-derived lymphocyte infusion 
DMSO Dimethylsulfoxide 
DNA DeoxyriboNucleic Aaid 
DPBS Dulbecco's phosphate-buffered saline  
E Glutamic acid 
EBV  Epstein-Barr-Virus 
EDTA Ethylenediaminetetraacetic acid 
EF1-α Elongation factor 1-alpha 
eGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ELISA  Enzyme-linked immunoabsorbent assay 
Env Envelope 
EP Electroporation 
E:T ratio Effector to target ratio 
F Phenylalanine 
FACS  Fluorescence-activated cell sorting 
FBS Fetal Bovine Serum 
FDA Food and drug administration 





Gag Group-specific antigen  
GM-CSF  Granulocyte-macrophage colony-stimulating factor 




HA-1 Histocompatibility antigen 1 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLA  Human leukocyte antigen 
HS Human serum 
HSA Human serum albumin 
I Isoleucine 
IFN-γ Interferon-gamma 
Ig  Immunglobulin 
IL  Interleukin 
iDCs Immature DCs 
IMDM Iscove's modified dulbecco's media 
IMGT ImMunoGeneTics 
IU  International unit 
ivtRNA In vitro transcribed RNA 
K Lysine 
L Leucine 
LAGE-1a Cancer/testis antigen 2 (CTAG2) isoform a 
LAGE-1b Cancer/testis antigen 2 (CTAG2) isoform b 
LCL Lymphoblastoid cell line 
LB Luria Broth Base 
LTR Long terminal repeat 
M Methionine 
MACS Magnetic-activated cell sorting 
MAGE-A1 MAGE Family Member A1 
MAGE-A3 MAGE Family Member A3 
MART-1 Melanoma antigen recognized by T Cells 
MCS Multiple cloning site 
mDCs Mature dendritic cells 
MEM NEAA Minimum essential medium non-essential amino acids 
MESV Murine embryonic stem cell virus 
MHC  Major histocompatibility complex 
ml Milliliter 
MoMuLV Moloney murine leukemia virus 
MPSV Myeloproliferative sarcoma virus 
mRNA Messenger RNA 
n.a. Not analyzed 
nt Nucleotide 
NCBI National center for biotechnology information 
NY-ESO1  Cancer/testis antigen 1B (CTAG1B) 
ORF  Open reading frame 
PB Pacific Blue 
PBL  Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS VLE Phosphate-buffered saline very low endotoxin 
pco Partial-codon-optimization 
PD-1 Programmed cell death protein-1 




PE-Cy7 Phycoerythrin – cynine 7 
PercP Peridinin-chlorophyll protein 
PFA Paraformaldehyde solution 





RACE-PCR  Rapid amplification of cDNA ends - polymerase chain reaction 
RNA Ribonucleic acid 




TAA  Tumor-associated antigen 
TAE Tris Acetate EDTA 
TAP  Transporter associated with antigen processing 
TCR  T cell receptor 
tgK562 Transgenic K562 cells 
TF Transfection 
TILs Tumor-infiltrating lymphocytes 
TNF-α Tumor necrosis factor-alpha 
TRAC TCR alpha constant segment 
TRAJ TCR alpha joining segment 
TRAV TCR alpha variable segment 
TRBC TCR beta constant segment 
TRBJ TCR beta joining segment 
TRBV TCR beta variable segment 
TSA Tumor-specific antigen  
UTR Untranslated region 
UV Ultra-violet 
V Valine 
VLE Very low endotoxin 
W Tryptophan 
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